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Abstract 
 
Sigma receptors originally thought to be an opioid receptor is now categorized 
as a distinct class of receptor. There are two main subtypes, the sigma-1 
receptor and an uncharacterised binding site, named the sigma-2 binding site. 
The presence of the sigma-2 binding site shows high correlation with 
proliferation of cells and is associated with cancer. 
 
I have categorized sigma-1 and sigma-2 binding sites in 11 human tumour cell 
lines. I have demonstrated that tumour cell lines from a range of tissues 
express both sigma-1 and sigma-2 binding sites. One exception is the MCF7 
breast cancer cell line, which lacks sigma-1 receptors. I show that the 
quantitation of sigma-2 binding sites using the “masking” protocols are flawed, 
significantly overestimating levels of sigma-2 binding sites. I propose novel 
protocols to determine levels of sigma-1 receptors and sigma-2 binding sites in 
cell lines and tissue. 
 
Using radioligand binding assays in MCF7 cells, I have characterised novel 
sigma-2 ligands. These ligands are simple ammonium salts containing a single 
nitrogen atom. They are simpler than the previously recognised pharmacophore 
for the sigma-2 site. I have shown that these simple ammonium salts show 
graded affinity for the sigma-2 binding site. The highest affinity ligands were 
dihexylammonium (pKi 7.58) and dioctylammonium (pKi 7.9). 
 
I have used these ammonium salts and previously characterised ligands to 
determine sigma-2 binding site biology. I have shown that the biological activity 
of these drugs is related neither to their hydrophobicity nor their ability to effect 
calcium signalling in cells. I propose that the Hill slope of binding is inversely 
related to the efficacy of a ligand to inhibit metabolic activity of cancer cells. 
Furthermore, I offer an explanation as to why concentrations of sigma-2 ligands 
far higher than their determined binding affinities are required to inhibit 
metabolic activity. 
.
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CO2 Carbon Dioxide 
DMEM Dulbecco Modified Eagle’s minimum essential 
media 
DMSO Dimethyl sulfoxide 
EC50 Effective concentration of a drug to cause 50% 
maximal  response 
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1.1 The importance of receptors and receptor theory 
 
A receptor is a small protein molecule usually embedded in the cell membrane, 
which transduces a chemical signal from an extracellular environment to the 
intracellular environment and hence helps the cell to respond to various stimuli. 
When a chemical signal binds to a receptor it results in transformational change, 
which further results in some form of cellular response. Although the majority of 
receptors are found on the cell membrane, they are also found in the cytoplasm 
and in the nucleus.  A general overview on receptors can be found in all 
pharmacology texbooks, including Rang and Dale’s Pharmacology (Rang & 
Dale's Pharmacology, 8th Edition, Authors: Ritter, Flower, Henderson and Rang, 
Paperback ISBN: 9780702053634, pp22-49). Based on their structure, 
receptors can be broadly classified into the following categories: 
 
Type 1 - Ligand-gated ion channels (Ionotropic receptors): These receptors are 
usually targets of neurotransmitters like GABA and acetylcholine (working 
through nicotinic acetylcholine receptors). Activation of these receptors by 
ligands results in the movement of ions across the cell membrane through the 
same protein. Several examples of cell surface (e.g. nicotinic and 5-
hydroxytryptamine (Wu et al., 2015) and intracellular (e.g. inositol 1,4,5-
trisphosphate (IP3) and ryanodine receptors (Seo et al., 2015) exist, allowing 
the flood of ions down a concentration gradient in an energy-independent 
manner. 
 
Type 2 - G protein-coupled receptors: This is the largest family of receptors and 
is composed of proteins containing seven transmembrane alpha helices.  The 
ligand-binding site for larger peptides is usually present on the extracellular 
domain. Endogenous ligands are usually different types of hormones (examples 
include histamine and acetylcholine (working through muscarinic acetylcholine 
receptors (Haga, 2013)) .  
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Type 3 - Kinase related receptors are composed of extracellular component, 
which binds to the ligand and intracellular component, which is linked with 
various downstream signalling pathways. Two subclasses of these receptors 
exist: those which intrinsic kinase activity, an example of which would include 
the insulin receptor (Taniguchi et al., 2006) and those without kinase activity 
that recruit an intracellular kinase following activation by a ligand, examples of 
which would include cytokine receptors (Abate et al., 2010) . 
 
Type 4 - Nuclear receptors, which can, again, be divided up into two major 
groups. Homodimeric nuclear receptors are usually found in the cytoplasm. 
Their endogenous ligands include testosterone and oestrogen (Mauvais-Jarvis, 
2011). Upon stimulation with a ligand, dimerization occurs and these receptors 
are trafficked into the nucleus, where they bind specific response elements on 
the DNA and regulate protein synthesis. Heterodimeric nuclear receptors pre-
exist as dimers with the retinoid X receptor (RXR) and are found in the nucleus. 
Examples of ligands include thyroid hormone (Rastinejad et al., 1995) and free 
fatty acids (Johnson et al., 1996). Upon stimulation with a ligand, dissociation 
from a co-repressor occurs and these receptors bind specific response 
elements on the DNA and regulate protein synthesis.  
 
Other receptors exist with different structures. Examples include the tumour 
necrosis factor (TNF) receptor (Tang et al., 1996) and the sigma-1 receptor 
(Schmidt et al., 2016), both of which exist as trimers. 
 
Binding of an agonist to the receptor results in a conformational change 
(Couette et al., 1996, Henchman et al., 2005), which results in altered 
downstream signalling pathways and hence the message is transduced from 
the extracellular environment to the intracellular area. For example, when an 
agonist binds the tyrosine kinase receptor, phosphorylation of tyrosine residues 
of the intracellular part of the receptor occurs and hence results in activation of 
signal transduction pathways; in receptors linked to ion channels it results in 
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opening of the ion channels allowing the movement of ions across the 
membrane down a concentration gradient (Jelacic et al., 1999). 
 
The two-state model of receptors suggests that a receptor exists in equilibrium 
between inactive (R) and active (R*) states (Black and Leff, 1983, Del Castillo 
and Katz, 1957) (see Fig 1-1). An agonist, which has higher affinity for the 
active form R* binds to it selectively. This removes the free active form from the 
equilibrium resulting in re-equilibration and a shift of the equilibrium to the right, 
creating more receptor in the active R* state, enhancing the physiological 
response. An inverse agonist has higher affinity for the receptor in the inactive 
R form and shifts the equilibrium to the inactive state, resulting in a negative 
physiological response.  
 
 
 
Figure 1-1: The two-state model of receptors. 
Receptors exist in an inactive form (R) and an active form (R*). Inverse agonists 
selectively bind R, whereas agonists selectively bind R*. Pure antagonists bind 
both R and R* with no selectivity. Figure taken from Rang and Dale’s 
Pharmacology, 6th Ed. 
 
A pure antagonist has the same affinity for both inactive R and active R* states 
of the receptor so binding of an antagonist does not alter the equilibrium and so 
gives no direct response, as shown in Figure 1-1. It does, however, inhibit the 
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binding of an agonist or inverse agonist preventing them from having their 
effects 
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Figure 1-2: Example of dose response curve to different types of ligands. 
A full agonist is able to produce a maximal response. Inverse agonists induced 
a negative response. Partial agonists produce a less than maximal response. 
Competitive antagonists have no effect, but do alter the ability of agonists to 
cause their effects. 
 
A full agonist may need to bind to a small number of receptors as compared to 
partial agonist to produce a physiological response, whereas a partial agonist 
may not be able to elicit a maximal physiological response despite occupying all 
the receptors. Potency relates to the concentration of a drug required to 
produce a physiological response of a given intensity (x-axis), it is measured by 
the effective concentration of a drug giving 50% of its maximal response (EC50). 
Efficacy describes the maximal size of a response elicited by a drug (y-axis), it 
is measured by the intrinsic activity (IA) of a drug in the specific system. A full 
agonist would have an IA of 1, whereas a partial agonist would have an IA of 
less than one. There is no relationship between potency and efficacy. 
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1.2 History of the sigma-2 binding site 
 
Although it has been more than 40 years since sigma receptors were initially 
identified as a subclass of opioid receptors, the understanding of sigma 
receptors is still far from complete. Initial work on sigma receptors was directed 
on their role in the central nervous system, however subsequently it was shown 
that these receptors are abundantly distributed outside the central nervous 
system as well (Vilner et al., 1995b).  
 
Martin et al. initially suggested the term sigma-opioid receptor in 1976 to explain 
the psychomimetic effects seen with benzomorphan, N-allyl-normetazocine 
(SKF 10047) and its analogues. Martin et al. (Martin et al., 1976) described the 
psychomimetic effects of SKF 10047 whilst working with morphine dependant 
and non-dependant chronic spinal dogs. Rather than causing analgesia, 
benzomorphans such as SKF 10047 and pentazocine caused psychomimetic 
effects. These receptors were suggested as novel opioid receptors in view of 
effects of SKF 10047 which could not be attributed to  (morphine) receptors,  
(ketocyclazocine) receptors or  receptors, and the fact that the effects were 
antagonized by naloxone, a universal opioid antagonist. Martin suggested SKF 
10047 to be agonist at sigma opioid receptor, in order to cause these effects 
(Martin et al., 1976). SKF 10047 was called an agonist because it caused 
tachycardia, tachypnea, mydriasis and raised body temperature, whereas  
receptor agonist resulted in bradycardia, low reparatory rate, hypothermia and 
miosis. Antagonists were agents that could block these responses. 
 
Whilst trying to characterise the sigma-opioid receptor, Su discovered a binding 
site that was labelled by SKF 10047, a sigma-opioid ligand, but showed no 
affinity to naloxone (Su, 1982). This binding site was different from what Martin 
et al. had suggested, since the latter was sensitive to naloxone. Experiments 
with SKF 10047 were repeated again and it was found that the psychomimetic 
effects of SKF 10047 were not antagonized by naltrexone, another potent 
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analogue of naloxone, hence the binding site identified by Su was different to 
the sigma opioid receptor (Su et al., 1988). Furthermore this binding site 
showed stereoselectivity for dextrorotatory benzomorphans such as (+) SKF 
10047 and (+) pentazocine, which was not characteristic of an opioid receptor.  
 
For some time the sigma receptor was confused with the phencyclidine (PCP) 
binding sites within the N-methyl-D-aspartate (NMDA) receptor (Mendelsohn et 
al., 1985, Zukin et al., 1984). However, in subsequent years further binding 
studies with specific ligands led to reclassification of these binding sites as 
unique entities unlike any other neurotransmitter or hormone binding protein 
(Quirion et al., 1987, Tam, 1985).  These receptors were later called “sigma 
receptors” distinguishing them from opioid receptors.  Su also noted that none 
of the endogenous opioid ligands inhibited sigma receptor binding.  Still no 
endogenous ligand for sigma receptors has been identified.  
 
1.3 Sigma-2 binding site structure and function 
 
Sigma receptors are classified in two main subtypes; sigma-1 and sigma-2, 
based on pharmacological and biochemical properties (Hellewell and Bowen, 
1990, Quirion et al., 1992). The subtypes differ mainly in their affinity for 
different drugs. The sigma-1 receptor has high affinity for the (+)-isomer of 
pentazocine and SKF 10047, whereas the sigma-2 binding site has high affinity 
for the (-)-stereoisomers (Bowen et al., 1993, Hellewell et al., 1994). Both 
subtypes also differ in distribution pattern, cellular localization and molecular 
weight (Itzhak, 1994, Torrence-Campbell and Bowen, 1996).  
 
The sigma-1 receptor has been cloned from human placental choriocarcinoma 
cells (Kekuda et al., 1996), human brain (Prasad et al., 1998), guinea-pig liver 
(Hanner et al., 1996), rat brain (Seth et al., 1998) and mouse brain (Pan et al., 
1998). Recently, the crystal structure of the sigma-1 receptor has been solved. 
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It appears to exist as a homotrimer and contains one transmembrane domain. 
The crystal structure of the sigma-1 receptor is shown in Figure 1-3. 
 
 
Figure 1-3: Crystal structure of the sigma-1 receptor 
A, viewed perpendicular to the membrane plane, the sigma-1 receptor shows a 
triangle structure comprising three tightly associated protomers, each with a 
single transmembrane domain at the corner of the oligometric triangle. From the 
side, the receptor reveals a flat membrane-associated surface. B, Colouring by 
electrostatic potential reveals a polar cytosolic surface, and a non-polar 
membrane-interacting surface flanked by positive charges. Images taken from 
(Schmidt et al., 2016). 
 
 
The sigma-2 binding site is not yet cloned. The molecular size of sigma-2 
binding site determined by photoaffinity labelling and sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis is reported to be 18-21kDa (Hellewell 
and Bowen, 1990, Hellewell et al., 1994). In order to visualize the sigma-2 
binding site, radioligands have been used. Unfortunately, these ligands do not 
completely discriminate between sigma-1 and sigma-2 binding sites. However, 
some studies have suggest that these two receptors are usually co-localized 
(Bouchard and Quirion, 1997, McCann et al., 1994), yet they may be present in 
different ratios (Leitner et al., 1994). A proposal that the sigma-2 binding site is 
the progesterone receptor membrane component-1 (Xu et al., 2011) has raised 
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fierce debate. Other research groups show they are different (Abate et al., 
2015a, Chu et al., 2015, Hiranita, 2016, Pati et al., 2016) while supporting data 
for co-identity from the original laboratory has also been published (Zeng et al., 
2016).  
 
1.4 Sigma-2 binding site distribution and cellular proliferation 
 
Sigma binding sites were initially discovered in the central nervous system. 
However, they are widely distributed in various tissues such as liver, kidney, 
endocrine and nervous system (Hellewell et al., 1994, Heroux et al., 1992). 
Sigma-2 binding site are found in high density in liver and kidney (Hellewell et 
al., 1994). In order to see if there was any relationship between sigma-2 binding 
site density and cellular proliferation Mach et al. conducted an important study 
in 1997. The author used a well-characterised in vitro mouse mammary 
adenocarcinoma, line 66, and showed that the sigma-2 binding site density was 
10 times more in proliferating cells as compared to quiescent cells (Mach et al., 
1997). Since Mach et al. used a single cell line further studies are needed to 
see if sigma-2 binding site density could be a biomarker for proliferation.  
 
In another important study, Al-Nabulsi et al. (Al-Nabulsi et al., 1999) 
investigated other factors apart from cell proliferation, which might affect the 
expression of sigma-2 binding sites. The sigma-2 binding site density in 
proliferative cells of cell line 67 (aneuploidy mouse mammary 
adenocarcinomas) was found to be 8 times higher than in quiescent cells, 
showing similar results to those previously reported by Mach et al. in diploid 
cells. In cell line 9L, cells formed a plateau phase from division-death 
equilibrium, unlike cell line 66 cells, which formed plateau by forming quiescent 
population of cells. Sigma-2 binding site density was reduced in plateau phase 
and it was independent of other factors like cell-cell contact, depletion of 
nutrition or altered metabolism.  Finally, when MCF7 cells were treated with 
tamoxifen, which is a cytostatic drug, a decrease in sigma-2 binding site density 
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was observed. Hence, it was concluded that sigma-2 binding site density was 
influenced by proliferation rate and not affected by other physiological or 
biological factors.  
 
1.5 Sigma-2 binding sites and cancer 
 
Cancer is characterised by uncontrolled cell growth and invasion and spread of 
cells from the site of origin to distant sites in the body. In 2000, Hanahan and 
Weinberg defined six hallmarks of cancer, which, according to them, were 
essential for carcinogenesis. These are shown in Figure 1-4. These hallmarks 
included acquiring growth signal autonomy, evasion of growth inhibitory signals, 
evasion of apoptosis, unlimited replicative potential, formation of new blood 
vessels and invasion and metastasis (Hanahan and Weinberg, 2000).  
 
Figure 1-4: Hallmarks of cancer 
Set of functional capabilities acquired by most of the cancer cells (Hanahan and 
Weinberg, 2000). 
 
Most of the agents that can cause cancer would usually cause alteration to 
DNA sequence ranging from point mutations to large chromosomal changes, 
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like chromosomal deletion or translocation. The abnormalities in genetic 
material can be caused by either carcinogens (e.g., tobacco smoke, radiation, 
chemicals, or infectious agents) or by random mutations during cell replication.  
The incidence of cancer has increased because we are living longer and with 
increasing age there is an increased chance of accumulating mutations, which 
could lead to carcinogenesis. 
 
In order to keep a check on the net number of cells, there are three important 
processes in place: First is cell proliferation, which includes both cell division 
and growth; second, programmed cell death or apoptosis; thirdly, cell 
differentiation. Any imbalance between cell growth, apoptosis or differentiation 
can lead to carcinogenesis. Two important gene groups that play pivotal roles in 
cell growth are oncogenes and tumour suppressor genes. Oncogenes (known 
as proto oncogenes in normal cells) have important roles in cell growth and 
hence a mutation of a proto-oncogene results in the up-regulation and 
increased production of proteins, driving cell division and growth (Vogt, 1993). 
Examples of oncogenes include the epidermal growth factor receptor, a tyrosine 
kinase receptor (Lurje and Lenz, 2009), the Myc gene, a transcription factor 
(Ruggero, 2009) and the GTPase, Ras (Bracquart et al., 2009). 
 
Tumour suppressor genes inhibit uncontrolled growth and multiplication. 
Hereditary syndromes that predispose individuals to cancer are caused by 
inheritance of germ line mutations of an allele and acquiring somatic mutations 
in a second allele later in life. This was first described by Knudson and is known 
as Knudson’s two-hit hypothesis. It describes a strict definition of tumour 
suppressor genes: genes in which a germ line mutation predisposes an 
individual to cancer (Knudson, 1971). P53 was the first tumour suppressor gene 
to be identified and it is mutated in about 50% of human tumours (Hollstein et 
al., 1991). P53 is at the heart of tumour suppressive mechanism and is also 
called “guardian of the genome”. It holds the cell in the G1 phase of the cell 
cycle so that the damaged DNA can be repaired and can even initiate apoptosis 
if the DNA cannot be repaired (Zilfou and Lowe, 2009). Other examples of 
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mutations in tumour suppressor genes include adenomatous polyposis coli 
(APC), which, when mutated, leads to an increased risk of colorectal cancer, 
and PTEN (phosphatase and tensin homolog on chromosome 10), which can 
act both as lipid and protein phosphatase. PTEN dephosphorylates 
phosphatidylinositol-3, 4, 5 trisphosphate (PIP3) to phosphatidylinositol 4, 5 
bisphosphate (PIP2), which antagonizes the PI-3 kinase pathway and inhibits 
cell proliferation (Chu and Tarnawski, 2004).   
 
Apart from being distributed in various tissues, sigma-2 binding sites are 
overexpressed in many cancer cell lines. Malignant cells express much higher 
density as compared to non-malignant cells of the same tissue (Aydar et al., 
2004).  In a study looking at sigma binding site expression in human brain 
tumours, Thomas et al. detected sigma receptors in 15 out of 16 cell lines 
examined. Very high densities of sigma-2 binding sites were found in brain 
metastasis from adenocarcinoma lung and in human neuroblastoma (Thomas 
et al., 1990). Sigma-2 binding sites were expressed in higher density as 
compared to sigma-1 receptor in renal and colorectal carcinoma (Bem et al., 
1991). Similarly, sigma-2 binding sites are overexpressed 1.5 to 4 times in high 
grade urothelial cancer as compared to low grade cancers (Colabufo et al., 
2006). In bovine high-grade cancer of urinary bladder sigma-2 binding site is 25 
to 44 times overexpressed whereas in low grade bladder cancers its only 3 to 5 
folds overexpressed (Roperto et al., 2010).  
 
1.6 Sigma-2 binding sites and their role in non-invasive 
imaging of cancer 
 
Sigma-2 binding site overexpression in various tumour cell lines and particularly 
in high grade tumours suggest that sigma receptor expression might be a 
biomarker of cellular proliferation and probably play an important role in tumour 
biology. 
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Given the fact that sigma 2 binding sites are found in high density in various 
cancer cell lines, the possibility of sigma ligands being used in diagnosis and 
treating cancer has been explored.  
 
The development of radiotracers for cancer imaging has been explored for 
more than two decades. The sigma receptor binding radiotracers have higher 
affinity for proliferating cells when compared to inflamed tissue and, hence, 
could be more sensitive and specific in providing information about a tumour’s 
proliferative status. Sigma ligands have been used in non-invasive imaging of 
the tumour using SPECT and PET. 
 
The first SPECT ligand IDAB for sigma receptor was developed in 1991 by 
Michelot et al. to image malignant melanoma (Michelot et al., 1993). For 
imaging purposes the compound was labelled with 123I. When used in mice 
bearing murine B16 melanoma, it showed a high tumour to muscle ratio, hence 
a phase II trial was conducted in 110 patients diagnosed with malignant 
melanoma using 123I-IDAB. The trial indicated that 123I-IDAB was useful in 
diagnosis of malignant melanoma (sensitivity 81% and specificity 100%) 
(Michelot et al., 1993). The same group carried out a follow up study for 48 
patients diagnosed with malignant melanoma and showed that IDAB 
scintigraphy could be used for staging malignant melanoma (Rodot et al., 1994). 
The results were not as encouraging when another study looked at IDAB 
scintigraphy in 26 patients with melanoma and non-small cell lung cancer: the 
sensitivity of the technique in melanoma was 64% and 22% for non-small cell 
lung cancer. Liver metastases from amelanotic melanoma were not detected 
(Everaert et al., 1997).  
 
For SPECT imaging the first sigma-2 specific SPECT ligands [(N-[2-((3’-
N’propyl-[3,3,1]aza-bicyclononan-3alpha-yl)(2”-methoxy-5-methyl-
phenylcarbamate)(2-mercaptoethyl)amino)acetyl]-2-aminoethanethiolato] 99mTc-
technetium (V) oxide, was reported in 2001 (Choi et al., 2001, Mach et al., 
2001). The non-radioactive surrogate bound preferentially to sigma-2 binding 
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sites and showed very little affinity to sigma-1 receptors. Biodistribution was 
studied in mice bearing a mouse mammary adenocarcinoma (cell line 66). 
Stereoselectivity of binding was significantly better for one of the enantiomers 
and tumour to muscle ratios reached a peak at 4 hours post-administration. 
Treatment with haloperidol (a mixed sigma-1 and sigma-2 binding site ligand) 
reduced the uptake of tracer by 30% and at 1 hour the tumour site only 
contained the parent compound.  It was postulated that breast tumours could be 
visualized provided a sigma-2 selective SPECT ligand was used, however 
increased uptake of the tracer in liver, kidney and bladder could potentially 
cause problems with interpreting the scan (Choi et al., 2001, Mach et al., 2001). 
 
Another radioiodinated sigma-2 ligand, 5-iodo-2,3-dimethoxy-N-[2-(6,7-
dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzamide, was developed by 
same authors and labelled with radioactive iodine (125I and 123I). The non-
radioactive bromide had high selectivity for sigma-2 binding sites and bound 
with high affinity. Biodistribution in mice carrying EMT6 cell lines (mouse 
mammary tumour) showed that tumour to muscle ratio of 7 was reached 2 
hours post-administration. Imaging hardly showed the tumour, suggesting that a 
high target to non-target ratio was required for successful microSPECT imaging 
(Hou et al., 2006).  
 
The tumour to muscle ratio is a scoring system developed for qualitative 
interpretation for PET imaging to grade the uptake in a tumour compared to 
adjacent normal tissue (Yeh et al., 1996). Hirata et al. prepared an iodinated 
analogue of SA4503, which had equal affinity to both sigma-1 receptors and 
sigma-2 binding sites. Different tumour cell lines were tested. Biodistribution 
studies in nude mouse bearing A375 (human melanoma cell line) showed that 
the tumour to muscle ratio of 7 was reached 24 hours post-administration. 
Lower values were achieved with neuroblastoma (SK-N-SH), cervical 
carcinoma (ME180) and glioma (C6) cells. There was good correlation between 
concentration of iodinated ligand and sigma-2 binding site density suggesting 
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that SPECT could be used to determine sigma-2 binding site density (Hirata et 
al., 2008).  
 
Radioiodinated vesamicol was tried as well and was found to have the best 
tumour to muscle ratio in mice bearing human prostate tumour (DU-145) cells. 
Once again increased uptake of radioactivity by kidneys and liver limited the 
interpretation of the scan (Ogawa et al., 2009). 
 
Research on developing sigma labelled ligands for PET imaging started in 1990 
with the aim of better understanding and mechanisms underlying movement 
disorders and mental health problems. Because of overexpression of sigma-2 
binding sites in various tumour cell lines the research was also directed to see if 
such radiotracers could be used in diagnosing cancer with the help of PET.  
 
Several ligands labelled with positron emitters were tested for imaging of sigma 
receptors in various tumour cell lines. One of the initial ligands with good results 
was 18F-1-(3-Fluoropropyl)-4-(4-cyanophenoxy-methyl) piperidine (FPS). It had 
subnanomolar affinity for sigma-1 receptor. In nude mouse harbouring B16 
melanoma tumour cells, the tracer achieved tumour/blood ratio of 124 and a 
tumour muscle ratio of greater than 7 at 4 hours post-administration 
(Waterhouse and Collier, 1997). After initial animal studies it was found to be 
safe in humans (Waterhouse et al., 2003).  
 
Radiotracers with high affinity for sigma-2 binding sites have also been 
developed. Cyclohexyl piperidine was labelled with 11C and tested in animals. 
PB167 known to have high affinity for sigma-2 binding sites was labelled with 
methoxy group but unfortunately there was no difference in uptake between 
normal tissue and the tumour (Abate et al., 2009, Colabufo et al., 2005, 
Colabufo et al., 2006). 11C-PB28 has been trialled in healthy mice and was 
found to be not suitable for sigma-2 binding site imaging since it could not be 
blocked with unlabelled PB28 (Kassiou et al., 2005). 
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Mach et al. prepared 4 11C labelled ligands with high affinity for the sigma-2 
binding site and tested them in mice bearing EMT6 breast tumours. One of the 
radiotracer achieved tumour to muscle ratio of 3 at 30 minutes post 
administration (Tu et al., 2005).  
 
5-76Br-bromo-N(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-2,3-
dimethoxybenzamide, a radiobrominated radiotracer with high affinity for sigma-
2 binding sites, was tested with good results. In mice bearing EMT6 tumours, 
tumour to muscle ratio of 10 was achieved at 4 hours after administration. Prior 
administration of a non-radioactive sigma ligand significantly reduced the 
tumour to muscle ratio from 8.6 to 3.6 at 2 hours. This radiotracer could not be 
used to image liver due to its high uptake. However, it was found to be suitable 
to image tumours in lung, head and neck or lower abdomen (Rowland et al., 
2006). 
 
Four benzamide analogues labelled with 18F were also evaluated for tumour 
imaging. These compounds had higher affinity for sigma-2 binding sites. One of 
the compounds showed activity almost similar to radiobrominated compound 
(Tu et al., 2007). 18F-WC-59, a radiolabelled azabicyclononane with sub 
nanomolar affinity and high selectivity for sigma-2 binding sites produced 
tumour to muscle ratio of maximally 2.5 when used in EMT6 tumour-bearing 
mice (Chu et al., 2009). In view of poor tumour to muscle ratio it could not be 
used in PET imaging.  
 
Over a period of time sigma-2 binding site-selective PET ligands have been 
developed showing some range of activity and application in tumour imaging. 
Since sigma-2 binding sites are overexpressed in most of the tumours from 
various tissues, sigma-2 labelled PET ligands seem to be the obvious choice for 
further research in search of ideal ligands in PET imaging of tumours.  
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1.7 Sigma-2 binding sites and apoptosis in tumour cells 
 
Apoptosis, or programme cell death, plays an important role in controlling the 
net number of cells and getting rid of damaged cells, and hence plays an 
important role in preventing carcinogenesis. Apoptosis can be initiated by 
extracellular signals, called “death factors” or intracellular changes due to 
damage to DNA, oxidative stress or calcium influx into the cytoplasm or 
released from the endoplasmic reticulum (Mattson and Chan, 2003).  
 
Extracellular signals activate the extrinsic pathway whereas intracellular 
changes activate the intrinsic pathway. The extrinsic pathway is activated by 
death signals (TNF or Fas ligand). Binding of these ligands to death receptors 
results in a conformational change of the receptor, which leads to activation of 
adaptor proteins.  Adaptor proteins cause aggregation of procaspase-8, a 
zymogen which is cleaved to form active caspase-8, which further activates the 
caspase cascade causing proteolysis and apoptosis (Wajant, 2002). 
 
The intrinsic pathway is activated by cellular stress, which activates Bax protein. 
Bax undergoes a conformational change and inserts into the outer 
mitochondrial membrane. Important regulators are released from the 
intermembrane space (Almonte-Becerril et al., 2010). Caspase-9 is activated 
which results in the caspase cascade and apoptosis. 
 
The role of the sigma-2 binding site in regulation of cell proliferation and cell 
viability has been extensively studied and cytotoxic effects of sigma ligands 
observed both in vivo and in vitro (Vilner and Bowen, 1993, Vilner et al., 1995a). 
Ligands with high affinity for the sigma-2 binding site exhibit cytotoxicity (Bowen 
et al., 1995) whereas other ligands with affinity for sigma-1 receptors or ion 
channels do not induce these cytotoxic effects on the cells. Cytotoxic effects are 
dose dependant with higher doses leading to death occurring in a shorter time.  
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Sigma-2 binding site ligands induce death by apoptosis (Crawford and Bowen, 
2002, Vilner et al., 1995a). 
 
Sigma-2 binding sites are thought to play an important role in cell survival and 
morphology (Guitart et al., 2004, Vilner et al., 1995a). It is believed that sigma-2 
binding site agonists stop tumour cell proliferation by inducing apoptosis 
whereas sigma-2 binding site antagonists promote tumour survival (Waarde et 
al 2010). Vilner et al., whilst working with C6 glioma cells, found that sigma 
ligands affected the cell morphology and caused death by inhibiting cell division 
(Vilner and Bowen, 1993, Vilner et al., 1995a). They showed a correlation 
between affinity of the drugs to the sigma-2 binding site and degree of inhibition 
of tumour cell growth. Kashiwage et al. showed that sigma-2 binding site 
ligands induced apoptosis by activating caspase-3, where sigma-1 receptor 
ligands did not have this effect (Kashiwagi et al., 2007), although Spruce had 
previously shown that the effects of rimcazole, a mixed sigma-1 antagonist and 
sigma-2 agonist, on caspase-3 activation were reversed by the sigma-1 
selective agonists SKF 10047 and (+) pentazocine (Spruce et al., 2004).   
 
By measuring the DNA fragmentation, annexin V and chromatin condensation, 
Hornick et al. showed that there was a correlation between apoptosis and 
affinities of sigma-2 binding site ligands (Hornick et al., 2010). Sigma-2 ligands 
CB-64D and CB-184 caused inhibition of tumour cell growth and apoptosis in 
both drug sensitive tumour cell lines MCF7 and drug resistant tumour cell lines 
such as MCF7/Adr, SKBr3 and T47D (Brent et al., 1996, Brent and Pang, 1995, 
Crawford and Bowen, 2002). Siramesine, a highly selective sigma-2 binding site 
ligand caused apoptosis in various tumour lines tested derived from breast, 
cervix, lung, prostate and connective tissue. It was particularly active against 
fibrosarcoma and breast carcinoma grafts in mice (Groth-Pedersen et al., 2007, 
Ostenfeld et al., 2005).  
 
The ability of sigma-2 ligands to induce apoptosis led to further investigation of 
downstream signalling pathways of sigma-2 binding sites. We know that 
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calcium plays a vital role in cytotoxicity and alteration in intracellular calcium 
levels can induce apoptosis in various cell lines (McConkey and Orrenius, 1996, 
Nicotera and Orrenius, 1998).  The role of calcium in apoptosis is shown in 
Figure 1-5. 
 
 
Figure 1-5: The role of calcium and cytochrome C in cellular apoptosis 
(Mattson and Chan, 2003).  
Cytochrome C release from the mitochondria can be activated by an increase in 
cytoplasmic calcium, caused by either calcium entry through channels at the 
plasma membrane or via release form intracellular stores by InsP3. 
 
Experiments using sigma-2 ligands showed both transient increase in 
intracellular calcium, which returned to baseline in about 8 minutes and a latent 
and more sustained rise in calcium levels. It was suggested that the transient 
rise results from calcium release from the endoplasmic reticulum and the latent 
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rise is due to release of calcium from mitochondrial stores (Vilner and Bowen, 
2000). 
 
Caspase inhibitors were found to block apoptosis induced by DNA damaging 
agents in wild type MCF7 cells, caspase inhibitors had little or no effect on 
sigma-2 ligand-related apoptosis (Crawford and Bowen, 2002). The rise in 
intracellular calcium levels caused by sigma-2 binding site ligands is possibly 
the mechanism by which these ligands induce apoptosis.  
 
1.8 Sigma-2 binding site ligands 
 
Sigma receptors were initially classified as a subtype of opioid receptors based 
on their affinity for benzomorphans like SKF 10047. Further studies confirmed 
that opioid receptors had high affinity for (-) SKF 10047 and sigma receptors 
had high affinity for (+) SKF 10047, hence classified as a distinct class of 
receptors (Khazan et al., 1984, Martin et al., 1976, Vaupel, 1983, Wong et al., 
1988). Binding studies with [3H] DTG revealed two subtypes of sigma receptors 
and sigma-1 receptor having higher affinity for (+) SKF 10047 (Hellewell and 
Bowen, 1990, Hellewell et al., 1994). In early 1990’s many derivatives of 
piperidine, pyrrolidine, dialkylamine and trialkylamine were developed which 
could bind to sigma receptors with high affinity (Berardi et al., 2009, Huang et 
al., 2001a, Narayanan et al., 2011, Newman et al., 2001). As a result of 
improvement in binding assays, new ligands with higher affinity for the sigma-2 
binding site were developed. Sigma-2 binding site ligands have been classified 
into four classes based on their structure.  
 
1. 6,7-dimethoxytetrahydroisoquinoline derivatives,  
2. Tropane related bicyclic structures,  
3. Siramesine related indole derivatives and  
4. Cyclohexylpiperazine analogues.  
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There is also a small group of ligands, which are structurally not related to any 
of the four classes.  
 
1.8.1 6,7-dimethoxytetrahydroisoquinoline derivatives 
 
Towards the late 1990’s whilst developing new amides for dopamine receptors, 
a series of piperidine and pyrrolidine derivatives were found to have high affinity 
for sigma receptors (Huang et al., 1998, Huang et al., 2001b, Mach et al., 2005, 
Mach et al., 2001, Mach et al., 2003). Further research was carried out to find 
ligands with high affinity for sigma-2 binding sites to be used in cancer imaging. 
A series of benzamides and carbamates were discovered which were found to 
have significantly high affinity for sigma-2 binding sites. A number of 
compounds from this family have been analysed to see if they could be used for 
PET imaging of cancer (Mach and Wheeler, 2009, Narayanan et al., 2011, 
Zeng et al., 2011). Some of the compounds from this family are shown in Table 
1-1. 
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No Name Structure sigma-1  
Ki (nM) 
sigma-2  
Ki (nM) 
 
1 
 
yun179 
 
 
>1000 
 
25.8 
 
2 
 
yun201 
 
 
189.1 
 
21.1 
 
3 
 
yun204 
 
 
1159 
 
17.6 
 
4 
 
yun234 
 
 
5484 
 
12.4 
 
5 
 
yun236 
 
 
2932 
 
16.3 
 
6 
 
yun242 
 
 
10412 
 
13.3 
 
7 
 
yun243 
 
 
3078 
 
10.3 
 
8 
 
 
 
534 
 
2.63 
 
Table 1-1: Sigma-2 binding site-selective 6,7-Dimethoxytetrahydroisoquinoline 
analogue ligands 
Adapted from (Huang et al., 2014). 
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1.8.2 Tropane and Granatane derivatives 
 
Since benzomorphan-based ligands had affinity for sigma receptors, this 
structure became the lead compound for further development of sigma ligands. 
Bowen et al. developed two of the well-known sigma-2 binding site ligands, CB-
64 D and CB-184 (Bertha et al., 1994, Bertha et al., 1995, Bowen et al., 1995). 
BIMU-1, another high affinity sigma-2 binding site ligand was used by many 
researchers to develop further sigma-2 binding site ligands.  
 
A number of compounds from this family have been developed into fluorescent 
sigma-2 binding site ligands and used in tumour imaging and assessment of 
cancer cell proliferation (Chu et al., 2009). Some of the compounds from this 
family with their affinities for both sigma-1 and sigma-2 binding site are shown 
in Table 1-2. 
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No Name Structure sigma-1 
Ki (nM) 
sigma-2 
Ki (nM) 
 
1 
 
BIMU-1 
 
 
6300 
 
32 
 
2 
 
()SM21 
 
 
>1000 
 
67.5 
 
3 
 
RHM-138 
 
 
544 
 
12.3 
 
4 
 
CB-64D 
 
 
3063 
 
16.5 
 
5 
 
CB-184 
 
 
7436 
 
13.5 
 
6 
 
ABN-1 
 
 
92.5 
 
10.5 
 
7 
 
yun245 
 
 
2250 
 
5.0 
 
8 
 
yun253 
 
 
162.5 
 
10.5 
 
Table 1-2: Sigma-2 binding site-selective granatane or tropane analogue 
ligands 
Adapted from (Huang et al., 2014). 
 
 
 
Chapter 1. Introduction 
 
 41 
1.8.3 Indole derivatives 
 
Indole is an aromatic heterocyclic organic compound with formula C8H7N. It has 
a bicyclic ring fused to a five membered nitrogen containing a pyrrole ring. 
Siramesine, an indole derivative (Moltzen et al., 1995, Perregaard et al., 1995, 
Soby et al., 2002) and one of the best known sigma-2 binding site ligands, was 
initially developed for treatment of anxiety and depression. Siramesine has 
been extensively studied and found to induce apoptosis in cancer cell lines both 
in vitro and in vivo (Jonhede et al., 2010, Ostenfeld et al., 2005). A number of 
siramesine analogues were derived by modifying the spiropiperidine structure. 
Some of these compound have been investigated in PET imaging. Some of the 
compounds from this family are shown in Table 1-3. 
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No Name Structure sigma-1 
Ki (nM) 
sigma-2 
Ki (nM) 
 
1 
 
Siramesine 
 
 
17 
 
0.12 
 
2 
 
 
 
 
290 
 
1.8 
 
3 
 
 
 
 
5.5 
 
0.3 
 
4 
 
 
 
 
150 
 
0.58 
 
5 
 
 
 
 
180 
 
2.6 
 
6 
 
 
 
 
23 
 
1.1 
 
7 
 
 
 
 
53 
 
0.9 
 
8 
 
 
 
5.7 
 
0.21 
 
Table 1-3: Sigma-2 binding site-selective indole analogue ligands 
Adapted from (Huang et al., 2014). 
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1.8.4 Cyclohexylpiperazine derivatives 
 
Cyclohexylpiperazine and cyclohexylpiperadines are the most extensively 
studied analogues for sigma receptors (Berardi et al., 2009, Huang et al., 1998, 
Huang et al., 2001a, Mir et al., 2012). Derivatives in this group are usually non-
selective for sigma receptors. PB28 is one of the most widely reported sigma-2 
binding site ligands, which shows 40-fold selectivity for the sigma-2 binding site. 
Some of the compounds are shown in Table 1-4. 
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No Name Structure sigma-1  
Ki (nM) 
sigma-2 
Ki (nM) 
 
1 
 
PB28 
 
 
13.6 
 
0.34 
 
2 
 
F281 
 
 
3450 
 
12.6 
 
3 
 
 
 
 
94.6 
 
5.92 
 
4 
 
 
 
 
78.7 
 
10.8 
 
5 
 
 
 
4.1 
 
0.3 
 
6 
 
 
 
158 
 
20.5 
 
7 
 
 
 
4162 
 
43.6 
 
8 
 
 
 
808 
 
64.4 
 
Table 1-4: Sigma-2 binding site-selective cyclohexylpiperazine analogue 
ligands. 
Adapted from (Huang et al., 2014). 
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1.8.5 Miscellaneous compounds with high affinity for sigma-2 binding 
sites 
 
In addition to the compounds mentioned above, there are some more sigma-2 
selective ligands, which are structurally unrelated to any of the four groups 
discussed earlier. It is interesting to note that some of these compounds have 
very simple structures and yet have very high affinity and selectivity for sigma-2 
binding sites as shown in Table1-5.  
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No Name Structure sigma-1  
Ki (nM) 
sigma-2 
Ki (nM) 
 
1 
 
yun202 
 
 
69.1 
 
4.8 
 
2 
 
yun209 
 
 
1499 
 
25.1 
 
3 
 
yun210 
 
 
231 
 
10 
 
4 
 
yun212 
 
 
534 
 
2.63 
 
5 
 
yun250 
 
 
809 
 
75.0 
 
6 
 
yun251 
 
 
751 
 
26.3 
 
7 
 
 
 
 
10320 
 
26.8 
 
8 
 
 
 
>10000 
 
39 
 
Table 1-5: Sigma-2 binding site-selective ligands - miscellaneous 
structures 
Adapted from (Huang et al., 2014). 
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1.9 The Sigma-2 binding site ligand pharmacophore 
 
As mentioned in the above section, a number of high-affinity sigma-2 binding 
site ligands have been developed, but still the exact binding requirement for 
sigma-2 binding sites has not been described. One of the main hurdles is 
probably the fact that the sigma-2 binding site has not been cloned yet. Several 
models for binding of ligands to the sigma-2 binding site have been proposed 
and each is based on a limited set of ligands. One such model was proposed by 
Huang et al. (Huang et al., 1998) based on phenylacetamides, a series of non-
selective ligands. This model proposed that hydrophobic and bulky substituents 
on aromatic ring of phenylacetamides were more favourable for sigma-2 binding.  
  
Cratteri et al. proposed a sigma-2 binding site pharmacophore based on 
tropane derivatives. According to this model, there was a shorter distance 
between the primary and secondary hydrophobic binding domains and a longer 
distance between the hydrogen bond donor and primary hydrophobic binding 
pocket as compared to the sigma-1 receptor pharmacophore (Cratteri et al., 
2004). Glennon et al. proposed a pharmacophore based on binding properties 
of piperidines, piperizines, long chain amines and long chain trialkylamines. 
According to Glennon et al., for a ligand to bind to sigma-2 binding site, it 
should have an amine site and two hydrophobic sites (Glennon, 2005). This 
group also conducted a 3D-QSAR study on PB28 and related 
cyclohexylpiperazines (Abate et al., 2009). A more recent binding model was 
proposed by Laurini et al. This binding model was based on 19 benzoxazolone 
derivatives (Laurini et al., 2010). According to this model, the sigma-2 binding 
site consists of an ionisable atom (PI), a hydrogen bond acceptor group (HBA), 
a hydrophobic aromatic site (HYAr), a hydrophobic aliphatic site (HYAI) and a 
generic hydrophobic site (HTY). HYAI was required for high sigma-2 affinity.  
Based on the structures of sigma-2 ligands, Huang et al. proposed a 
hypothetical sigma-2 binding model as shown in Figure 1-6. 
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Figure 1-6: Hypothetical sigma-2 binding site binding model 
This sigma-2 binding model consists of an electrostatic of hydrogen bond, a 
large hydrophobic binding pocket, a small hydrophobic binding pocket and an 
additional hydrophobic binding site (Huang et al., 2014). 
 
Huang et al. (Huang et al., 2014) also summarised the binding profile of the 
sigma-2 binding site ligands as follows: 
 
Ligands with high affinity for sigma-2 binding sites contain a basic nitrogen and 
a hydrophobic moiety. Additional hydrophobic moieties are not needed but it 
increases sigma-2 binding site affinity and selectivity. A bulky hydrophobic 
moiety increases sigma-2 binding site binding. 
 
The basic nitrogen may be quaternised in physiological conditions to interact 
with a carboxylic group of the receptor and a secondary nitrogen, which is four 
or more carbon units apart; this may increase sigma-2 binding site binding 
(Glennon, 2005). 
 
1.10 Sigma-2 binding sites and lipid rafts 
 
Until the molecular identity of the sigma-2 binding site is established, our ability 
to determine its subcellular location and trafficking around the cell are severely 
hindered. Some attempts have been made in determining some characteristics. 
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Using liver extracts, Torrence-Campbell and Bowen showed that sigma-2 
binding sites were resistant to solubilisation with detergents like 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) or Triton X-
100, suggesting they are located in lipid rafts (Torrence-Campbell and Bowen, 
1996). Sucrose gradient purification and co-localisation with flotillin-2 further 
confirmed the association with these lipid rafts (Gebreselassie and Bowen, 
2004). 
 
According to fluid mosaic model proposed by Singer and Nicholson, the cell 
membrane is composed of a phospholipid bilayer and membrane proteins, 
which give structure to the membrane (Singer and Nicolson, 1972). The plasma 
membrane contains micro domains, called lipid rafts, which are enriched with 
cholesterol, sphingolipids such as sphingomyelin and 
glycosylphosphatidylinositol (GPI)-linked proteins (Brown and London, 1998, 
Brown and London, 2000, Dobrowsky, 2000, Edidin, 2003, Simons and Ikonen, 
1997). Lipid rafts can incorporate the cholesterol binding protein called caveolin 
and form specialised structure called caveolae (Brown and London, 1998, 
Dobrowsky, 2000). Lipid raft domains are resistant to solubilisation by 
detergents such as Triton X-100 and CHAPS and hence can be isolated using 
sucrose density gradient centrifugation techniques. Lipid rafts are believed to 
play a number of important roles such as cell signalling, membrane trafficking, 
molecular sorting and cell signal transduction of receptors (Brown and Rose, 
1992, Dobrowsky, 2000, Fiedler et al., 1993, Ikonen, 2001, Nguyen and Hildreth, 
2000, Oliferenko et al., 1999, Palestini et al., 2000, Rodgers and Rose, 1996, 
Veri et al., 2001, von Haller et al., 2001). Lipid rafts are also involved in cellular 
differentiation and programmed cell death (apoptosis) (Galbiati et al., 2001, 
Zhang et al., 2010). The distribution of the lipid raft over the cell membrane 
differs depending on the cell type, for example lipid rafts are more abundant on 
somal and axonal membranes than on dendritic membranes (Suzuki, 2002). 
Sphingolipid metabolism has been shown to involved in cell growth (Kolesnick 
and Kronke, 1998). Bowen et al. had demonstrated that treatment of breast 
cancer cell lines and neuroblastoma cell resulted in increase in ceramide and 
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sphingosylphosphorylcholine, with concomitant decrease in sphingomyelin 
(Bowen, 2001, Crawford et al., 2002).  
 
The fact that sigma-2 binding sites are overexpressed in tumour cell lines and 
also plays important role in cell growth and proliferation suggests that it can 
induce sphingolipid-dependant apoptosis. 
 
These findings would place the sigma-2 binding site in the inner leaflet of the 
plasma membrane. 
 
Using a different approach, Zeng et al., used fluorescently labelled sigma-2 
ligands and monitored their location (Zeng et al., 2011). The first, SW107, co-
localised with the plasma membrane marker FM 1-43FX, whereas the location 
of the second, K05-138, was less clear, colocalising with markers for the 
mitochondria, lysosomes, endoplasmic reticulum, and possibly, plasma 
membrane. Such differences could be accounted for by agents stimulating 
trafficking of the receptor, or the drugs in isolation. 
 
1.11 Sigma-2 binding sites and PGRMC1 
 
PGRMC1 (progesterone receptor membrane component 1) is a heme-binding 
protein, related to cytoplasmic cytochrome b5 domain. Its molecular weight 
ranges between 22 and 28kDa (Cahill, 2007, Peluso et al., 2012a, Peluso et al., 
2012b). PGRMC1 is overexpressed in certain cancers like colorectal, breast, 
thyroid and lung (Rohe et al., 2009), and is required for cancer growth, 
proliferation and metastasis (Ahmed et al., 2010). AG-205, an antagonist of 
PGRMC1 inhibits ERK1/2 pathway and hence reduces cancer cell proliferation. 
Due to similarities between PGRMC1 and the sigma-2 binding site, Mach et al. 
conducted experiments and showed that WC-21, a fluorescent highly selective 
sigma-2 ligand, cross-linked with a protein that showed sequence  homology 
with PGRMC1, and also that cells with increased PGRMC1 expression had high 
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sigma-2 binding, while cells with decreased PGRMC1 levels showed reduced 
sigma-2 binding. Based on these conclusions, they suggested that the sigma-2 
binding site was likely to be PGRMC1 (Xu et al., 2011).  They also managed to 
show that anti-PGRMC1 antibody and SW120 (a fluorescent sigma-2 ligand) 
labelled the same intracellular sites under confocal microscopy. 
 
Despite these above findings, several questions remain to be answered. For 
example, the molecular weight of the sigma-2 binding site is around 21.5kDa 
(Hellewell et al., 1994, Wheeler et al., 2000) whereas PGRMC1 has a molecular 
weight of 22 to 28kDa (Cahill, 2007, Peluso et al., 2012a, Peluso et al., 2012b), 
PGRMC1 ligands do not seem to bind the sigma-2 binding site and similarly 
sigma-2 binding site ligands do not seem to bind to PGRMC1. PGRMC1 can 
bind to p450 but sigma-2 binding sites do not (Rohe et al., 2009). 
 
It has also been found that inhibition of PGRMC1 by AG-205 reduced tumour 
proliferation whereas inhibition of the sigma-2 binding site by antagonists 
stimulated tumour proliferation and activation of the sigma-2 binding site by 
agonists caused apoptosis (Jonhede et al., 2010, van Waarde et al., 2010). It is 
worth mentioning that the definitions of agonist and antagonist in this context 
are not clear and not universally accepted. 
 
1.12 Aim of my thesis 
 
The proposed pharmacophore of the sigma-2 binding site has been based on 
original opioid receptor ligands and further developed after identification of 
agents like DTG, which often contain more than 1 nitrogen and have complex 
aromatic ring structures. A number of studies looking for structure-activity 
relationships between ligands and the sigma-2 binding site have been carried 
out earlier (Ablordeppey et al., 2000, Ablordeppey et al., 2002, Glennon, 2005, 
Glennon et al., 1994, Glennon et al., 1991a, Glennon et al., 1991b, Glennon et 
al., 1991c). Almost all the studies looked at complex structures and therefore 
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did not come up with simple sigma-2 ligands. Earlier work from this laboratory 
(Brimson, 2010) has shown that ligands with much more simple structures had 
high affinity for the sigma-1 receptor and were more selective than some 
commercially available ligands. In this thesis, I have assessed the affinity of 
these same simple ligands for the sigma-2 binding site in order to reduce the 
complexity of the sigma-2 binding site pharmacophore. In addition, I have used 
these simple drugs alongside commercially available drugs to understand the 
pharmacology of the sigma-2 binding site. Furthermore based on the activity of 
ligands I have tried to define agonist and antagonist. 
 
I also wished to determine whether the source of the tumour cell being treated 
would affect the outcome of sigma-2 agonist treatment. To this end, I have 
screened a number of cell lines from a number of different sources. All but one 
(MCF7) also contained sigma-1 receptors, restricting my attempts to determine 
this outcome. During these studies, I have also established a novel protocol for 
assessing sigma-1 receptor and sigma-2 binding site content in cell lines and  
tissues. 
Chapter 2. Materials and methods 
 
 53 
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2.1 General Materials 
 
General laboratory chemicals were purchased from Sigma Aldrich Company Ltd 
(Dorset UK). Tissue culture media, trypsin and Foetal Bovine Serum (FBS) 
were purchased from Gibco. Ninety six-well plates and tissue culture flasks 
were purchased from Fisher Scientific (Loughborough, Leicestershire, UK) 
 
2.2 Tissue Culture 
 
A range of cancer cell lines were used in these studies. These include 
oesophageal: OE21, OE33 and FLO-1; breast: MCF7 and MDA-MB-468;  
colorectal: Caco-2, SW480, HT-29 and HCT 116; human embryonic kidney: 
293; and lung: A549. MCF7 cells were chosen as they are reported to not 
express sigma-1 receptors (Vilner et al., 1995b), whereas MDA-MB-468 cells, 
which are also a breast cancer cell line have been widely used to study the 
sigma-1 receptor (Spruce et al., 2004) (Brimson, 2010). Other cell lines were 
used as their sigma-1 and sigma-2 status was unknown or required verifying. 
They were tested in order to seek out cell lines that lacked sigma-2 binding 
sites and could, therefore, be used as negative controls for later studies. 
A549, MDA-MB-468, 293, MCF7, FLO-1 and HCT 116 cells were grown in 
Dulbecco Modified Eagle’s minimum essential medium (DMEM),(Gibco, 
#41965). SW480 cells were grown Leibovitz’s L-15 medium (Gibco, #11415), 
Caco-2 cells were grown in minimum essential medium (Gibco, #32360), HT-29 
cells were grown in McCoys’s 5a medium (Gibco, #26600). OE21 and OE33 
were grown in RPMI 1640 medium (Gibco, #21875). All of the above growth 
media were supplemented with 1% L-glutamine and 10% heat inactivated FBS 
(Gibco, #10500). The cells were incubated at 37°C in a humidified air and 5% 
CO2 atmosphere. All the cell lines used in these studies were adherent, as such, 
they were propagated in monolayers. 
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2.3 Cell propagation and storage 
 
Handling of cells was performed in a Class II biological safety cabinet, which 
had been switched on at least 15 minutes prior to use. All surfaces were wiped 
clean with a solution consisting of 70% ethanol in water and allowed to air dry. 
Single-use pipettes and tissue culture consumables were handled in this clean 
environment using aseptic technique. Cell morphology and confluency were 
observed using an inverted phase contrast microscope (Olympus CK2-TR).  
 
When cells reached 80% confluency, they were harvested using 0.25% w/v 
trypsin 0.91mM EDTA (Gibco, #25200) (typically, 5ml was used for a 175cm2 
tissue culture flask) and incubated at 37°C until the cells had detached from the 
flask. An equal volume of pre-warmed medium containing 1% L-glutamine and 
10% FBS was added before transferring to new tissue culture flasks containing 
required volume of tissue culture medium. The FBS in the medium acted as a 
trypsin inhibitor. In practice, cells were routinely split once a week, with a split 
ratio of 1:5 or 1:10, depending on the growth characteristics of each cell line 
and in line with the suppliers. Medium was exchanged after 3 and 6 days. 
 
When freezing the cells down for storage, the trypsinized cells were transferred 
to a sterile centrifuge tube and centrifuged at 500g for 1 minute. The pellet was 
resuspended in freezing mixture (90% DMSO and 10% culture medium) and 
transferred to 2ml cryogenic vials. The cells were chilled slowly to 4°C before 
being placed at -20°C overnight. The following day the vials were transferred to 
-80°C ultra freezer for long-term storage. 
 
When thawing the cells, the vials were taken from -80°C freezer and placed into 
a 37°C water bath to thaw rapidly. Once thawed the contents of the vials were 
transferred to a tissue culture flask containing growth medium, pre-warmed to 
37°C in humidified air incubator with 5% CO2. The flasks were incubated 
overnight and the following day the medium was changed to remove all cells 
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that failed to adhere to the flask; this also allowed much of the DMSO to be 
removed from the culture medium. Cells were then allowed to grow to 80% 
confluency, harvested and again grown to 80% confluency before being used in 
experiments. 
 
2.4 General Ligand preparation 
 
The simple amines were purchased from Sigma Aldrich (Dorset UK), Fluka 
(Sigma-Aldrich, Dorset, UK) or Arcos Organics (Fisher Scientific, Loughborough, 
UK) as either Hydrochloride Salts (HCl) or as a free base 
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Name Salt/Base Vender Chemical 
formula 
Structure 
Primary amines 
 
Propylammonium Free base Fluka C3H9N  
Butylammonium Free base Fluka C4H11N 
 
Pentylammonium Free base Fluka C5H13N 
 
Hexylammonium Free base Fluka C6H15N    
Branched-chain Primary amines 
 
1-Adamantly 
ammonium 
Free base Sigma 
Aldrich 
C10H17N NH2
 
2-Adamantly 
ammonium 
HCl•  Sigma 
Aldrich 
C10H17N NH2
 
Secondary amines 
 
Dimethylammonium HCl•  Sigma 
Aldrich  
C2H7N 
 
Diethylammonium HCl•  Sigma 
Aldrich 
C4H11N 
 
Dipropylammonium HCl•  Sigma 
Aldrich 
C6H15N 
 
Dibutylammonium Free base Sigma 
Aldrich 
C8H19N 
 
Dipentylammonium Free base Sigma 
Aldrich 
C10H23N 
 
Dihexylammonium Free base Sigma 
Aldrich 
C12H27N 
 
Branched chain Secondary amines 
 
Diisopropyl 
ammonium 
Free base Sigma 
Aldrich 
C6H15N 
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Diisobutylammonium HCl•  Sigma 
Aldrich 
C8H19N 
 
Bis-2-(ethyl)hexyl 
ammonium 
Free base Sigma 
Aldrich 
C16H35N 
 
Di-sec-butyl 
ammonium 
Free base Sigma 
Aldrich 
C8H19N 
 
Tertiary amines 
 
Trimethylammonium HCl•  Fluka C3H9N  
 
 
Triethylammonium  HCl•  Fluka C6H15N 
 
Tripropylammonium HCl•  Sigma 
Aldrich 
C9H21N 
 
 
Tributylammonium 
 
 
 
HCl•  Fluka C12H27N 
 
Tripentylammonium Free base  Sigma 
Aldrich 
C15H33N 
 
Trihexylammonium Free base Sigma 
Aldrich 
C18H39H 
 
Trioctylammonium Free base Sigma 
Aldrich 
C24H51N 
 
Tridodecylammonium 
 
 
 
Free base Sigma 
Aldrich 
C36H75N 
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Branched-chain tertiary amines 
 
Triisopentyl 
ammonium 
Free base Fluka  C15H33N 
 
                          Quaternary amines 
 
 
Tetramethyl 
ammonium 
HCl•  Acros 
Organic
s 
C4H12N 
N
+
 
Tetraethylammonium HCl•  Sigma 
Aldrich 
C8H20N 
N
+
 
Tetrapropyl 
ammonium 
HCl•  Acros 
Organic
s  
C12H28N 
N
+
 
Tetrabutylammonium HCl•  Sigma 
Aldrich 
C16H36N 
N
+
 
 
Table 2-1: Simple amine structure, salt and where it was purchased. 
 
The free base amines were made soluble in water by making HCl salt. 5ml of  
free base amine was dissolved in 15ml of ether, and hydrochloric acid (HCl) 
was added slowly until the mixture turned acidic, measured using universal 
indicator paper (Sigma-Aldrich, Dorset UK). The formed solid was filtered and 
the remaining solvent was removed under vacuum. If the solid did not come out 
of solution the solvents were removed under vacuum. 
 
2.5 General Radioligand binding 
Cells were harvested prior to the experiments using 0.25% trypsin 1mM EDTA 
and stored at -20°C. On the day of experimentation, cells were thawed and 
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resuspended in Tris-buffered saline (TBS) (50mM Tris HCl pH 8.5). The cells 
were sonicated using six 5 second pulses separated by a 5 second pause using 
a sonicating probe. The output was adjusted to permit cavitation of the 
suspension, optimising cell disruption. Membranes were harvested by 
centrifugation at 4°C and 2000g for 15 minute. The supernatant was discarded 
and the pellet was resuspended in TBS. Assays were performed at room 
temperature in 4ml polystyrene tubes. 
 
2.5.1 Saturation binding assays 
2.5.2 Pentazocine 
[3H] (+) Pentazocine was prepared at a concentration of 1024nM 
(approximately, exact concentration was determined by counting a sample and 
using specific activity calculations for each experiment). Serial 1:1 dilutions 
were prepared to give concentrations of approximately (see above) 512, 256, 
128, 64, 32 and 16nM. These concentrations were selected as they bracket the 
Kd of (+) pentazocine previously published for the sigma-1 receptor (17nM) 
(Brimson et al., 2011). Ten μl were added to the tubes, with a final volume of 
100μl consisting of membranes (exact amount of protein was calculated for 
individual experiments using the “Bradford” assay as explained later in this 
chapter), and, where appropriate, 10µl of 10mM haloperidol to determine non-
specific binding. The amount of protein added was optimized for each cell line 
to permit a high signal-to-noise ratio while preventing ligand depletion. In order 
to standardize this, conditions were chosen where no more than 10% of the 
radioligand was bound to the membranes. Assays were permitted to incubate at 
room temperature for 4 hours (time required to reach equilibrium) before the 
separation of bound from free ligand. After equilibration, the membranes were 
harvested using a vacuum filtration manifold (Millipore) through GF/C glass fibre 
filters, washing two times with 3ml ice-cold wash buffer (10mM Tris HCl 150mM 
NaCl, pH 7.4). The glass fibre filter containing the cell membranes bound to the 
radioligand were placed in scintillation vials with 2ml of scintillant (Optiphase, 
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Fisher Scientific). The glass fibre filters were allowed to soak overnight before 
counting in a Perkin Elmer Liquid scintillation analyzer Tricarb 2800TR (5 
minute counts). 
 
2.5.3 DTG 
[3H] DTG was prepared at a concentration of 2056nM approximately (exact 
concentration was determined by counting a sample and using specific activity 
calculations for each experiment). Serial 1:1 dilutions were prepared to give 
concentrations of approximately (see above) 1024, 512, 256, 128, 64, 32 and 
16nM. These concentrations were selected as they bracket the Kd of DTG 
previously published for the sigma-1 receptor and sigma-2 binding site (36nM 
and 40nM, respectively) (Lever et al., 2006).  Ten μl was added to each tube, 
with a final volume of 100μl consisting of membranes, and, where appropriate, 
10µl of 10mM haloperidol to determine non-specific binding. Assays were 
permitted to incubate at room temperature for 4 hours before the separation of 
bound from free ligand. After equilibration the membranes were harvested using 
a vacuum filtration manifold (Millipore) through GF/C glass fibre filters, washing 
two times with 3ml ice-cold wash buffer. The glass fibre filter containing the cell 
membranes bound to the radioligand were placed in scintillation vials with 2ml 
of scintillant. The glass fibre filters were allowed to soak overnight before 
counting in a Perkin Elmer Liquid scintillation analyzer Tricarb 2800TR (5 
minute counts). 
 
2.6 Competition binding assay 
Radioligands were diluted in TBS to 500nM and 10l were added to the tubes 
giving final assay concentrations of approximately 50nM (exact concentration 
was determined by scintillation counting for each experiment). The unlabeled, 
competing ligand was prepared at 10 times the required concentration, and 
10l was added to the tube. Initial tests were performed using a single high 
concentration of competing ligand (1mM where possible). Those ligands that 
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showed significant binding were then tested more rigorously using a range of 
concentrations permitting 0-100% reduction of radioligand binding in order to 
determine a pKi. The volume was made to 50l TBS, before adding 50l of cell 
membranes to make a final volume of 100l. The assay was allowed to 
equilibrate for at least 4 hours at room temperature. After equilibration, the cell 
membranes were harvested using a vacuum filtration manifold and processed 
as above. 
 
 
2.7 Protein measurement 
 
Protein amounts were determined using BioRad Protein Dye Reagent, based 
on Coomassie Brilliant Blue G250. Bovine serum albumin (BSA) was dissolved 
in water and eight dilutions of BSA (ranging from 0-400g/ml) were prepared as 
protein standard. Ten l of the standard and sample solution was added in 
duplicates to a 96-well plate. 100l of Protein Dye Reagent (prepared by 
diluting 1 part Dye Reagent Concentrate with 4 parts distilled water) was added 
to all the wells. Following an incubation of 10 minutes the absorbance was 
measured at 595nm (Bradford, 1976) . 
 
2.8 MTS cell proliferation assay 
 
The cells were harvested with 0.25% trypsin and 1mM EDTA and centrifuged at 
240g for 5 minutes. The pellet was washed in fresh DMEM containing 10% FCS, 
cells were counted and seeded into each well of a 96 well plate and allowed to 
adhere overnight. The drugs were added on day 2 and the cells incubated 
overnight (10X concentration and 10l into 90l of DMEM to give 1X in the well). 
Initial screens were performed using a single high concentration of ligand (1mM 
where possible). Those ligands that showed significant reduction of metabolic 
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activity were then tested more rigorously using a range of concentrations 
permitting 0-100% reduction of metabolic activity in order to determine a pIC50. 
The day after drug addition the metabolic activity was measured using the 
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS) 
(Promega Southampton UK). Metabolically active cells converted 3-
(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
terazolium (MTS) into soluble formazan, and absorbance (490nm) was 
measured at 0, 1, 2 and 3 hours. The amount of formazan produced is directly 
proportional to the number of metabolically active cells in the well. Linear 
regression was performed to determine the rate of growth under each condition. 
To determine % inhibition, the absorbance of drug-treated wells was compared 
with control wells (vehicle only, 100%) and wells containing no cells (0%). IC50 
values were calculated using non-linear regression (GraphPad Prism, version 
7.0 for Macintosh). 
  
2.9 Fura-2 Calcium measurement 
 
On the day of experimentation, cells were harvested with 0.25% trypsin 1mM 
EDTA and centrifuged at 240g for 5 minutes.  The pellet was resuspended in 
Krebs’-like buffer containing 115mM NaCl, 5mM KCl, 1mM NaH2PO4, 0.5mM 
MgSO4, 11mM glucose, 1.36mM CaCl2, 0.1% BSA, 50mM Tris (note that Tris 
and not 4-(2-hydroxyethyl)-1-piperzineethanesulfonic acid (HEPES) was used 
to buffer the cells as HEPES has sigma-1 receptor affinity (of approximately 
10mM, (Brimson et al., 2011) pH 7.4. Approximately 20 million cells were 
resuspended in 2ml of buffer. The cells were loaded with 5µM cell permeable 
Fura-2-acetoxymethyl ester (Fura-2-AM) (Invitrogen, UK) (5mM stock, in 
DMSO) and incubated at room temperature for 45 minutes. Loading at room 
temperature rather than 37C reduced the cellular compartmentalization of the 
Fura-2 resulting in better cytoplasmic loading of the cells (Roe et al., 1990). 
The cells were then harvested by centrifugation at 240g for 5 minutes and 
washed in warmed Krebs’-like buffer three times before being made up to 1 
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million cells per ml and incubated at room temperature for a further 30 minutes 
to allow the acetoxymethyl groups to be removed by cellular esterases resulting 
in free Fura-2 in the cells. The cells were then kept in suspension in the dark at 
room temperature before use in calcium measurements. Two ml of Fura-2 
loaded cells were placed in a cuvette with a magnetic stirring bar and placed 
into the fluorometer, (Perkin Elmer luminescence spectrometer LS-50B) and 
were maintained at 37°C. The cells were excited at 340nm and 380nm and 
emissions were recorded at 510nm. Fura-2 undergoes an excitation shift 
between 335nm (calcium free) and 363nm (calcium saturated) whilst the 
emission wavelength remains unchanged. This can be visualized by scanning 
the excitation wavelength between 300nm and 400nm and recording the 
emission at 510nm. 
 
 
Figure 2-1: Fluorescence excitation spectra of Fura-2 
Multiple solutions containing between 0 and 39.8μM free [Ca2+], scanned 
between 250nm and 450nm and emission (Em) read at 510nm. Data obtained 
from Invitrogen. 
 
The largest dynamic range for [Ca2+] dependent fluorescent signals is obtained 
by using the ratio of fluorescence emitted at 510nm after excitation at 340nm 
and 380nm. The affinity of Fura-2 for calcium (Kd 225nM) permits this dye to 
measure cytoplasmic calcium at physiologically relevant concentrations. At low 
concentrations of dye, taking 340/380nm ratios allows accurate measurements 
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of intracellular calcium and allows for differences in dye loading, cell thickness 
and other problems that can effect calcium measurements. 
 
Upon introduction of the cells to the fluorometer, cells were given 30 seconds to 
establish a baseline calcium level prior to the addition of drug. Drugs were 
made up at 100 times concentration and pH balanced to 7.4 before 20μl was 
injected into the cuvette resulting in 1 x concentration in the cuvette. At the end 
of each individual experiment 20μl of 1mg/ml digitonin was added to the cuvette 
to permeabilise the cells allowing calcium to flood the dye giving a maximum 
fluorescence, followed by 60μl of 0.5M EDTA pH 8.5 to chelate the calcium 
giving a minimum fluorescence. These values were then used to calculate the 
cytosolic calcium concentration of the cells, using the (Grynkiewicz et al., 1985) 
equation. 
[Ca2+]i = Kd (R-Rmin) / (R-Rmax). 
 
Where the Kd for Fura-2 is 225nM, R is the ratio of emissions recorded at 
340nm and 380nm, Rmin is the minimum ratio of emissions recorded at 340nm 
and 380nm after the addition of EDTA chelating the calcium, and Rmax is the 
maximum ratio emissions recorded at 340nm and 380nm after the addition of 
digitonin causing the Fura-2 to be saturated with calcium. Unloaded cells were 
used to check autofluorescence and drug fluorescence. The data were then 
transferred into GraphPad Prism for graphical representation. 
 
2.10 Data analysis 
 
Saturation data analysis was analysed using GraphPad Prism (version 7.0 for 
Macintosh) non-linear regression analysis to fit saturation curves and calculate 
maximal radioligand binding and dissociation constants.  
Equation: S = Bmax· [L] / Kd + [L] 
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Where S is the Specific binding, [L] is the concentration of free radioligand, Bmax 
is the total number of receptors expressed in the same units as S (i.e. sites/cell, 
cpm or fmol/mg protein) and Kd is the equilibrium dissociation constant 
expressed in the same units as [L] (usually nM). 
Non-linear regression was performed, rather than the traditional Scatchard plots 
due to the fact that transforming the data to a linear form distorts the 
experimental error, whilst linear regression assumes that the scatter around the 
line follows the Gaussian distribution and that the standard error around X is the 
same for every point, this is not true for the transformed data, and there are 
much larger errors associated at the low concentrations of bound ligand, and 
therefore they have undue influence over the slope of the regression line 
resulting in a Kd and Bmax further from the true value than using non-linear 
regression. 
One-way ANOVA was performed for all saturation curves. Data obtained from 
the highest concentration of ligand was used as a comparator. F and p values 
are given for each curve. 
Competition binding data was analysed using GraphPad Prism non-linear curve 
fitting software in one of the two ways. 
 
 The equation used to fit competition binding data in Chapter 4 was the 
sigmoidal dose response (variable slope) model. 
 
Equation: Y=Bottom + (Top-Bottom) / 1+(10^((LogIC50-X)·Hillslope))  
Where X is the logarithm of the concentration of competing ligand, Y is the 
response (i.e. Counts per minute or % specific radio ligand binding) and the Hill 
slope is the slope factor, a number that describes the steepness of the curve. A 
one site competitive binding curve that follows the law of mass action will have 
a slope of -1 (negative as the slope goes down).  The IC50 is dependent on the 
Ki of the ligand for the receptor, but also dependent on the concentration of 
radio labelled drug used in the assay (i.e. increasing the radiolabelled drug 
concentration will change the IC50 whilst the Ki remains the same).  
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Competition assays performed in chapter 3 were analysed differently. The 
ligands here (DTG and (+) pentazocine) bind each site with a Hill slope of unity. 
[3H] DTG binds both sigma-1 and sigma-2 sites with equal affinity, whereas (+) 
pentazocine binds sigma-1 receptors with much higher affinity than the sigma-2 
binding site. In these assays a two-site fit was used. Affinities are known for 
each ligand, so it is the proportion of high and low affinity sites for (+) 
pentazocine that are being determined using the following equations. 
 
 
logEC50Lo=log(10^logKiLo*(1+HotNM/HotKdNMLo)) 
logEC50Hi=log(10^logKiHi*(1+HotNM/HotKdNMHi)) 
Span=Top - Bottom 
Part1=FractionHi*Span/(1+10^(X-LogEC50Hi) ) 
Part2=(1-FractionHi)*Span/(1+10^(X-LogEC50Lo) ) 
Y=Bottom + Part1 + Part2 
 
Computer-assisted data analysis, therefore, permitted me to determine the 
proportion of sites with high and low affinity for (+) pentazocine. 
 
The unpaired two-tailed Student’s t-test was only performed when comparing 
two sets of data pairwise. Gaussian distribution and sphericity were assumed in 
all cases. Values for Kd, Ki, K50, EC50 and IC50 were transformed to pKd, pKi, 
pK50, pEC50 and pIC50 before any statistical manipulation was attempted, as 
these are not normally distributed otherwise. A p values < 0.05 is considered 
statistically significant. 
 
Unpaired, two-tailed one-way ANOVA was performed when comparing more 
than two sets of data. When comparing “all means” with each other, Tukey post 
hoc analyses were performed when necessary. When data sets were compared 
against a “control” group only, Bonferroni post hoc analyses were performed 
when necessary. Gaussian distribution and sphericity were assumed in all 
cases. Values for Kd, Ki, K50, EC50 and IC50 were transformed to pKd, pKi, pK50, 
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pEC50 and pIC50 before any statistical manipulation was attempted, as these 
are not normally distributed otherwise. An adjusted p value < 0.05 is considered 
statistically significant. 
 
 
Two-way ANOVA was performed for the competition binding curves. Data for 
each cell line (row factor) was compared with that obtained for MCF7 between 
the concentrations of 10nM and 10μM (column factor). Those with p <0.05 
(following the Bonferroni adjustment for multiple comparisons) were deemed 
significantly different to MCF7 data points. An adjusted p value < 0.05 is 
considered statistically significant. 
 
 
In order to give a more true representation of the drugs affinity for the receptor, 
the IC50 was converted to a Ki value using the Cheng Prusoff equation (Cheng 
and Prusoff, 1973). 
 
Equation: Ki=IC50/(1+ ([Radioligand] /Kd))  
 
The Ki value is derived from the IC50 which is on a log scale, therefore it does 
not make sense to present mean Ki values ± standard error of the mean (SEM) 
as the error is not symmetrical around the mean. The Ki was also converted into 
pKi (-logKi), which is normally distributed therefore the SEM is symmetrical 
about the mean pKi.  
 
MTS assays were read using a Versamax plate reader, and the data collected 
using Softmax Pro software. Data were analysed as described for ligand 
binding to sigma-2 receptors above, using competition binding data with a 
sigmoidal dose response (variable slope) model. 
 
Equation: Y=Bottom + (Top-Bottom) / 1+(10^((LogIC50-X)·Hillslope 
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Linear regression was performed using the least squares (ordinary) fit. Data 
were unweighted. The equation of best fit is presented, along with R2, F and p 
values. 
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Chapter 3. CHARACTERISATION OF SIGMA-1 
RECEPTORS AND SIGMA-2 BINDING SITES IN 
HUMAN CANCER CELL LINES 
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3.1 Background  
 
Sigma receptors were initially described as novel opioid receptors but later they 
were found to be a distinct class of receptors due to their ability to bind to 
different drugs. Pharmacological studies have characterised two subtypes: 
sigma-1 and sigma-2. These subtypes differ in their ability to bind to different 
drugs. Sigma receptors were initially identified in central nervous system and 
since then extensive work has been done to delineate their physiological roles 
and potential clinical uses (Bowen, 2000, Debonnel, 1993, Matsumoto et al., 
2003, Maurice et al., 2001, Novakova et al., 1998) 
 
Sigma-1 receptors have been identified and cloned (Abate et al., 2010, Hanner 
et al., 1996, Kekuda et al., 1996, Mei and Pasternak, 2001) whereas the 
existence of the sigma-2 binding site has only been proven pharmacologically 
(Guitart et al., 2004). Photoaffinity studies have revealed molecular weight of 
sigma-1 receptor to be 25kDa and 18-21kDa for sigma-2 binding site (Hellewell 
and Bowen, 1990, Hellewell et al., 1994). In addition to the central nervous 
system, sigma receptors are also found in high density in endocrine, immune, 
reproductive tissues (Wolfe et al., 1989), liver and kidney (Hellewell et al., 1994). 
  
Endogenous ligands for sigma receptors have not been identified, however 
steroids hormones, sphingolipid-derived amines and N,N-dimethyltryptamine 
(DMT) were investigated to see if they could be potential endogenous ligands 
(van Waarde et al., 2010). Both subtypes, in particular sigma-2 binding sites are 
overexpressed in rapidly dividing normal cells and in tumour cell lines derived 
from various tissues (Vilner et al., 1995a). These included lung, breast, prostate, 
melanoma glioma and neuroblastoma. In small cell lung cancers the sigma-2 
binding sites are overexpressed up to 6-fold and similarly the plasma levels 
were significantly elevated in patients with non-small cell lung cancer. It has 
been concluded that the sigma-2 binding site is a potential tumour and serum 
biomarker and could be used as a therapeutic target for lung cancer (Mir et al., 
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2012). Expression of sigma-1 receptors and sigma-2 binding sites in various 
human tumour cell lines is show in Table 3-1  
 
Cell Line Origin Radioligand Bmax 
(fmol/mg 
protein 
or %) 
A375 Melanoma 3H-(+) pentazocine 34 
A375 Melanoma 3H-DTG (+1µM DEX) 3403 
BE(2)-C Neuroblastoma 3H-(+) pentazocine 2980 
LNCa.FGG Prostate cancer 3H-(+) pentazocine 1196 
LNCa.FGG Prostate cancer 3H-DTG (+1µM DEX) 727 
MCF7 Breast 
adenocarcinoma 
3H-(+) pentazocine 0 
MCF7 Breast cancer 3H-DTG (+1µM DEX) 2071 
NCI-H727 Lung carcinoid 3H-(+) pentazocine 26 
NCI-H727 Lung carcinoid 3H-DTG (+1µM DEX) 2835 
SK-N-SH Neuroblastoma 3H-(+) pentazocine 975 
SK-N-SH Neuroblastoma 3H-DTG (+1µM DEX) 944 
T47D Breast cancer 3H-(+) pentazocine 108 
T47D Breast cancer 3H-DTG (+1µM DEX) 1221 
Th-P1 Leukaemia 3H-(+) pentazocine 1411 
Th-P1 Leukaemia 3H-DTG (+1µM DEX) 491 
U-138MG Glioblastoma 3H-(+) pentazocine 1115 
U-138MG Glioblastoma 3H-DTG (+1µM DEX) 3136 
 
Table 3-1: Expression of sigma receptors in human cancer cell lines.  
Sigma-1 and sigma-2 binding site expression in various cancer cell lines.  
DEX = dextromethorphan, adapted from (van Waarde et al., 2010). 
 
Sigma-1 receptors have been well studied and several functions have been 
described, which include: modulation and synthesis of dopamine and 
acetylcholine (Booth and Baldessarini, 1991, Patrick et al., 1993), modulation of 
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NMDA-stimulated neurotransmitter release (Gonzalez-Alvear and Werling, 1995, 
Monnet et al., 1996), modulation of opioid analgesia (King et al., 1997) and 
neuroprotective and anti-amnesic activity (Maurice and Lockhart, 1997). Sigma-
2 binding sites are mainly involved in regulation of cell proliferation and viability 
(Bowen, 2000). The cytotoxicity of sigma-2 binding site ligands was confirmed 
in vitro using both neuronal and non neuronal cell lines (Vilner and Bowen, 
1993, Vilner et al., 1995a). Exposure to sigma-2 binding site ligands resulted in 
assumption of spherical shape, detachment from surface followed by cell death. 
These effects are dose dependent hence with higher doses the changes and 
cell death occurs quicker. The mode of cell death is apoptotic (Crawford and 
Bowen, 2002, Vilner et al., 1995a). 
 
The main purpose of this chapter was to determine the level of expression of 
sigma-1 receptor and sigma-2 binding site in different human cell lines 
(oesophageal: OE21, OE33 and FLO-1, breast: MCF7, MDA-MB-468, 
colorectal: Caco-2, SW480, HT-29 and HCT 116, human embryonic kidney 
cells: 293 and lung: A549. By determining which cells express which proteins, I 
could then attempt to distinguish which protein plays a role in particular 
biochemical events and determine whether sigma-1 and sigma-2 proteins could 
potentially act additively, synergistically or in opposition to each other. 
 
3.2 Expression of sigma-1 receptor 
 
Saturation binding experiments were carried out in order to calculate the 
number of sigma-1 receptors expressed on the cancer cell lines (Bmax) and 
equilibrium dissociation constant (Kd) of [3H] (+) pentazocine. Non-specific 
binding was carried out in the presence of 1mM haloperidol. Specific binding 
was calculated by subtracting the non-specific binding from total [3H] (+) 
pentazocine binding.  Bmax and Kd were calculated using nonlinear regression 
software (GraphPad Prism, California). 
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3.3 Oesophageal cancer cell lines (FLO-1, OE21 and OE33) 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] (+) pentazocine binding to cell membranes from three oesophageal cancer 
cell lines: FLO-1, OE21 and OE33. 
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Figure 3-1: Saturation binding of [3H] (+) pentazocine to oesophageal 
cancer cell lines (A: FLO-1, B: OE21 and C: OE33). 
Saturation binding curve for [3H] (+) pentazocine to oesophageal cancer cell 
lines. Non-specific binding was determined in the presence of 1mM haloperidol. 
Figure represents mean ± SEM from 3-5 independent experiments. One-way 
ANOVA, using the highest concentration of ligand as comparator, shows a 
strong concentration-dependant increase in ligand binding: A (FLO-1) [F(6,13) = 
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24.6, p < 0.0001]; B (OE21) [F(5,30) = 11.0, p < 0.0001]; C (OE33) [F(6,14) = 
20.7, p < 0.0001]. 
 
All three oesophageal cancer cell lines expressed binding sites for [3H] (+) 
pentazocine. The mean pKd ± SEM of [3H] (+) pentazocine for the sigma-1 
receptor expressed in FLO-1, OE21 and OE33 cells was determined as 7.38 ± 
0.05, 7.43 ± 0.12 and 7.15 ± 0.07. The Bmax was determined as 1100 ± 100, 
2250 ± 150 and 2400 ± 300fMol/mg protein respectively. Data were calculated 
from 3-5 independent saturation binding experiments. 
 
3.4 Breast cancer cell lines (MCF7, MDA-MB-468) 
 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] (+) pentazocine to cell membranes from two breast cancer cell lines: MDA-
MB-468 and MCF7. Figure 3-2 shows saturation binding curve for [3H] (+) 
pentazocine in membranes prepared by sonicating breast cancer cell lines. Bmax 
and Kd were calculated using GraphPad Prism. 
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Figure 3-2: Saturation binding of [3H] (+) pentazocine to MDA-MB-468 cells 
Saturation binding curve for [3H] (+) pentazocine to membranes prepared from 
MDA-MB-468 breast cancer cells. Non-specific binding was determined in the 
presence of 1mM haloperidol. Figure represents mean ± SEM from 3 
independent experiments. One-way ANOVA, using the highest concentration of 
ligand as comparator, shows a strong concentration-dependant increase in 
ligand binding: [F(6,14) = 4.9, p = 0.0065] 
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MCF7 showed no specific binding site for [3H] (+) pentazocine. The mean pKd ± 
SEM of [3H] (+) pentazocine for the sigma-1 receptor expressed in MDA-MB-
468 was 7.65 ± 0.13 and the Bmax was found to be 1700 ± 150fMol/mg protein. 
Data were calculated from 3 independent saturation experiments. 
 
3.5 Colorectal cancer cell lines (Caco-2, HCT 116, HT-29 and 
SW480) 
 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] (+) pentazocine for four colorectal cancer cell lines: Caco-2, HCT 116, HT-
29 and SW480. Figure 3-3 shows saturation binding curve for [3H] (+) 
pentazocine to membranes prepared by sonicating colorectal cancer cell lines. 
Bmax and Kd were calculated using GraphPad Prism. 
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Figure 3-3: Saturation binding of [3H] (+) pentazocine to colorectal cancer 
cell lines (A: Caco-2, B: HCT 116, C: HT-29 and D: SW480) 
Saturation binding curve for [3H] (+) pentazocine to membranes prepared from 
colorectal cancer cell lines. Non-specific binding was determined in the 
presence of 1mM haloperidol. Figure represents mean ± SEM from 3 
independent experiments. One-way ANOVA, using the highest concentration of 
ligand as comparator, shows a strong concentration-dependant increase in 
ligand binding: A (Caco-2) [F(6,27) = 30.1, p < 0.0001]; B (HCT 116) [F(6,14) = 
4.1, p = 0.015]; C (HT-29) [F(6,14) = 14.4, p < 0.0001]; D (SW480) [F(6,14) = 
6.86, p = 0.0015]. 
 
 
The mean pKd ± SEM of [3H] (+) pentazocine for the sigma-1 receptor 
expressed on Caco-2, HCT 116, HT-29 and SW480 cells was determined as 
7.40 ± 0.07, 7.28 ± 0.04, 7.41 ± 0.04 and 7.78 ± 0.00, the Bmax was determined 
as 2400 ± 50, 1700 ± 600, 2250 ± 300 and 2250 ± 500fMol/mg protein 
respectively. Data were calculated from 3 independent saturation experiments. 
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3.6 Human embryonic kidney cell line (293) 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] (+) pentazocine for 293 cells. Figure 3-4 shows saturation binding curve for 
[3H] (+) pentazocine to membranes prepared by sonicating colorectal cancer 
cell lines. Bmax and Kd were calculated using GraphPad Prism. 
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Figure 3-4: Saturation binding of [3H] (+) pentazocine to 293 cells 
Saturation binding curve for [3H] (+) pentazocine to membranes prepared from 
293 cells. Non-specific binding was determined in the presence of 1mM 
haloperidol. Data were calculated from 3 independent saturation experiments. 
One-way ANOVA, using the highest concentration of ligand as comparator, 
shows a strong concentration-dependant increase in ligand binding: [F(6,14) = 
12.0, p < 0.0001]. 
 
 
The mean pKd ± SEM of [3H] (+) pentazocine for the sigma-1 receptor 
expressed in 293 cells was 7.63 ± 0.08 and the Bmax was found to be 1600 ± 
250fMol/mg protein. Data were calculated from 3 independent saturation 
experiments. 
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3.7 Lung cancer cell line (A549) 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] (+) pentazocine for A549 cells. Figure 3-5 shows saturation binding curve 
for [3H] (+) pentazocine in membranes prepared by sonicating lung cancer cell 
lines.  
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Figure 3-5: Saturation binding of [3H] (+) pentazocine to A549 cells 
Saturation binding curve for [3H] (+) pentazocine to membranes prepared from 
A549 cells. Non-specific binding was determined in the presence of 1mM 
haloperidol. Data were calculated from 3 independent saturation experiments. 
One-way ANOVA, using the highest concentration of ligand as comparator, 
shows a strong concentration-dependant increase in ligand binding: [F(6,33) = 
13.9, p < 0.0001]. 
 
 
The mean pKd ± SEM of [3H] (+) pentazocine for the sigma-1 receptor 
expressed in A549 cells was 7.6 ± 0.09 and the Bmax was found to be 1300 ± 
150fMol/mg protein. Data were calculated from 3 independent saturation 
experiments. 
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Table 3-2 shows a summary of the findings from all cell lines studied. 
 
Origin Cell Line Bmax ± SEM 
fMol/mg 
protein 
pKd ± SEM R2 
Oesophagus FLO-1 1100 ± 100 7.38 ± 0.05 0.9 
OE21 2250 ± 150 7.43 ± 0.12 0.9 
OE33 2400 ± 300 7.15 ± 0.07 0.9 
     
Breast  MCF7 No binding   
 MDA-MB-468 1700 ± 150 7.6 ± 0.13 0.9 
     
Colorectal Caco-2 2400 ± 50 7.40 ± 0.07 0.9 
 HCT 116 1700 ± 600 7.28 ± 0.04 0.9 
 HT-29 2250 ± 300 7.41 ± 0.04 0.9 
 SW480 2250 ± 500 7.78 ± 0.00 0.9 
     
Human embryonic 
kidney  
293 1600 ± 250 7.63 ± 0.08 0.9 
     
Lung  A549 1300 ± 150  7.60 ± 0.09 0.9 
 
Table 3-2: Binding parameters of sigma-1 receptors in various human 
tumour cell lines. 
Sigma-1 binding was carried out as described in chapter 2 “Materials and 
Methods”. [3H] (+) pentazocine concentration was varied in 6 concentrations 
over a range of 4-128nM. Apart from the MCF7 cell line, all the cell lines 
expressed sigma-1 receptors. Unpaired 1-way ANOVA, followed by post hoc 
Tukey (“all means”) comparison, with p value adjusted for multiple comparisons, 
shows a significant difference in Bmax values: [F(10,29) = 3.52, p = 0.0039]. 
MCF7 cells expressed significantly fewer sigma-1 receptors than all other cell 
lines, p < 0.022 for all cases. All other comparisons show no significant 
difference between Bmax values. Unpaired 1-way ANOVA, followed by post hoc 
Tukey (“all means”) comparison, with p value adjusted for multiple comparisons, 
shows a significant difference in pKd values: [F(9,28) = 3.60, p = 0.0044]. The 
pKd for OE33 cells was found significantly different to SW480 (p = 0.015) and 
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A549 (p = 0.017) cells. All other comparisons show no significant difference 
between pKd values. 
 
3.8 Measurement of pan-sigma binding 
The standard protocol used for determining sigma-2 binding site presence and 
number relies on [3H]-DTG. DTG is a pan-sigma ligand, binding both sigma-1 
(Ki 35.5nM) and sigma-2 (Ki 39.9nM) (Lever et al., 2006) sites with equal affinity. 
As most binding assays have been performed in tissues or cell lines containing 
sigma-1 receptors, it has become standard to determine sigma-2 binding in the 
presence of either (+) pentazocine or dextrallorphan (Chu et al., 2015, Vilner et 
al., 1995b). This protocol, while fully integrated into the sigma receptor 
researcher’s toolkit, is seriously flawed. I will explain why: 
 
(+) pentazocine and dextrallorphan are not specific for the sigma-1 receptor. (+) 
pentazocine has a range of published affinities between 1.6nM (Xu et al., 2015) 
and 17nM (Brimson et al., 2011, Vilner and Bowen, 2000) for the sigma-1 
receptor. Its affinity for sigma-2 binding sites is between 728nM (Xu et al., 2015) 
and 6.6µM (Vilner and Bowen, 2000).  
 
(+) Pentazocine binds with a Hill slope of one and so from these data, one can 
model a saturation binding isotherm. This will show the relative binding of (+) 
pentazocine to sigma-1 and sigma-2 binding sites at different concentrations as 
shown in Figure 3-6. 
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Figure 3-6: Binding profile of a ligand. 
Figure showing the binding profile of a ligand with Hill slope of unity. The Kd, at 
which 50% of the receptors are bound, and 100% binding, which the 
rectangular hyperbola approaches but never reaches are shown. 
 
If one draws the best (greatest difference between sigma-1 (1.6nM) and sigma-
2 (6600nM)) affinities and worst (least difference between sigma-1 (17nM) and 
sigma-2 (728nM) case scenarios for (+) pentazocine, and compares the 
“masking” described at concentrations used (100nM and 1µM) it is clear that 
data can be easily misinterpreted (Figure 3-7). 
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Figure 3-7: Binding profile of sigma receptors in the best case scenario  
Figure shows the calculated binding of pentazocine to receptors with affinity of 
1.6nM (highest reported affinity for sigma-1 receptors) and 6.6µM (lowest 
claimed affinity for sigma-2 binding site). Dotted lines show commonly used 
concentrations of (+) pentazocine. 
From the data in Figure 3-7, one can calculate that, in the absence of 
competing agents, 100nM (+) pentazocine would bind 97.8% of sigma-1 
receptors and 1.49% of sigma-2 binding sites whereas 1µM (+) pentazocine 
would bind 99.1% of sigma-1 receptors and 13.2% of sigma-2 binding sites. 
This is the “best case” scenario. 
 
The worst case scenario is shown in Figure 3-8. One can calculate that, in the 
absence of competing agents, 100nM (+) pentazocine would bind 85.4% of 
sigma-1 receptors and 12.2% of sigma-2 binding sites whereas 1µM (+) 
pentazocine would bind 98.0% of sigma-1 receptors and 58.1% of sigma-2 
binding sites. 
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Figure 3-8: Binding profile of sigma receptors in the worst case scenario. 
Figure showing the worst case scenario of calculated binding of (+) pentazocine 
to receptors with affinity of 17nM (lowest reported affinity for sigma-1 receptors) 
and 728nM (highest claimed affinity for sigma-2 binding site). Dotted lines show 
commonly used concentrations of (+) pentazocine. 
 
From these numbers alone, it is clear that the accepted protocol for sigma-2 
binding site characterisation should not be used. 
 
Furthermore, when the addition of a second drug that binds both sites non-
selectively, matters are further complicated. Simplified curves were drawn 
based on DTG competing at the sigma-1 receptor and at the sigma-2 binding 
site in isolation. It was acknowledged that the situation was more complex as 
binding and release of each drug to one target (e.g. sigma-1 receptor) would 
have an impact on second target (e.g. sigma-2 binding site). Using a calculation 
based on Cheng and Prusoff (Cheng and Prusoff, 1973) the inhibition of binding 
of a ligand based on the affinities and concentration of each ligand could be 
determined. 
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Where: 
fi fraction inhibition 
I added unlabelled drug 
Ki affinity of inhibitor 
LT total labelled drug added 
Kd affinity of labelled drug 
 
In the scenarios below “labelled” will used for (+) pentazocine, as its 
concentration remains constant, and “unlabelled” will be used for DTG (actually 
the radioligand), as its concentrations are varied in a saturation assay. 
 
Modelling the dissociation of (+) pentazocine at 100nM with affinities of 1.6nM 
and 17nM with a range of DTG concentrations 0 – 256nM with an affinity of 
35.5nM for the sigma-1 receptor (Lever et al., 2006) shows how DTG will 
compete with (+) pentazocine at the sigma-1 receptor with increasing effect, 
meaning that each point will have different amounts of DTG bound . 
 
 
Figure 3-9: Percentage change in (+) pentazocine displacement with 
increasing DTG concentration. 
Figure showing the percentage of (+) pentazocine displaced from the sigma-1 
receptor as DTG concentration increases to prepare a saturation binding curve. 
Data are modelled for the two commonly used concentrations of (+) 
pentazocine (100nM and 1µM) and an affinity of (+) pentazocine for the sigma-1 
receptor of 1.6nM. 
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Figure 3-9 shows that DTG can readily displace a significant percentage of (+) 
pentazocine from this receptor, even with the higher affinity estimate for (+) 
pentazocine used. 
 
When the lower affinity of (+) pentazocine (17nM) is substituted into these 
calculations, the effects of DTG on (+) pentazocine binding, and hence the 
amount of DTG (tritiated signal in a binding assay) increases further as shown 
in Figure 3-10. 
 
 
Figure 3-10: (+) Pentazocine displacement with increasing DTG 
concentration 
Figure showing the percentage of (+) pentazocine displaced from the sigma-1 
receptor as DTG concentration increases to prepare a saturation binding curve. 
Data are modelled for the two commonly used concentrations of (+) 
pentazocine (100nM and 1µM) and an affinity of (+) pentazocine for the sigma-1 
receptor of 17nM. 
 
DTG will readily displace the (+) pentazocine bound to the sigma-2 binding sites, 
with modelled data for (+) pentazocine concentrations of 100nM and 1µM and 
affinities of 738nM and 6.6µM shown below in Figure 3-11. 
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Figure 3-11: Percentage displacement of (+) pentazocine with increasing 
DTG concentration. 
Figure showing the percentage of (+) pentazocine displaced from the sigma-2 
binding site as DTG concentration increases to prepare a saturation binding 
curve. Data are modelled for the two commonly used concentrations of (+) 
pentazocine (100nM and 1µM) and an affinity of (+) pentazocine for the sigma-2 
binding site of 728nM. 
 
 
 
Figure 3-12: Displacement of (+) pentazocine form sigma-2 binding site 
with increasing concentration of DTG. 
Figure showing the percentage of (+) pentazocine displaced from the sigma-2 
binding site as DTG concentration increases to prepare a saturation binding 
curve. Data are modelled for the two commonly used concentrations of (+) 
pentazocine (100nM and 1µM) and an affinity of (+) pentazocine for the sigma-2 
binding site of 6.6µM. 
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Calculations with dextrallorphan yield similar data.  
 
Since the affinity of dextrallorphan for the sigma-2 binding site has not been 
defined, the only data point found (Hellewell and Bowen, 1990) for this ligand, 
was used, which was obtained using [3H] DTG and [3H] (+)-3-(3-
hydroxyphenyl)-N-(1-propyl)piperidine (PPP) in PC-12 cells. This appears to be 
the only paper in which the binding of dextrallorphan to sigma-2 sites is 
reported and the only time PC-12 cells have been used to study sigma-2 sites. 
Both these issues raise concern. In this paper, dextrallorphan is described as 
displacing less than 30% of [3H] DTG or [3H] PPP when used at 5µM. As a 
similar statement regarding other drugs showing less than 30% displacement at 
10µM is made elsewhere, The affinity was estimated based on 30% 
displacement of 5nM DTG, with an affinity of 23.7nM and 3nM PPP with an 
affinity of 86.3nM. 
 
Entering these values into the above equation gives K30 (as only 30% was 
displaced) values for dextrallorphan of between 6550nM (calculated using PPP) 
and 18760nM (calculated using DTG). From a rectangular binding isotherm, 
30% binding corresponds to a concentration 42% of the Ki. This estimates the 
Ki of dextrallorphan for the sigma-2 binding site of 15µM and 44.7µM. 
 
Taking these values, one can then estimate the binding of dextrallorphan to 
sigma-2 binding sites and determine how much will bind under experimental 
conditions. 
 
Modelling rectangular hyperbolae with these affinities shows that 1µM 
dextrallorphan will bind between 6.3% (taking an affinity of 15µM) and 2.2% 
(taking an affinity of 44.7µM) of the sigma-2 binding sites. 
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Figure 3-13: Calculated binding dextrallorphan to sigma-2 sites. 
Figure showing the calculated binding of dextrallorphan to sigma-2 sites with 
affinity of 15µM (highest calculated affinity for sigma-2 binding sites using PPP 
data) and 44.7µM (highest calculated affinity for sigma-2 binding site using DTG 
data). Dotted line shows the commonly used concentration of dextrallorphan. 
 
The only published affinity of dextrallorphan for the sigma-1 receptor shows a Ki 
of 16.1nM (Hellewell and Bowen, 1990) A second paper (Largent et al., 1987) 
gives an IC50 (163nM) along with Kd (30nM) and concentration (1-2nM) of the 
ligand ([3H] PPP) binding assays were performed using. From this, we can 
calculate a Ki of 153-158nM. I will model data using these two affinities (16.1nM 
and 155nM) in order to estimate binding achieved when the “masking” protocol 
is used.  
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Figure 3-14: Binding of dextrallorphan at two different affinities. 
Calculated binding of dextrallorphan to receptors with affinity of 16.1nM (highest 
affinity for sigma-1 receptor) and 155nM (lowest calculated affinity for sigma-1 
receptor). Dotted line shows the commonly used concentration of 
dextrallorphan. 
 
Using these calculations, 1µM dextrallorphan binds 97.8% (using 16.1nM 
affinity) or 86.3% (using 155nM affinity) of the sigma-1 receptors present as 
shown in Figure 3-14. 
 
Modelling the dissociation of dextrallorphan at 1 µM with affinities of 16.1µM 
and 155µM with a range of DTG concentrations 0 – 256nM with an affinity of 
39.9nM for the sigma-1 receptor (Lever et al., 2006) shows how DTG will 
compete with dextrallorphan at the sigma-1 receptor with increasing effect, 
meaning that each point will have different amounts of DTG bound. 
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Figure 3-15: Displacement of dextrallorphan with increasing concentration 
of DTG. 
Figure showing the percentage of dextrallorphan (1µM) displaced from the 
sigma-1 receptor as DTG concentration increases to prepare a saturation 
binding curve. Data are modelled for the two reported affinities of dextrallorphan 
for the sigma-1 receptor. 
 
DTG readily displaces dextrallorphan from the sigma-2 binding site as shown in 
Figure 3-16 
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Figure 3-16: Percentage displacement of dextrallorphan with increasing 
DTG concentration. 
Figure showing the percentage of dextrallorphan (1µM) displaced from the 
sigma-2 binding site as DTG concentration increases to prepare a saturation 
binding curve. Data are modelled for the two reported affinities of dextrallorphan 
for the sigma-2 binding site. 
 
From the above data, it is clear that none of the masking protocols widely 
accepted should be used. Summary of these findings are tabulated below 
(Table 3-3, 3-4, 3-5, 3-6). 
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(+) Pentazocine 
concentration 
(µM) 
sigma-1 
affinity 
(nM) 
% sigma-1 
binding 
sigma-2 
affinity 
(nM) 
% sigma-2 
binding 
     
0.1 1.6 97.8 6,600 1.49 
0.1 17 85.4 728 12.2 
1 1.6 99.1 6,600 13.2 
1 17 98.0 728 58.1 
 
Table 3-3: Summary of range of (+) pentazocine binding to sigma binding 
sites. 
Table summarising the range of calculated binding of (+) pentazocine to sigma-
1 and sigma-2 sites under standard conditions used. 
 
Dextrallorphan 
concentration 
(µM) 
sigma-1 
affinity 
(nM) 
% sigma-1 
binding 
sigma-2 
affinity 
(nM) 
% sigma-2 
binding 
     
1 16.1 97.8 15,000 6.3 
1 155 86.3 44,700 2.2 
 
Table 3-4: Summary of range of dextrallorphan to sigma binding sites. 
Table summarising the range of calculated binding of dextrallorphan to sigma-1 
and sigma-2 sites under standard conditions used. 
 
Addition of DTG will compete with the binding of (+) pentazocine and 
dextrallorphan to both sigma-1 and sigma-2 sites. When performing saturation 
binding curves, it is common to use concentrations in excess of 200nM. The 
table below shows calculated displacement of (+) pentazocine and 
dextrallorphan at 256nM DTG from the sigma-1 and sigma-2 sites. 
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Masking agent Concentration 
(µM) 
sigma-1 
affinity (nM) 
% displacement 
(+) Pentazocine 0.1 1.6 10.1 
 0.1 17 51.2 
(+) Pentazocine 1 1.6 1.1 
 1 17 10.8 
Dextrallorphan 1 16.1 10.2 
 1 155 16.2 
 
Table 3-5: Displacement of (+) pentazocine or dextrallorphan by DTG. 
Table showing the percent displacement of (+) pentazocine or dextrallorphan 
from the sigma-1 receptor by 256nM DTG. 
 
 
Masking agent Concentration 
(µM) 
sigma-2 
affinity (µM) 
% displacement 
    
(+) Pentazocine 0.1 0.728 84.9 
 0.1 6.6 86.3 
(+) Pentazocine 1 0.728 73.0 
 1 6.6 84.8 
    
Dextrallorphan 1 15 85.7 
 1 44.7 86.2 
 
Table 3-6: Displacement of (+) pentazocine or dextrallorphan by DTG 
(256nM). 
Table showing the percent displacement of (+) pentazocine or dextrallorphan 
from the sigma-2 binding site by 256nM DTG. 
 
The data above shows several reasons why the masking protocol is seriously 
flawed.   
In the case of (+) pentazocine, 100nM (and an affinity of 17nM, the value 
obtained in our laboratory) would only bind 85.4% of the sigma-1 receptors, 
even in the absence of DTG. As DTG is added, up to 51.2% would be 
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competed out at a concentration of 256nM DTG. This is the equivalent of 43.7% 
of the sigma-1 receptors being bound by [3H] DTG. 
 
The use of 1µM (+) pentazocine would decrease the effects of DTG, with only 
10.8% of the sigma-1 receptors being bound by the radioligand at 256nM. At 
this concentration of (+) pentazocine (1µM) however, 58.1% (assuming an 
affinity of 728nM) of the sigma-2 binding sites would be bound by (+) 
pentazocine and only 73.0% of these would be released upon addition of 
256nM DTG. 
 
Dextrallorphan fairs little better. Whilst it does bind few sigma-2 binding sites – 
fewer than 6.3% at the standard concentration of 1µM (assuming an affinity of 
15µM, based on a single published observation), it may mask only 86.3% of the 
sigma-1 receptors (using the affinity of 155nM). Again, addition of DTG at 
256nM will release and bind to some 16.2% of these sigma-1 sites. 
 
It is for these reasons that the experiments were performed using DTG in the 
absence of any masking agent. Furthermore, the exclusive use of the masking 
protocol when determining the presence of sigma-2 binding sites may explain 
why no cell line has been found to lack sigma-2 binding sites. The description 
above could show a signal equivalent to 27% of the sigma-1 receptors with 
dextrallorphan and up to 58% with 100nM (+) pentazocine. 
 
Saturation and competition binding experiments were carried out in order to 
calculate the number of sigma-2 binding sites expressed on the cancer cell 
lines (Bmax) and equilibrium dissociation constant (Kd) of [3H] DTG. Non-specific 
binding was carried out in the presence of 1mM Haloperidol. Bmax and Kd were 
calculated using nonlinear regression software (GraphPad Prism, California). 
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3.9 Oesophageal cancer cell lines (OE21, OE33 and FLO-1) 
 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for three oesophageal cancer cell lines: FLO-1, OE21 and OE33. 
Figure 3-17 shows saturation binding curve for [3H] DTG in membranes 
prepared by sonicating oesophageal cancer cell lines. Bmax and Kd were 
calculated using GraphPad Prism. 
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Figure 3-17: Saturation binding of [3H] DTG in oesophageal cancer cell 
lines (A: FLO-1, B: OE21 and C: OE33). 
Saturation binding curve for [3H] DTG to membranes prepared from 
oesophageal cancer cell lines. Non-specific binding was determined in the 
presence of 1mM haloperidol. Figure represents mean ± SEM from 3 
independent experiments. One-way ANOVA, using the highest concentration of 
ligand as comparator, shows a strong concentration-dependant increase in 
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ligand binding: A (FLO-1) [F(6,13) = 20.0, p < 0.0001]; B (OE21) [F(6,14) = 10.1, 
p = 0.0002]; C (OE33) [F(6,14) = 79.8, p < 0.0001]. 
 
 
The mean pKd ± SEM of [3H] DTG for pan-sigma binding in FLO-1, OE21 and 
OE33 was 7.79 ± 0.12, 7.64 ± 0.15 and 7.72 ± 0.02. The Bmax was found to be 
1050 ± 100, 1400 ± 350 and 1100 ± 50fMol/mg protein. Data were calculated 
from 3 independent experiments. 
 
3.10 Breast cancer cell lines (MCF7, MDA-MB-468) 
 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for two breast cancer cell lines: MDA-MB-468 and MCF7. Figure 3-18 
shows saturation-binding curve for [3H] DTG in membranes prepared by 
sonicating MCF7 and MDA-MB-468 cell line. Bmax and Kd were calculated using 
GraphPad Prism. 
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Figure 3-18: Saturation binding of [3H] DTG in breast cancer cell lines (A: 
MCF7, B: MDA-MB-468) 
Saturation binding curve for [3H] DTG in breast cancer cell lines. Non-specific 
binding was determined in the presence of 1mM haloperidol. Figure represents 
mean ± SEM from 3 independent experiments. One-way ANOVA, using the 
highest concentration of ligand as comparator, shows a strong concentration-
dependant increase in ligand binding: A (MCF7) [F(6,14) = 5.32, p = 0.0048]; B 
(MDA-MB-468) [F(6,14) = 9.71, p = 0.0003]. 
 
The mean pKd ± SEM of [3H] DTG for pan-sigma binding in MCF7 and MDA-
MB-468 was 7.92 ± 0.03 and 7.88 ± 0.01, respectively. The Bmax was found to 
be 2050 ± 100 and 850 ± 200fMol/mg protein. This is a representative of 3 
independent saturation experiments. 
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3.11 Colorectal cancer cell lines (Caco-2, SW480, HT-29 and 
HCT 116). 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for four colorectal cancer cell lines: Caco-2, HCT 116, HT-29 and 
SW480. Figure 3-19 shows saturation binding curve for [3H] DTG in membranes 
prepared by sonicating colorectal cancer cell lines. Bmax and Kd were calculated 
using GraphPad Prism. 
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Figure 3-19: Saturation binding of [3H] DTG to colorectal cancer cell lines 
(A: Caco-2, B: HCT 116, C: HT-29 and D: SW480) 
Saturation binding curve for [3H] DTG to membranes prepared from colorectal 
cancer cell lines. Non-specific binding was determined in the presence of 1mM 
haloperidol. Figure represents mean ± SEM from 3 independent experiments. 
One-way ANOVA, using the highest concentration of ligand as comparator, 
shows a strong concentration-dependant increase in ligand binding: A (Caco-2) 
[F(6,14) = 14.4, p < 0.0001]; B (HCT 116) [F(6,13) = 49.9, p < 0.0001]; C (HT-
29) [F(6,14) = 10.5, p = 0.0002]; D (SW480) [F(6,28) = 4.8, p = 0.0018]. 
The mean pKd  ± SEM of [3H] DTG for pan-sigma binding in Caco-2, HCT 116,  
 
HT-29 and SW480 cells was found to be 7.28 ± 0.07, 7.48 ± 0.05, 7.55 ± 0.06 
and 7.65 ± 0.03. The Bmax was determined 2750 ± 450, 1050 ± 100, 2750 ± 650 
and 1700 ± 100fMol/mg protein. This is a representative of 3 independent 
saturation experiments. 
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3.12 Human embryonic kidney cell line (293)  
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for 293 cells. Figure 3-20 shows saturation binding curve for [3H] DTG 
in membranes prepared in membranes prepared by sonicating colorectal 
cancer cell lines. Bmax and Kd were calculated using GraphPad Prism. 
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Figure 3-20: Saturation binding of [3H] DTG to 293 cells 
Saturation binding curve for [3H] DTG to membranes prepared from 293 cells. 
Non-specific binding was determined in the presence of 1mM haloperidol. 
Figure represents mean ± SEM from 3 independent experiments. One-way 
ANOVA, using the highest concentration of ligand as comparator, shows a 
strong concentration-dependant increase in ligand binding: [F(6,21) = 55.4, p < 
0.0001]. 
 
The mean pKd ± SEM of [3H] DTG for pan-sigma binding in 293 cells was 7.81 
± 0.05 and the Bmax was found to be 1700 ± 100fMol/mg protein. This is a 
representative of 3 independent saturation experiments. 
3.13 Lung cancer cell line (A549). 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for A549 cells. Figure 3-21 shows saturation binding curve for [3H] 
 Chapter 3. Results 
 
 104 
DTG in membranes prepared by sonicating colorectal cancer cell lines. Bmax 
and Kd were calculated using GraphPad Prism. 
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Figure 3-21: Saturation binding of [3H] DTG in A549 
Saturation binding curve for [3H] DTG to membranes prepared from A549 cells. 
Non-specific binding was determined in the presence of 1mM haloperidol. 
Figure represents mean ± SEM from 3 independent experiments. One-way 
ANOVA, using the highest concentration of ligand as comparator, shows a 
strong concentration-dependant increase in ligand binding: [F(6,14) = 26.8, p < 
0.0001]. 
 
 
The mean pKd ± SEM of [3H] DTG for pan-sigma binding in A549 was 7.64 ± 
0.07. The Bmax was found to be 1550 ± 150fMol/mg protein. Data were 
calculated from 3 independent saturation experiments. 
In order to determine the relative ratio of sigma-1 receptors to sigma-2 binding 
sites, one should be able to subtract the Bmax of (+) pentazocine (sigma-1 
receptors) from the DTG binding (pan-sigma ligand, binding to both sigma-1 
receptors and sigma-2 binding sites). 
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Origin Cell Line Sigma-1 Bmax   
fMol/mg 
protein 
PanSigma-2 
Bmax   
fMol/mg 
protein 
Calculated 
sigma-2 
Bmax 
Oesophagus FLO-1 1100 1050 -50 
OE21 2250 1400 -850 
OE33 2400 1100 -1300 
     
Breast  MCF7 No binding 2050 2050 
 MDA-
MB-468 
1700 850 -850 
     
Colorectal Caco-2 2400 2750 350 
 HCT 116 1700 1050 -650 
 HT-29 2250 2750 550 
 SW480 2250 1700 -550 
     
Human 
embryonic 
kidney  
293 1600 1700 100 
     
Lung  A549 1300 1550 250 
 
Table 3-7: Calculation of sigma-2 binding site density. 
 
It is clear that (+) pentazocine binding was higher in most cases, indicating this 
simple calculation was inappropriate. Therefore a second series of experiments 
were performed to calculate an accurate ratio of sigma-1 to sigma-2 sites. 
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3.14 Competition binding 
In order to calculate sigma-2 binding site density in cancer cell lines from 
various tissues I carried out competition binding of [3H] DTG and (+) 
pentazocine in these cell lines.  
 
3.14.1 Oesophageal cancer cell lines 
 
Competition binding experiments were carried out to determine the proportion 
of sigma-1 receptors to sigma-2 binding sites in three oesophageal cancer cell 
lines: FLO-1, OE21 and OE33. Figure 3-22 Figure 3-22 shows competition 
binding curves in membranes prepared by sonicating oesophageal cancer cell 
lines. 
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Figure 3-22: Competition binding between [3H] DTG and (+) pentazocine in 
oesophageal cancer cell lines. 
Data represented as percent specific binding of [3H] DTG in presence of 
increasing concentration of (+) pentazocine. A: FLO-1, B: OE21 and C: OE33 
cell lines. Figure represents mean ± SEM from 3-5 independent experiments. 
MCF7 data are shown to highlight the binding profile of a pure sigma-2 
population. Two-way ANOVA, comparing the effects of cell line and 
concentration of (+) pentazocine (between 10nM and 10μM), was performed. 
All 10 cell lines were compared pair-wise with MCF7 cells only. The 
concentration of (+) pentazocine had a major effect [F(6,207) = 655, p < 0.0001], 
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contributing to 84% of the variation; cell type also had an effect [F(10, 207) = 
35.1, p < 0.0001]. * signifies data point significantly different to MCF7 results at 
that data point. 
  
The percentage of sigma-1 binding sites in FLO-1, OE21 and OE33 was found 
to be 29, 49 and 12%, respectively and sigma-2 binding sites was found to 
contribute 71, 51 and 88%. 
 
3.14.2 Breast cancer cell lines 
 
Competition binding experiments were carried out to determine the proportion 
of sigma-1 receptors to sigma-2 binding sites in two breast cancer cell lines: 
MCF7 and MDA-MB-468. Figure 3-23 shows competition binding curves in 
membranes prepared by sonicating breast cancer cell lines. 
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Figure 3-23: Competition binding between [3H] DTG and (+) pentazocine in 
breast cancer cell lines. 
Data represented as percent specific binding of [3H] DTG in presence of 
increasing concentration of (+) pentazocine A: MCF7, B: MDA-MDA-468 cell 
lines. Figure represents mean ± SEM from 3-5 independent experiments. MCF7 
data are shown to highlight the binding profile of a pure sigma-2 population. 
Two-way ANOVA, comparing the effects of cell line and concentration of (+) 
pentazocine (between 10nM and 10μM), was performed. All 10 cell lines were 
compared pair-wise with MCF7 cells only. The concentration of (+) pentazocine 
had a major effect [F(6,207) = 655, p < 0.0001], contributing to 84% of the 
variation; cell type also had an effect [F(10, 207) = 35.1, p < 0.0001]. * signifies 
data point significantly different to MCF7 results at that data point. 
 
 
The percentage of sigma-1 binding sites for MDA-MB-468 cells was found to be 
36% and sigma-2 was 64%.  There was no sigma-1 expression in the case of 
MCF7 cells. 
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3.14.3 Colorectal cancer cell line 
Competition binding experiments were carried out to determine the proportion 
of sigma-1 receptors to sigma-2 binding sites in four colorectal cancer cell lines: 
Caco-2, HCT 116, HT-29 and SW480 cells. Figure 3-24 shows competition 
binding curves in membranes prepared by sonicating colorectal cancer cell 
lines. 
 
 
Figure 3-24: Competition binding between (+) pentazocine and [3H] DTG in 
colorectal cancer cell lines. 
Data represented as percent specific binding of [3H] DTG in presence of 
increasing concentration of (+) pentazocine A: Caco-2, B: HCT 116 C: HT-29 
and D: SW480 cell lines. Figure represents mean ± SEM from 3-5 independent 
experiments. MCF7 data are shown to highlight the binding profile of a pure 
sigma-2 population. Two-way ANOVA, comparing the effects of cell line and 
concentration of (+) pentazocine (between 10nM and 10μM), was performed. 
All 10 cell lines were compared pair-wise with MCF7 cells only. The 
concentration of (+) pentazocine had a major effect [F(6,207) = 655, p < 0.0001], 
contributing to 84% of the variation; cell type also had an effect [F(10, 207) = 
35.1, p < 0.0001]. * signifies data point significantly different to MCF7 results at 
that data point 
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The percentage of sigma-1 binding sites in Caco-2, HCT 116, HT-29 and 
SW480 was found to be 20, 40, 23 and 19%, respectively. Sigma-2 binding 
sites contributed 80, 60, 77 and 81%, respectively. 
 
3.14.4 Human embryonic kidney (293) and lung cancer (A549) cell lines. 
 
Competition binding experiments were carried out to determine the proportion 
of sigma-1 receptors to sigma-2 binding sites in human embryonic kidney and 
lung cancer cell lines: 293 and A549 cells. Figure 3-25 shows competition 
binding curves in membranes prepared by sonicating 293 and A549 cell lines.  
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Figure 3-25: Competition binding of (+) pentazocine and [3H] DTG in 
human embryonic and lung cancer cell lines. 
Data represented as percent specific binding of DTG in presence of increasing 
concentration of (+) pentazocine. A: 293, B: A549 cell lines. Figure represents 
mean ± SEM from 3 independent experiments. MCF7 data are shown to 
highlight the binding profile of a pure sigma-2 population. Two-way ANOVA, 
comparing the effects of cell line and concentration of (+) pentazocine (between 
10nM and 10μM), was performed. All 10 cell lines were compared pair-wise 
with MCF7 cells only. The concentration of (+) pentazocine had a major effect 
[F(6,207) = 655, p < 0.0001], contributing to 84% of the variation; cell type also 
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had an effect [F(10, 207) = 35.1, p < 0.0001]. * signifies data point significantly 
different to MCF7 results at that data point. 
The percentage of sigma-1 sites in 293 and A549 was found to be 40 and 29%, 
respectively. Sigma-2 binding sites contributed 60 and 71%, respectively.  
 
Figure 3-26 shows a summary of the relative ratio of sigma-1 receptors in all of 
the cancer cell lines tested. 
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Figure 3-26: Summary of the relative ratio of sigma-1 and sigma-2 binding 
sites in a range of cells. 
The graph shows the contribution of sigma-1 receptors as a percentage of all 
sigma binding sites, as determined by competition binding assays. Data 
represents mean ± SEM from 3-5 independent experiments. Unpaired 1-way 
ANOVA, followed by post hoc Tukey (“all means”) comparison, with p value 
adjusted for multiple comparisons, shows a significant difference in % sigma-1 
receptor expression values: [F(10,32) = 5.47, p = 0.0001]. MCF7 cells express 
a significantly lower % sigma-1 receptors than: 293 cells (p = 0.015); HCT 116 
cells (p = 0.0022); MDA-MB-468 cells (p = 0.031); and OE21 cells (p = 0.0005). 
OE33 cells express a significantly lower % sigma-1 receptors than: OE21 cells 
(p = 0.0027); and HCT 116 cells (p = 0.0141). OE21 cells express a significantly 
higher % sigma-1 receptors than: Caco-2 cells (p = 0.040); FLO-1 cells (p = 
0.0313); and SW480 cells (p = 0.0428). All other comparisons show no 
significant difference. 
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Concentration of sigma-2 binding site was determined by subtracting sigma-1 
receptor density from pan-sigma binding site density as show in table 3-14 
below. 
 
Origin Cell 
Line 
DTG Bmax 
fMol/mg 
protein 
Sigma-1 
binding 
site % 
Sigma-1 
receptor 
fMol/mg 
protein 
Sigma-2 
binding 
site % 
Sigma-2 
binding 
site 
fMol/mg 
protein 
Oesophagus FLO-1 1050 29 305 71 745 
OE21 1400 49 685 51 715 
OE33 1100 12 130 88 970 
       
Breast  MCF7 2050 0 0 100 2050 
MDA-
MB-468 
850 36 305 64 545 
       
Colorectal Caco-2 2750 20 550 80 2200 
HCT 
116 
1050 40 420 60 630 
HT-29 2750 23 630 77 2120 
SW480 1700 19 325 81 1375 
       
Human 
embryonic 
kidney  
293 1700 40 680 60 1020 
       
Lung  A549 1550 29 450 71 1100 
 
Table 3-8: Calculation of sigma-1 and sigma-2 binding sites based on 
competition binding assay. 
 
 Chapter 3. Results 
 
 115 
3.15 Discussion 
In this chapter, it was shown that tumour cell lines from various tissues express 
both sigma-1 receptors and sigma-2 binding sites. Most cell lines express both 
sigma-1 receptors and sigma-2 binding sites. This finding is consistent with 
previous studies done to quantify these receptors in various tumour cell lines. 
MCF7 cell lines only expressed sigma-2 binding sites and failed to show any 
specific binding to [3H] (+) pentazocine, which is again consistent with previous 
findings (Vilner et al., 1995b). 
 
These calculations now bring into question the previously accepted method of 
calculating sigma-2 levels in cell lines (DTG in the presence of pentazocine or 
dextrallorphan). These calculations show clearly that the number of sigma-2 
binding sites have been greatly overestimated in nearly all previous publications 
in this field, as its likely that, if present, sigma-1 receptors will have also been 
bound by radioligand. Only time will tell if these findings can be published and 
whether fellow experimenters in the field will take heed. 
 
In order to address this failing, an alternative approach was taken. Sigma-1 
Bmax ((+) pentazocine) and pan-sigma levels (DTG) were determined to 
calculate sigma-1 and sigma-2 levels. This calculation has led to several cell 
lines having negative levels of sigma-2 sites, as the Bmax from DTG binding was 
lower than that of (+) pentazocine levels. Other groups have performed sigma-2 
binding assays using increasing DTG concentrations in the presence of (+) 
pentazocine or dextrallorphan. This method can skew data, as (+) pentazocine 
and dextrallorphan have appreciable affinities for sigma-2 sites. While the 
concentrations of these ligands would not appreciably compete with high 
concentrations of DTG for the sigma-2 site, calculations show that they would 
also impact on the [3H] DTG binding at low concentrations.  
 
This is not the only error caused by such an approach. Radioligand binding is 
one of the few assays performed where concentrations of materials are 
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determined solely by either counting the amount of radiochemical present or 
measuring the volume of liquid removed. Radioligands are prepared and 
shipped with specific activity values provided. Should these be erroneous or 
subject to chemical breakdown of the radioligand, permitting radioactive 
material to be present which is not the ligand will lead to incorrect values being 
determined. Tritium exchange is common with some chemicals, where the 
radioactive component of the ligand exchanges protons with some other 
material, including water. This would permit tritiated water to contribute to the 
radioactive signal without contributing to the binding.  
 
Secondly, whilst quality control of manufacture is not in question with 
commercial suppliers of radioligands, many ligands are provided in volatile 
solvents. Removal of a fixed amount of liquid from a “fresh” bottle may contain 
much less radioligand than after several months’ storage and use when a bottle 
has been opened many times and solvent evaporation can be significant from a 
small initial volume. 
 
It was not found necessary to compare the density of sigma-1 and sigma-2 
binding sites – they do appear, after all, to be very different proteins. However, 
the scientific field has grouped these targets together and frequently performs 
such comparisons. This is seen in countless publications. The currently 
favoured method appears flawed. Initial attempts to use an alternative protocol 
((+) pentazocine Bmax for sigma-1 receptors and DTG Bmax for all sigma 
receptors followed by simple arithmetic) failed. 
 
At this point, it was considered whether the presence of sigma-2 sites in (+) 
pentazocine quantification of sigma-1 receptors was also a problem. 
 
In “worst case” scenario, where the affinity of pentazocine for the sigma-2 
binding site is 728nM, approximately 12.2% of the sigma-2 sites are occupied at 
a concentration of 100nM. There is no need to consider the higher 
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concentration (1µM), as this would not be used when performing saturation 
binding analyses. 
 
Binding assays with [3H] (+) pentazocine used up to 128nM, at which 
concentration 15.1% of the sigma-2 binding sites would be occupied.  
 
Could this explain why the (+) pentazocine saturation data overestimate sigma-
1 receptor number? During the masking protocol, the lifespans of the ligand-
protein complex for unlabelled (+) pentazocine and dextrallorphan are 
unimportant, as it is their effects under equilibrium that one is interested in. The 
proportion of sites occupied is all that matters. In such binding assays, the 
lifespan of the radioligand-target is important, as, at the end of the assay bound 
is separated from free by rapid washing and filtering. As the equilibrium 
constant Kd equals Koff/Kon (the Koff rate, or dissociation rate divided by Kon, the 
association rate) there is a direct relationship between Kd and Koff. I do not have 
and cannot calculate the Kon for (+) pentazocine to both the sigma-1 receptor 
and sigma-2 site; I will assume, for the sake of this discussion, they are similar. 
Koff for sigma-2 would then be 728/17 of that for sigma-1 receptor (relative Kd 
values). The dissociation rate for pentazocine for the sigma-2 site would be 43 
times faster than for the sigma-1 site.  
 
Association rate constants (Kon) are commonly in the range of 105- 106 M-1. s-1. 
Using these values to plot the dissociation rate, expressed as t1/2 (half time = 
ln(2)/Koff), one can see that as Kd increases, the half-life decreases (Figure 3-
27)  
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Figure 3-27: Relationship between Kd and off rate. 
Figure showing relationship between Kd and half time of dissociation. Plots are 
presented for Kon of 105 and 106 M-1.s-1. Dotted lines represent the highest 
affinity of (+) pentazocine for the sigma-2 binding site (728nM) and the lowest 
affinity of (+) pentazocine for the sigma-1 receptor (17nM). The graph is plotted 
using a log scale, but values are presented in standard format to aid 
comprehension. 
 
From the above graph, we can see that for (+) pentazocine binding to the 
sigma-1 receptor the half-life of dissociation is between 41 and 408 seconds, 
using Kon of 106 and 105 M-1.s-1, respectively. Taking the smallest value would 
mean that after 41 seconds half of the (+) pentazocine would have dissociated 
from the receptor. For (+) pentazocine binding to the sigma-2 binding site the 
half-life of dissociation is between 0.95 and 9.5 seconds, using Kon of 106 and 
105 M-1.s-1, respectively. Typically, binding assay wash protocols are complete 
in under 5 seconds. 
 
In such a scenario, the dissociation from the sigma-1 receptor would be 
negligible whereas that to the sigma-2 would be either complete (t1/2 0.95 s) or 
significant (t1/2 9.5 s). As there was no evidence of pentazocine binding to 
MCF7 cells which have no sigma-1 receptors yet an abundance of sigma-2 
binding sites, it would appear that, whilst one should consider the possibility, 
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[3H] (+) pentazocine binding to sigma-2 sites does not appear to cause an 
artefactual signal. 
 
Using solely [3H] DTG to obtain a pan-sigma Bmax and (+) pentazocine 
competition to obtain a ratio of sigma-1 to sigma-2 sites is the best approach if 
direct comparisons are needed. Computer assisted data analysis (e.g. 
GraphPad Prism, as used here) is sufficiently developed to determine the 
presence of relatively small proportions of one receptor or the other. By using 
the protocol used here, we can be confident that a direct ratio is well defined 
and reliable.  
 
The presence of sigma-2 binding sites in all tumour cell lines considered here 
and other publications (van Waarde et al., 2010, Vilner et al., 1995b) (although 
see the caveat above), and its higher levels than in non-cancer cells does 
suggest it is a useful target both for tumour imaging as well as possible targeted 
therapy against such tumours. Till date no one has been able to find a cell line 
which does not possess sigma-2 binding sites and it is overcome by the use of 
the sigma-1–specific ligand (+) pentazocine which can be used to selectively 
bind sigma-1 receptors at the concentrations used in radioligand binding 
competition assays. 
 
It has been confirmed and verified that MCF7 cells do not express sigma-1 
receptors and these cells remain the only cells routinely used which lack sigma-
1 receptors allows their use in drug discovery to search out sigma-2 binding site 
ligands in the absence of interference from sigma-1 receptor binding. The use 
of (+) pentazocine in cells containing sigma-1 receptors and DTG in cells 
lacking sigma-1 receptors now allows me to use these protocols in considering 
the affinities of a range of potential ligands at these two sites. Furthermore, it 
was possible to determine the effects of sigma-2 ligands on the biology of cells 
without the interference of sigma-1 receptors. This will be the target of the 
following two chapters: MCF7 cells will be used to determine the affinity and 
cytotoxicity of a range of novel compounds identified as having a graded affinity 
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and range of effects on cells through sigma-1 receptors; these will be compared 
with established ligands known to have effects through the sigma-2 binding site. 
A549 and MDA-MB-468 cell lines were also used since they contain both 
sigma-1 receptors and sigma-2 binding sites in order to determine whether the 
effects through these two proteins can be determined as being additive, 
synergistic or antagonistic towards each other. 
 
One further problem does arise: Direct comparison of [3H] (+) pentazocine 
binding and the calculated number of sigma-1 receptors from [3H] DTG 
competition binding assays do not correlate well (Table 3-9). 
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Origin Cell Line Determined Bmax 
fMol/mg protein 
Calculated Bmax 
Sigma-1 receptor, 
fMol/mg protein 
Oesophagus FLO-1 1100 305 
OE21 2250 685 
OE33 2400 130 
    
Breast  MCF7 0 0 
 MDA-MB-
468 
1700 305 
    
Colorectal Caco-2 2400 550 
 HCT 116 1700 420 
 HT-29 2250 630 
 SW480 2250 325 
    
Human 
embryonic 
kidney  
293 1600 680 
    
Lung  A549 1300 450 
 
Table 3-9: Calculation of sigma-1 and sigma-2 binding sites based on 
competition binding assay. 
Table showing the experimentally derived Bmax of sigma-1 receptors in a range 
of cancer cell lines from [3H] (+) pentazocine saturation binding assays 
alongside the calculated Bmax from [3H] DTG saturation and (+) pentazocine 
competition assays.  
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Figure 3-28: Comparison of sigma-1 Bmax calculated by two methods. 
Figure comparing experimentally derived Bmax of sigma-1 receptors in a range 
of cancer cell lines from [3H] (+) pentazocine saturation binding assays 
alongside the calculated Bmax from [3H] DTG saturation and (+) pentazocine 
competition assays. Linear regression shows the line y = 0.1594x + 132.6, R2 = 
0.27 [F(1,9) = 3.38, p = 0.099]. 
 
From the above table and figure, it is clear that there are other issues, which 
require resolving. There is little correlation between sigma-1 receptor densities 
calculated by the two methods. This would suggest that, while [3H] DTG 
competition with (+) pentazocine is a good method for calculating relative 
proportions of sigma-1 receptors to sigma-2 binding sites, the two-step nature 
of calculating a Bmax indirectly may introduce additional errors. Comparing my 
internal data, with pKd [3H] DTG (this chapter) 7.92 and Ki DTG (Chapter 4) 8.0 
(both determined using MCF7 cells) would suggest that the [3H] DTG used in 
my studies is comparable in affinity to the unlabeled DTG and has neither 
degraded nor contains significant levels of contaminants. 
 
However, the affinity of [3H] (+) pentazocine for the sigma-1 receptor in this 
study (pKd 7.15 – 7.78, this chapter) is also similar to that previously found in 
several previous studies (Brimson et al., 2011, Spruce et al., 2004), and the 
affinity of (+) pentazocine for the sigma-2 binding site (355nM, Chapter 4) is 
higher than previously described (Vilner and Bowen, 2000, Xu et al., 2015). 
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This suggests that all reagents used are active and performing as should be 
expected. An alternative suggestion could be that [3H] (+) pentazocine is 
binding sites not recognised by [3H] DTG. By removing one artefact have I 
introduced another?  
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Chapter 4.  AFFINITY OF AMMONIUM SALTS AND 
SIGMA-2 LIGANDS TO THE SIGMA-2 BINDING SITE. 
 
 
Chapter 4. Results 
 
 125 
 
4.1 Background 
 
Sigma receptors were initially described in 1976 as a subtype of opioid 
receptors based on the effects produced by SKF 10047 which could not be 
attributed to  (morphine),  (ketocyclazocin), or  receptors (Martin et al., 
1976) and hence called it sigma opioid receptor. In 1982 Su, whilst working with 
[3H] SKF 10047, managed to characterise a protein with nanomolar affinity (Su, 
1982). This protein was different from the sigma opioid receptor identified by 
Martin et al., in 1976, as it had no affinity for naloxone, an opioid antagonist and 
showed stereoselectivity for dextrorotatory benzomorphans, which is opposite 
to other opioid receptors. Su proposed that it was a distinct class of receptor, 
different from other opioid receptors and called it the sigma binding site (Su, 
1982). 
 
Classification of sigma receptors led to research and synthesis of compounds 
and they were screened for binding affinities for sigma-1 and sigma-2 binding 
sites. Initially many piperazine, piperidine dialkylamine and trialkyamine 
derivative were synthesized and shown to bind with high affinity to sigma-1 and 
sigma-2 binding sites (Berardi et al., 2009, Huang et al., 1998, Huang et al., 
2001a, Narayanan et al., 2011, Newman et al., 2001). With subsequent 
improvement in binding assays, more selective ligands towards both subtypes 
of sigma binding sites became available. Sigma-2 binding site ligands can be 
classified in four classes based on their structure (Huang et al., 2014).  
 
1. 6,7-dimethoxytetrahydroisoquinoline derivatives,  
2. Tropane related bicyclic structures,  
3. Siramesine related indole derivatives and  
4. Cyclohexylpiperazine analogues.  
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There is also a small group of ligands, which are structurally not related to any 
of the four classes. 
 
Despite extensive research and development of high affinity sigma-2 binding 
site ligands, the pharmacophore model for sigma-2 binding site is still not 
available. One of the main reasons for not having a pharmacophore is probably 
because the sigma-2 binding site is not cloned and also the fact that there is 
diverse range of molecules that bind to sigma-2 binding site. There are several 
binding models available for the sigma-2 binding site, each based on a limited 
number of sigma-2 ligands. One of the models is proposed by Glennon 
(Glennon, 2005), based on his work with piperidines, piperazine, long chain 
dialkylamines and long chain trialkylamines.  According to this model, for a 
ligand to fit sigma-2 binding site binding pocket, compounds should possess an 
amine site and two hydrophobic sites. One of the hydrophobic site being phenyl 
group and five carbon units away from the amine and the other hydrophobic site 
four carbon units away from amine site as shown in Figure 4-1. 
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Figure 4-1: Hypothetical sigma-2 binding site pharmacophore. 
The sigma-2 binding site pocket consists of an amine binding site and two 
hydrophobic sites. Hydrophobic region A is situated at a distance of four carbon 
atoms whereas hydrophobic region B seems to accommodate a phenyl group 
at a distance of five carbon atom away from amine (Glennon 2005). 
  
 
It has been previously suggested that ligands with phenylpropylamine-based 
structures are more likely to result in high-affinity sigma-2 selective ligands 
(Maeda et al., 2002). However, molecules based on simple ammonium salts 
have not been investigated as yet. The purpose of this section of my thesis was 
to investigate the affinity of ammonium salts and to compare it with 
commercially available sigma-2 ligands. The ammonium salts differ from 
commonly used sigma-2 ligands, which often contains more than one nitrogen 
and have complex aromatic ring structures. I have used MCF7 cells as they 
have been identified to only have sigma-2 binding sites and lack sigma-1 
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receptors (Vilner et al., 1995b). Since sigma-1 and sigma-2 are different 
proteins, using MCF7 cells would exclude the effects of sigma-1 receptors. 
 
4.2 Saturation [3H] DTG binding in MCF7 cells 
 
Saturation binding experiments were carried out to determine Bmax and Kd of 
[3H] DTG for breast cancer cell line MCF7. Figure 4-2 shows saturation-binding 
curve for [3H] DTG in membranes prepared by sonicating MCF7 cell line. Bmax 
and Kd were calculated using nonlinear regression software (GraphPad Prism, 
California). 
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Figure 4-2: Saturation binding of [3H] DTG in MCF7 cells 
The mean pKd ± SEM of [3H] DTG for the sigma-2 binding site in MCF7 cells 
was 7.92 ± 0.03 and the Bmax was found to be 2050 ± 100fMol/mg protein. Non-
specific binding was determined in the presence of 1mM haloperidol. Figure 
represents mean ± SEM from 3 independent experiments. One-way ANOVA, 
using the highest concentration of ligand as comparator, shows a strong 
concentration-dependant increase in ligand binding [F(6,14) = 5.32, p = 0.0048]. 
Data previously shown in Figure 3-18. 
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4.3 Simple straight chain ammonium salts 
 
The primary ammonium salt consists of single nitrogen and a single carbon 
chain. There have been a number of previous studies looking at structural 
relationship between sigma receptor ligands and their affinity to sigma receptors 
(Ablordeppey et al., 2000, Glennon et al., 1991c). The importance of nitrogen 
atom for sigma receptors ligands has been shown for the phenylalkylpiperidines 
and phenylalkylpiperzines (Ablordeppey et al., 2000), however no one has 
looked at simple molecules as the ammonium salts discussed in this chapter. 
 
4.4 Primary ammonium salt affinity for the sigma-2 binding site 
 
The primary ammonium salts consist of a single carbon and a single carbon 
chain. The affinity of primary ammonium salts for sigma-2 binding site was 
calculated using radioligand binding. In order to visualise the affinities for the 
sigma-2 binding site more clearly with symmetrical errors, the Ki values 
obtained from the competition binding curves were converted into pKi values (-
log10Ki) shown in Figure 4-3. 
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Figure 4-3 Summary of primary ammonium salt binding to the sigma-2 
binding site. 
The affinities of the primary ammonium salts for the sigma-2 binding site (pKi ± 
SEM) were: butylammonium 3.26 ± 0.05; pentylammonium 3.9 ± 0.1; 
hexylammonium 5.1 ± 0.2; octylammonium 5.2 ± 0.2 and decylammonium 5.2 ± 
0.2. Error bars represent SEM from 3-5 independent experiments. Unpaired 1-
way ANOVA, followed by post hoc Tukey (“all means”) comparison, with p value 
adjusted for multiple comparisons, shows a significant difference in affinities 
[F(4,15) = 45.5, p < 0.0001]. Propylammonium is excluded from statistical 
analysis, as I was unable to obtain a value, due to low affinity. Butylammonium 
has significantly lower affinity than all others (p ≤ 0.038). Pentylammonium has 
significantly lower affinity than the remaining ammonium salts (p ≤ 0.0002). The 
affinities of hexylammonium, octylammonium and decylammonium are not 
significantly different from each other.  
 
Of the primary amines tested, all except propylammonium were found to bind to 
sigma-2 binding sites. A trend was observed between carbon chain length and 
affinity for sigma-2 binding site. There was a slight increase in affinity for the 
sigma-2 binding site in the primary ammonium salts as the carbon chain length 
increases from 4 to 6, peaking at pKi 5.1 for hexylammonium. Since the affinity 
did not increase any further with increase in carbon chain length I did not 
investigate primary ammonium salts beyond decylammonium. 
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4.5 Secondary ammonium salt affinity for the sigma-2 binding 
site 
 
The secondary ammonium salts consist of single nitrogen and two carbon 
chains. Dimethylammonium has been shown to interfere with cell growth and 
has a toxic effect on tumour cells (Guest and Varma, 1991). The mechanism by 
which dimethylammonium causes these effects has not been investigated. The 
affinity of secondary ammonium salts to sigma-2 binding site was determined 
by radiolabelled competition binding assay. In order to visualize the affinities for 
sigma-2 binding site more clearly, Ki values obtained from competition binding 
curves were converted into pKi values. The pKi values (± SEM) are shown in 
Figure 4-4. 
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Figure 4-4: Summary of Secondary ammonium salt binding to the sigma-2 
binding site 
The affinities of the secondary ammonium salts for the sigma-2 binding site (pKi 
± SEM) were: dipropylammonium 4.10 ± 0.07; dibutylammonium 5.64 ± 0.07; 
dipentylammonium 6.9 ± 0.2; dihexylammonium 7.58 ± 0.06 and 
dioctylammonium 7.9 ± 0.5. Error bars represent SEM from 3-5 independent 
experiments. Unpaired 1-way ANOVA, followed by post hoc Tukey (“all means”) 
comparison, with p value adjusted for multiple comparisons, shows a significant 
difference in affinities [F(4,15) = 40.2, p < 0.0001]. Dipropylammonium has 
significantly lower affinity than all others (p < 0.004). Dibutylammonium has 
significantly lower affinity than the remaining ammonium salts (p < 0.02). The 
affinities of dipentylammonium, dihexylammonium and dioctylammonium are 
not significantly different from each other. 
 
A similar trend was observed with secondary ammonium salts. As the chain 
length increased, so did the affinity peaking at pKi of 7.9 for dioctylammonium. 
There was an increase in affinity for the sigma-2 binding site as the carbon 
chain length increases from 3 to 6; however the increase was not large enough 
to warrant continuing investigating longer chain lengths ammonium salts in this 
series. 
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4.6 Tertiary ammonium salt affinity for the sigma-2 binding site 
 
The tertiary ammonium salts discussed in this section consist of single central 
nitrogen and three straight carbon chains. The preliminary data showed that the 
triethylammonium has sigma-2 binding site affinity therefore the tertiary 
ammonium salts series from trimethylammonium with three single carbons to 
tridodecylammonium with twelve carbons were investigated. The affinity for the 
tertiary ammonium salts was investigated using radioligand binding competition 
assays. In order to visualise the affinities for the sigma-2 binding site more 
clearly, Ki values obtained from the competition binding curves were converted 
into pKi values. The pKi (± SEM) values are represented in Figure 4-5. 
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Figure 4-5: Summary of tertiary ammonium salts binding to the sigma-2 
binding site.  
The mean pKi ± SEM values for tertiary ammonium salts were: 
triethylammonium 3.66 ± 0.04; tripropylammonium 4.36 ± 0.07; 
tributylammonium 5.5 ± 0.2; tripentylammonium 6.1 ± 0.1; trihexylammonium 
6.63 ± 0.03; trioctylammonium 3.74 ± 0.06 and tridodecylammonium 4.1 ± 0.6. 
Error bars represent SEM from 3-5 independent experiments. Unpaired 1-way 
ANOVA, followed by post hoc Tukey (“all means”) comparison, with p value 
adjusted for multiple comparisons, shows a significant difference in affinities 
[F(6,21) = 23.8, p < 0.0001]. Triethylammonium, tripropylammonium, 
trioctylammonium and tridodecylammonium have significantly lower affinity than 
tributylammonium, tripentylammonium and trihexylammonium (p ≤ 0.049). 
Tributylammonium has significantly lower affinity than trihexylammonium (p = 
0.049). No other comparison show significant differences. 
 
 
On assessing the affinities of tertiary ammonium salts, the same trend persists. 
Increasing the length of the alkyl group resulted in increased affinity. The affinity 
peaked at pKi 6.63 for trihexylammonium and further increased in the chain 
length resulted in rapid decline in the affinity. Introduction of branched chain 
alkyl groups showed no reproducible pattern: triisopropylammonium had lower 
affinity than tripropylammonium, triisobutylammonium had same affinity as 
tributylammonium, and triisopentylammonium showed slightly better affinity 
Chapter 4. Results 
 
 135 
than tripentylammonium. There was a decrease in affinity from six to the twelve 
carbon long chain (tridodecylammonium pKi 4.1 ± 0.6) therefore no ammonium 
salts were tested with carbon chains longer than twelve. 
 
4.7 Quaternary ammonium salt affinity for the sigma-2 binding 
site 
 
The quaternary ammonium salts discussed in this section consist of a single 
positive nitrogen and 4 straight carbon chains. A series of quaternary 
ammonium salts from one carbon to four carbons in chain length was tested for 
sigma-2 binding site affinity using radioligand competition assays. In order to 
visualise the affinities for sigma-2 binding site more clearly, Ki values obtained 
from the competition binding were converted into pKi values shown in Figure 
4-6 
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Figure 4-6: Summary of quaternary ammonium salt binding to the sigma-2 
binding site 
The mean pKi ± SEM values for quaternary ammonium salts were: 
tetrapropylammonium 3.5 ± 0.2 and tetrabutylammonium 4.22 ± 0.08. Error bars 
represent SEM from 3-5 independent experiments. Unpaired student’s t-test 
shows that the affinity of tetrabutylammonium is significantly higher than 
tetrapropylammonium (p = 0.016). 
 
Tetramethylammonium and tetraethylammonium had no affinity with in the 
range tested. Quaternary ammonium salts showed only little affinity for the 
sigma-2 binding site and there was little increase in affinity as the carbon chain 
length increased, therefore no larger quaternary amines were tested for sigma-
2 binding site affinity.  
 
4.8 Simple branched chain ammonium salts 
In an earlier section of this chapter I identified 4 high affinity sigma-2 binding 
site ligands, dipentylammonium, dihexylammonium, dioctylammonium and 
dicyclohexylammonium. In order to try to find higher affinity ligands I moved on 
to investigate branched chain ammonium salts. The branched chain ammonium 
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salts remain simple ammonium salts, and are the simplest variation on that 
could alter the affinity for the sigma-2 binding site.  
 
4.9 Primary branched chain ammonium salt affinity for sigma-2 
binding site affinity 
 
Despite the straight chain primary ammonium salts having low affinity for the 
sigma-2 binding site, the branched chain primary ammonium salts were 
investigated for their affinities for sigma-2 binding site. The affinities of 1-
adamantylammonium and 2-adamantylammonium were assessed using 
radioligand competition binding and the Ki values obtained from the competition 
binding were converted to pKi as shown in the Figure 4-7. 
 
     
Figure 4-7: Summary of simple primary branched chain primary 
ammonium salt binding to the sigma-2 binding site. 
The affinities of these agents for the sigma-2 binding site (pKi ± SEM) were: 1-
adamantylammonium 5.04 ± 0.05 and 2-adamantylammonium 5.5 ± 0.2. Error 
bars represent SEM from 3-5 independent experiments. Unpaired student’s t-
test shows that the affinities of 1-adamantylammonium and 2-
adamantylammonium are not significantly different from each other (p = 0.067). 
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Unlike simple straight chain ammonium salts, branched chain ammonium salts 
had very low affinity for sigma-2 binding site. The affinity of 1-
adamantylammonium for the sigma-2 binding site was pKi 5.04 and 2-
adamantylammonium was pKi 5.5. No other primary branched chain ammonium 
salts were assessed for binding to sigma-2 binding site. 
 
4.10 Secondary branched chain ammonium salt affinity for the 
sigma-2 binding site 
 
In order to assess the structure activity relationship of the simple ammonium 
salts with the sigma-2 binding site, some simple branched ammonium salts that 
were of similar chain length to the straight chain ammonium salts with high 
affinity for the sigma-2 binding site, were tested for the sigma-2 binding site 
affinity using [3H] DTG in the radioligand binding competition assay. In order to 
compare the affinities of the simple branched chain ammonium salts K i values 
obtained were converted to pKi, as shown in the Figure 4-8. 
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Figure 4-8: Summary of the simple secondary branched chain ammonium 
salts to the sigma-2 binding site 
The affinities (pKi ± SEM) of the secondary branched ammonium salts for the 
sigma-2 binding site were: diisopropylammonium 4.1 ± 0.1; 
diisobutylammonium 5.2 ± 0.2; di-sec-butylammonium 5.2 ± 0.2; bis-2-
(ethyl)hexylammonium 4.0 ± 0.2 and dicyclohexylammonium 6.86 ± 0.03. Error 
bars represent SEM from 3-5 independent experiments. Unpaired 1-way 
ANOVA, followed by post hoc Tukey (“all means”) comparison, with p value 
adjusted for multiple comparisons, shows a significant difference in affinities 
[F(4,15) = 50.8, p < 0.0001]. All comparisons showed highly significant 
differences (p < 0.002), except diisopropylammonium compared with bis-2-
(ethyl)hexylammonium, and diisobutylammonium compared with di-sec-
butylammonium, which are not significantly different from each other. 
 
 
Of the simple branched secondary amines tested dicyclohexylammonium had 
the highest affinity with a pKi of 6.86. Compared to simple straight chain 
secondary ammonium salts the simple branched ammonium salts were found to 
have low affinities and I could not see a trend of increasing affinity with 
increasing chain length.  
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4.11 Tertiary branched chain ammonium salt affinity for the 
sigma-2 binding site 
 
The simple straight chain tertiary ammonium salts with carbon chain length 
between five and six carbons had the highest affinity for the sigma-2 binding 
site, therefore triisopentylammonium (being the longest simple branched chain 
ammonium salt commercially available) was tested for sigma-2 binding site 
affinity using [3H] DTG in the radioligand binding competition assay. In order to 
compare the affinities of the simple branched chain ammonium salts K i values 
obtained were converted to pKi, as shown in the Figure 4-9. 
 
 
Figure 4-9: Summary of the simple tertiary branched chain ammonium 
salts to the sigma-2 binding site. 
The affinities (pKi ± SEM) of the tertiary branched ammonium salts for the 
sigma-2 binding site were: triisobutylammonium 5.46 ± 0.06 and 
triisopentylammonium 6.40 ± 0.09. Error bars represent SEM from 3-5 
independent experiments. Unpaired student’s t-test shows that 
triisopentylammonium has significantly higher affinity than triisobutylammonium 
(p = 0.0001). 
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The affinity of tertiary branched chain ammonium salts was somewhat similar to 
simple straight chain tertiary ammonium salts. Triisopentylammonium had the 
highest affinity for sigma-2 binding site with pKi of 6.40.  
 
4.12 Sigma-2 ligands affinity for the sigma-2 binding site 
 
In order to compare the affinities of the various commercially available sigma-1 
receptor and sigma-2 binding site ligands, these were also considered and 
tested for sigma-2 binding site affinity using [3H] DTG in the radioligand binding 
competition assay. In order to compare the affinities of these ligands Ki values 
obtained were converted to pKi as shown in Figure 4-10. 
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Figure 4-10: Summary of affinity of sigma-2 ligands to the sigma-2 binding 
site 
The affinities (pKi ± SEM) of the sigma-2 ligands were: ifenprodil 9.4 ± 0.3; DTG 
8.0 ± 0.1; PB28 7.84 ± 0.09; SM21 7.2 ± 0.2; PPCC 7.0 ± 0.3; rimcazole 6.2 ± 
0.1; haloperidol 6.2 ± 0.2; IPAG 6.16 ± 0.09; AG-205 5.4 ± 0.05; progesterone 
4.9 ± 0.2 and SKF 10047 4.84 ± 0.06. Error bars represent SEM from 3-5 
independent experiments. Unpaired 1-way ANOVA, followed by post hoc Tukey 
(“all means”) comparison, with p value adjusted for multiple comparisons, 
shows a significant difference in affinities [F(10,33) = 63.3, p < 0.0001]. 
Ifenprodil binds with significantly higher affinity than all other agents (p < 0.001). 
DTG binds with significantly higher affinity to other reagents (p ≤ 0.013) except 
PB28 and SM21 (ns). PB28 and SM21 bind with significantly higher affinity to 
the remaining drugs (p < 0.025), except each other and PPCC (ns). PPCC 
binds with significantly higher affinity than AG-205, progesterone and SKF 
10047 (p < 0.0001). Rimcazole, haloperidol and IPAG bind with significantly 
higher affinity than progesterone and SKF 10047 (p ≤ 0.0005). All other 
comparisons show no significant differences. 
 
 
Amongst commercially available sigma-2 binding site ligands, ifenprodil had the 
highest affinity (pKi 9.4) and SKF 10047 had the lowest affinity (pKi 4.84). 
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4.13 Discussion 
4.13.1 Primary ammonium salts 
These ammonium salts are different from previously known ligands in their 
simplicity and they have never been tested before. Eight primary ammonium 
salts were tested for sigma-2 binding site affinity. A trend was seen in affinity of 
primary ammonium salts, the affinity increased as the chain length increased, 
peaking at pKi of 5.1 for hexylammonium. Any further increase in chain length 
did not increase the affinity. The primary ammonium salts 1-
adamantylammonium and 2-adamantylammonium are more complex in 
structure than the other primary ammonium salts tested. Both the salts showed 
similar binding affinities and had slightly low affinity for sigma-2 binding site as 
shown in Table 4-1. 
 
Ammonium salt Sigma-2 binding site 
affinity (pKi) * 
         nH 
Propylammonium <3 - 
Butylammonium 3.26 0.86 ± 0.09 
Pentylammonium 3.9 1.0 ± 0.1 
Hexylammonium 5.1 0.72 ± 0.04 
Octylammonium 5.2 0.9 ± 0.2 
Decylammonium 5.2 0.92 ± 0.06 
1-adamantylammonium 5.04 0.73 ± 0.03 
2-adamantylammonium 5.5 0.8 ± 0.2 
 
Table 4-1: Affinity of primary ammonium salts for the sigma-2 binding site. 
* SEM removed for clarity; these values can be found earlier in this chapter. 
Unpaired 1-way ANOVA, with p value adjusted for multiple comparisons, shows 
no significant difference in Hill slope values [F(6,21) = 0.71, p = 0.64]. 
Propylammonium was excluded from this analysis. 
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4.13.2 Secondary ammonium salts 
 
Twelve secondary amines were tested in [3H] DTG competition assay ranging 
from dimethylammonium with 2 single carbon chains to dioctylammonium with 2 
eight-carbon chains. There was increased affinity with addition of carbon to the 
chain until eight-carbon chain long dioctylammonium, which had a pKi of 7.9 
Table 4-2). 
 
Adding side branches to the chains of these simple ammonium salts altered 
their affinity for the sigma-2 binding site. The most significant change in affinity 
for the sigma-2 binding site was observed with bis-2(ethyl)hexylammonium, by 
adding an ethyl group (C2H5) to the 2nd carbon along each of the carbon chains 
of dihexylammonium resulted in a 300-fold reduction of affinity as shown in 
Table 4-2. 
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Ammonium salt Sigma-2 binding site 
affinity (pKi) * 
nH 
Dimethylammonium <3 - 
Diethylammonium <3 - 
Dipropylammonium 4.10 0.8 ± 0.1 
Diisoproplyammonium 4.1 0.75 ± 0.09 
Dibutylammonium 5.64 0.6 ± 0.1 
Diisobutylammonium 5.2 0.78 ± 0.05 
Di-sec-butylammonium 5.2 0.8 ± 0.1 
Dipentylammonium 6.9 0.67 ± 0.04 
Dihexylammonium 7.58 0.68 ± 0.06 
Dicyclohexylammonium 6.86 0.72 ± 0.07 
Bis-2-(ethyl)Hexylammonium 4.0 0.65 ± 0.04 
Dioctylammonium 7.9 0.6 ± 0.2 
 
Table 4-2: Affinity of secondary ammonium salts for the sigma-2 binding 
site. 
* SEM removed for clarity; these values can be found earlier in this chapter. 
Unpaired 1-way ANOVA, with p value adjusted for multiple comparisons, shows 
no significant difference in Hill slope values [F(9,30) = 0.64, p = 0.76]. 
Dimethylammonium and diethylammonium were excluded from this analysis. 
 
4.13.3 Tertiary and quaternary ammonium salts. 
When I looked at the affinities of tertiary ammonium salts several trends were 
the same. Increase in the length of alkyl group resulted in increased affinity. 
Increasing the chain length further resulted in a rapid decline in affinity. 
Introduction of branched chain alkyl groups showed no reproducible pattern. 
Triisopropylammonium had lower affinity than tripropylammonium, 
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triisobutylammonium had the same affinity as tributylammonium whereas 
triisopentylammonium showed slightly higher affinity than tripentylammonium as 
shown below in Table 4-3. 
 
Ammonium salt Sigma-2 binding site 
affinity (pKi) * 
nH 
Trimethylammonium <3 - 
Triethylammonium 3.66 0.88 ± 0.02 
Ethyldiisopropylammonium 4.44 0.70 ± 0.02 
Tripropylammonium 4.36 0.93 ± 0.07 
Triisopropylammonium <3 - 
Tributylammonium 5.5 0.68 ± 0.05 
Triisobutylammonium 5.46 0.7 ± 0.2 
Tripentylammonium 6.1 0.8 ± 0.2 
Triisopentylammonium 6.4 0.73 ± 0.05 
Trihexylammonium 6.63 0.7 ± 0.1 
Trioctylammonium 3.74 1.1 ± 0.1 
Tridodecylammonium 4.1 0.7 ± 0.2 
 
Table 4-3: Affinity of tertiary ammonium salts for the sigma-2 binding site. 
* SEM removed for clarity; these values can be found earlier in this chapter. 
Unpaired 1-way ANOVA, with p value adjusted for multiple comparisons, shows 
no significant difference in Hill slope values [F(9,30) = 1.32, p = 0.27]. 
Trimethylammonium and triisopropylammonium were excluded from this 
analysis. 
 
Four quaternary ammonium salts were tested, all of which had low affinities for 
the sigma-2 binding site. Tetrabutylammonium had the highest affinity, with pKi 
4.22, and since there was no increase in the affinity with increase in carbon 
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chain length, no further quaternary amines were tested for sigma-2 binding site 
affinity. 
4.13.4 Commercially available sigma ligands 
Several commercially available sigma ligands were tested for affinity for sigma-
2 binding site. Ifendprodil had the highest affinity with pKi 9.4. (+) Pentazocine, 
the classical sigma-1 receptor ligand, bound as well but with lower affinity as 
shown in the Table 4-4 
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Compound name    Sigma-2 binding site  
affinity (pKi) * 
nH 
Pentazocine 6.45 0.73 ± 0.06 
Haloperidol 6.2 1.1 ± 0.2 
DTG 8.0 0.6 ± 0.1 
Rimcazole 6.2 0.7 ± 0.1 
Progesterone 4.9 0.7 ± 0.2 
IPAG 6.16 0.7 ± 0.1 
RU-486 <3 - 
Ifenprodil 9.4 0.5 ± 0.1 
PPCC 7.0 0.58 ± 0.08 
SM21 7.2 0.63 ± 0.03 
SKF10047 4.84 0.94 ± 0.04 
AG-205 5.40 1.06 ± 0.03 
Spermidine <3 - 
Spermine <3 - 
Table 4-4: Affinity of commercially available sigma ligands for the sigma-2 
binding site. 
* SEM removed for clarity; these values can be found earlier in this chapter. 
Unpaired 1-way ANOVA, followed by post hoc Tukey (“all means”) comparison, 
with p value adjusted for multiple comparisons, shows a significant difference in 
Hill slope values [F(10,33) = 3.22, p = 0.0054]. The Hill slope for ifenprodil was 
significantly lower than haloperidol (p = 0.019) and AG-205 (p = 0.036). All 
other comparisons show no significant differences. 
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4.14 Summary 
 
Simple ammonium salts show graded response in affinities for sigma-2 binding 
site. Straight chain primary, secondary and tertiary ammonium salts have 
sigma-2 binding affinity, which increase as the carbon chain length between 4 
and 6 carbons. Any further increase in the number of carbons has no effect on 
the affinity. Decylammonium, dioctylammonium and trihexylammonium were 
found to have the highest affinities of primary, secondary and tertiary 
ammonium salts for sigma-2 binding site. 
 
It is also shown that branched chain ammonium salts have lower affinity for the 
sigma-2 binding site. Two branched chain ammonium salts, bis-2-
(ethyl)hexylammonium and triisopentylammonium particularly stood out. 
Although the affinity of most of the ammonium salts was low was compared to 
known sigma-2 ligands, some of the salts had affinities comparable to 
commercially available sigma-2 ligands. In vitro results suggest that two 
ammonium salts had affinity for the sigma-2 binding site comparable to 
commercial sigma-2 binding site ligands: dihexylammonium, with pKi 7.58 and 
dioctylammonium, with pKi 7.9. In the next chapter, it will be investigated if they 
have activity in vivo. 
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Chapter 5. BIOLOGICAL ACTIVITY OF SIGMA-2 
BINDING SITE LIGANDS 
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5.1 Background  
Determining structure-activity relationships for receptors is routinely performed 
by medicinal chemists. Much of this is an academic activity, as the information 
discovered may not inform the requirements of drugs turning into medicines. 
This is particularly the case when drug targets are not on the cell surface. In the 
case of the sigma-2 binding site, while its identity is not known, its location is 
(Peluso et al., 2009). As an intracellular protein, structural requirements have to 
be balanced with bioavailability and cell membrane permeability. 
 
Functional assays to determine whether a drug is binding its target bring 
together the determination of whether a drug reaches its target and then 
whether it has an effect. 
In the case of the sigma-2 binding site, few functional assays are routinely 
used: 
5.1.1 Effects on electrically stimulated bladder 
Kinney et al. have previously used electrically stimulated guinea pig ileum to 
study the effects of sigma-2 ligands, with correlations between affinity and effect 
being present (Kinney et al., 1995). Colabufo et al. also used this assay, 
although the presence of many other receptors that could interfere with data 
interpretation was acknowledged (Colabufo et al., 2003). As most interest in 
sigma-2 ligands concerns their effects on tumour growth and development, 
more recent assays have focused on their effects on cell growth and 
proliferation.  
5.1.2 MTS cell “viability” assays.  
The MTS (or older MTT/XTT) assay merely records cellular metabolic activity. 
As such, it is used to measure cell number (Tan et al., 2013), toxicity of drugs 
(Spruce et al., 2004), even in bacteria (Belanger et al., 2011) to name a few. It 
is not specific in any way and is subject to interference by reducing agents 
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(Bernas and Dobrucki, 2002, Chakrabarti et al., 2000, Collier and Pritsos, 2003, 
Ulukaya et al., 2004). In order to test the effects of sigma-2 ligands, a fixed 
number of cells are seeded into wells and, following prolonged incubation with 
the test drugs, metabolic activity is then assessed. The read-out requires 
interpretation as quiescent cells (non-dividing cells in G0) will appear the same 
as cells blocked in the cell cycle or dead cells. This is an important distinction 
as bacteriostatic drugs (agents that stop bacteria from dividing while present, 
but will then allow them to restart their growth once the drug is removed or 
metabolised) have very different roles to bactericidal drugs (these kill the 
bacteria). Likewise in oncology, drugs that prevent tumours from growing are 
useful as in many cases the immune system will be able to destroy the tumour if 
its growth is retarded (Zitvogel et al., 2008). The MTS assay also does not 
distinguish between why a population of cells has a reduced signal. This is 
important when looking at experimental drugs causing cell death. The 
differences between death by apoptosis or necrosis are great. 
5.1.3 Lactate dehydrogenase (LDH) assays 
These assays measure the release of LHD from a cell. LDH is present in most 
cell types and can leak out when the cell membrane becomes damaged. By the 
time the plasma membrane becomes permeable to this large protein (140 kDa) 
it has passed the point of no return and is inviable. It does not distinguish 
between necrosis and late-stage apoptosis (Chan et al., 2013). This event is 
more closely linked to the death of a cell than MTS metabolism. As the LDH 
assay can be used to measure cell death, Colabufo and colleagues (Colabufo 
et al., 2009b) have discriminated between antiproliferative effects of agents 
(using an assay like MTS) with that of cytotoxicity. In this respect, one should 
be able to distinguish between cytotoxic and cytostatic effects of drugs. Data 
from 2009 does show differences between doses required of some sigma-2 
ligands to cause cytotoxicity and have antiproliferative effects. Unfortunately as 
the assays were performed 24 and 48 hours after drug treatment, it is possible 
that these differences were due to the protocols used and not necessarily 
separation of effects. Others outside the field of sigma-2 signalling have 
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compared the two assays in greater detail (Smith et al., 2011). Due to its 
simplicity, the MTS assay is by far the most widely accepted assay used.  
 
Cell death occurs via two major routes: apoptosis and necrosis (Criddle et al., 
2007). Apoptosis, or programmed cell death, is an ordered series of events and 
occurs naturally during development of the foetus – a key example is the 
development of individual fingers as the interdigital cells undergo apoptosis, 
revealing five digits from what was a single paddle (Suzanne and Steller, 2013). 
When a cell undergoes apoptosis, the cell shrinks, the plasma membrane flips, 
exposing phosphatidylserine to the extracellular environment, DNA is lysed into 
a characteristic ladder and small subcellular packages are created, allowing the 
dead cell contents to be phagocytosed by neighbours. Necrosis usually occurs 
as a consequence of insult – physical damage to cells, treatment with harsh 
chemicals or toxins. Cells swell and the contents are released, causing damage 
to neighbouring cells. 
Apoptosis requires the activation of a series of biochemical events. This 
includes a pulse of calcium which precedes activation of a series of caspase 
protease enzymes (Tantral et al., 2004), leading to the study of calcium 
homeostasis (Vilner and Bowen, 2000) and use of caspase-3 assays to 
determine the activity of sigma-2 ligands (Zeng et al., 2014). 
 
5.1.4 Calcium homeostasis 
 
Spruce et al. have previously studied calcium regulation following treatment of 
sigma-1 receptors (Spruce et al., 2004). These studies were preceded by 
studies comparing the effects of sigma ligands acting through sigma-1 
receptors and sigma-2 binding sites. Vilner and Bowen (1999) showed that the 
ligands used activated calcium release from intracellular stores, as they were 
abolished if cells were pretreated with the endoplasmic/sarcoplasmic reticulum 
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calcium ATPase poison thapsigargin (Vilner and Bowen, 2000). Thapsigargin 
acts by preventing uptake into this pool allowing for calcium stores to be 
depleted, as these stores are leaky. The role of extracellular calcium was 
downplayed, as its removal, while affecting the calcium response to KCl, only 
affected the calcium response to one of the sigma ligands tested. Vilner and 
Bowen claimed there was a correlation between affinity of a ligand for the 
sigma-2 binding site and its ability to cause a calcium response. I have 
reproduced a figure of this correlation. I remain unconvinced that the correlation 
is valuable information. 
 
 
Figure 5-1: Correlation between affinity for the sigma-2 binding site and 
calcium response 
Correlation of calcium response at a fixed concentration of ligand (100 µM) and 
affinity for the sigma-2 binding site, data taken from Vilner and Bowen (Vilner 
and Bowen, 2000). Linear regression shows the line y = -27.26x – 126.6, R2 = 
0.322 [F(1,14) = 6.65, p = 0.022]. 
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5.1.5 Caspase activation assays 
 
Caspases are calcium-activated proteases. Caspase-3 cleaves the specific 
peptide sequence DVED, allowing assays to be developed in which a 
fluorophore (for example rhodamine) is quenched by positioning the peptide 
such that until cleaved the rhodamine does not fluoresce (Zeng et al., 2014). 
This is one of the few routinely used assays that distinguishes between death 
by apoptosis (positive result) and necrosis (negative result). 
I have used two of the above methods, the MTS assay to determine which 
agents decrease metabolic activity and have revisited the calcium response 
data in order to determine whether a correlation does exist. By comparing the 
affinity, EC50 for reduction in metabolic activity and size of calcium response, I 
hope to shed more light on distinguishing agonists from antagonists, and 
propose if partial agonists exist in this system. 
 
5.2 Results 
5.2.1 Effects of ammonium salts on cellular proliferation 
The ability of the amines and several previously characterised sigma ligands to 
affect proliferation of MCF7 cells was determined. MCF7 cells were used as 
they had previously (Vilner et al., 1995b) and currently (this study) been 
identified as having sigma-2 binding sites but lacking sigma-1 receptors. While 
sigma-1 and sigma-2 are believed to be proteins with different characteristics, 
localisation and properties, many ligands have cross-reactivity. Using MCF7 
cells devoid of sigma-1 receptors means that the effects of this protein are 
excluded, helping clarify the role of sigma-2 binding sites in cell death and the 
effects of these compounds on the sigma-2 binding sites without interference 
from the sigma-1 receptor. 
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From binding data, we see that most of the simple primary, secondary, tertiary 
and, to a lesser extent, quaternary amines bind the sigma-2 binding site. In 
order to determine their biological activity, the standard assay used was to look 
at their effects on metabolic activity. I have done this in MCF7 cells as these 
cells lack sigma-1 receptors, which would confound my data.  
 
 
 
Chapter 5. Results  
 
 157 
 
Ammonium salt Sigma-2 
binding 
site affinity 
(pKi) * 
nH * pIC50  
MCF7 
% 
Inhibition 
of  
100M 
rimcazole 
clogD  
(pH 
7.4) 
Propylammonium <3 - - 0.5 ± 0.5 -2.45 
Butylammonium 3.26 0.86 - 0 -2.12 
Pentylammonium 3.9 1.0 - 0.3 ± 0.3 -1.34 
Hexylammonium 5.1 0.72 - 0 -1.02 
Octylammonium 5.2 0.9 3.13 ± 
0.03 
0 -0.07 
Decyl 
Ammonium 
5.41 0.92 4.06 ± 
0.08 
4.0 ± 0.6 1.07 
1-adamantyl 
Ammonium 
5.0 0.73 - 0.5 ± 0.3 -0.37 
2-adamantyl 
Ammonium 
5.5 0.8 - 0.8 ± 0.5 -0.61 
 
Table 5-1: Primary ammonium salts characteristics 
Table showing characteristics of ammonium salts. Mean ± SEM were calculated 
from 3-5 individual experiments. * SEM removed for clarity; these values can be 
found in Chapter 4. Unpaired 1-way ANOVA, followed by post hoc Tukey (“all 
means”) comparison, with p value adjusted for multiple comparisons, shows a 
significant difference in the ability to reverse the effects of rimcazole [F(4,15) = 
11.8, p = 0.0002]. Decylammonium shows a greater ability to reverse the effects 
of rimcazole than all other agents tested (p < 0.0015). All other comparisons 
show no significant difference. Butylammonium, hexylammonium and 
octylammonium were excluded from these comparisons. 
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Of the primary amines tested, while all above propylammonium bound the 
sigma-2 binding site in vitro, only octylammonium and decylammonium salts 
inhibited growth of MCF7 cells. This identified them as agonists at the sigma-2 
binding site. That other amines were without effect did not indicate they were 
antagonists. An antagonist, by definition has no effect alone but blocks the 
effects of an agonist in that system. In order to determine whether these agents 
were antagonists, MCF7 cells were pretreated with the potential antagonist 
(1mM) prior to addition of 100M rimcazole, a known agonist that inhibits MCF7 
proliferation. A sub-maximal dose of rimcazole was used in order to make the 
assay sensitive to inhibition whilst allowing for any unexpected potentiation to 
also be observed. With one exception (decylammonium), none of the agents 
tested reversed the growth inhibition induced by rimcazole. This could suggest 
that the sigma-2 binding site is not on the cell surface, and access requires 
compounds to either be transported to the site or diffuse through membranes. 
More so, it suggests these compounds are unable to access the sigma-2 site in 
living cells.  Decylammonium reversed the rimcazole effects but only slightly. 
 
5.2.2 Physiochemical properties of primary ammonium salts 
In order to explain these findings, the physicochemical properties of these 
sigma-2 binding site ligands were considered. When comparing the 
octanol:water partition coefficient at pH 7.4 (presented as a calculated log D at 
pH 7.4 or clogD (7.4) from the ACD calculation present on the chemspider.com 
website), a trend appeared. Increasing the chain length increased the 
proportion of material partitioning into the organic layer. It was only those 
materials which partitioned equally or more towards the octanol layer that 
showed biological activity. Comparing the acid dissociation constant (pKa) 
values of these materials, the amine group is dominant, giving the molecules a 
pKa of over 10, indicating they would exist in a protonated form at neutral pH 
values. In contrast to the straight-chained decylammonium, the more complex 
structures of 1- and 2-adamantylammonium (which still contained 10 carbons),  
were unable to alter metabolic activity of MCF7 cells. One may be able to 
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explain this by the reduction in the clogD (7.4) caused by the crown-like 
structure of these adamantylammonium compounds, as compared to the 
straight-chained decylammonium compound. 
 
It was decided to use logD, not logP in all the observations. LogP is concerned 
with the partition coefficient of the uncharged molecule. LogD, is the partition 
coefficient of all species at the defined pH, which was used as 7.4 – the pH of 
the plasma and generally accepted as the pH of the “extracellular space”. logD 
tells us what proportion of these molecules would partition into an aqueous 
phase and what proportion into octanol. If a molecule would evenly separate 
into both, there would be 50% in octanol, 50% in water 50/50 gives 1 and log1 = 
0, so anything with a negative logD would favour partitioning to the water, 
anything with logD greater than 1 favours octanol). As we believe the sigma-2 
binding site to be intracellular, a high octanol:water solubility ratio would be 
favoured. Progesterone would seem a reasonable benchmark and has a clogD 
of 3.72. (as this is a log scale, there would be 103.72 - 5200 times more 
progesterone in the octanol than in the water). 
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Ammonium salt Sigma-2 
binding 
site 
affinity 
(pKi) * 
nH * pIC50 
MCF7 
% Inhibition 
of 100M 
rimcazole 
clogD 
(pH 7.4) 
Dimethylammonium <3 - - 0 -3.18 
Diethylammonium <3 - - 0.3 ± 0.3 -2.21 
Dipropylammonium 4.10 0.8 - 1.0 ± 0.6 -1.25 
Diisopropylammonium 4.1 0.75 - 0.8 ± 0.5 -1.45 
Dibutylammonium 5.64 0.6 - 0.8 ± 0.8 -0.43 
Diisobutylammonium 5.2 0.78 - 0.5 ± 0.3 -0.61 
Di-sec butylammonium 5.2 0.8 - 0.3 ± 0.3 -0.62 
Dipentylammonium 6.9 0.67 - 0 0.65 
Dihexylammonium 7.58 0.68 3.40 ± 
0.07 
0.3 ± 0.3 1.38 
Dicyclohexylammoniu
m 
6.86 0.72 3.75 ± 
0.02 
0.8 ± 0.3 0.62 
Bis-2-ethylhexyl 
ammonium 
4.0 0.65 - 0 3.38 
Dioctylammonium 7.9 0.6 4.44 ± 
0.08 
30 ± 6 3.88 
Table 5-2: Secondary ammonium salts characteristics. 
Table showing characteristics of secondary ammonium salts. Mean ± SEM 
were calculated from 3-5 individual experiments. * SEM removed for clarity; 
these values can be found in Chapter 4. Unpaired 1-way ANOVA, followed by 
post hoc Tukey (“all means”) comparison, with p value adjusted for multiple 
comparisons, shows a significant difference in the ability to reverse the effects 
of rimcazole [F(8,27) = 22.9, p < 0.0001]. Dioctylammonium shows a greater 
ability to reverse the effects of rimcazole than all other agents tested (p < 
0.0001). All other comparisons show no significant difference. 
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Dimethylammonium, dipentylammonium and bis-2-(ethyl)hexylammonium were 
excluded from these comparisons. 
 
5.2.3 Physiochemical properties of secondary ammonium salts 
A similar trend was observed with secondary ammonium salts. As chain length 
increased, so did affinity, peaking at just above 10nM (dioctylammonium, pKi 
7.9). Dialkylammonium salts with fewer than six carbons per chain did not affect 
metabolic activity of MCF7 cells either by reducing activity or reversing the 
effects of rimcazole. As with the primary ammonium salts, the clogD (7.4) 
increases with chain length. While the clogD (7.4) of dipentylammonium (0.65) 
is greater than that of the active octylammonium (clogD (7.4) -0.07), this too 
was inactive. Dihexylammonium and dicyclohexylammonium were both active, 
reducing metabolic activity to similar extents with similar pIC50 values.  The 
compound with highest affinity for the sigma-2 binding site was also most 
effective in reducing metabolic activity. Dioctylammonium was found to have a 
pKi of 7.9 and pIC50 of 4.44. Strangely, it was also the only secondary 
ammonium salt to (partially) reverse the effects of rimcazole. 
Introduction of branched side chains had differing effects: no difference was 
observed when comparing dipropylammonium with diisopropylammonium. The 
affinities of diisobutylammonium and di-sec-butylammonium were marginally 
lower than that for dibutylammonium, whereas the difference between 
dihexylammonium and dicyclohexylammonium was moderate, but these salts 
showed approximately 1000-fold higher affinity than bis-2-
(ethyl)hexylammonium. The lack of biological effect of bis-2-
(ethyl)hexylammonium, despite such subtle differences, may have been due to 
the low affinity of this potential ligand. Positive clogD (7.4) values again appear 
to be necessary for these compounds to be active. 
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Ammonium salt Sigma-2 
binding 
site 
affinity 
(pKi) * 
nH * pIC50 
MCF7 
% Inhibition 
of 
100M 
rimcazole 
clogD 
(pH 7.4) 
Trimethylammonium <3 - - 0 -2.14 
Triethylammonium 3.66 0.88 - 1.0 ± 0.4 -1.18 
Ethyldiisopropyl 
ammonium 
4.44 0.70 - 0.8 ± 0.5 -0.55 
Tripropylammonium 4.36 0.93 - 0.3 ± 0.3 0.52 
Triisopropyl 
ammonium 
<3 - - 0 -0.18 
Tributylammonium 5.5 0.68 - 0 1.69 
Triisobutyl 
ammonium 
5.46 0.7 - 0.3 ± 0.3 2.03 
Tripentylammonium 6.1 0.8 - 0.3 ± 0.3 3.73 
Triisopentyl 
ammonium 
6.4 0.73 - 0 2.68 
Trihexylammonium 6.63 0.7 3.9 ± 
0.2 
14 ± 3 4.85 
Trioctylammonium 3.74 1.1 - 0 8.10 
Tridodecyl 
ammonium 
4.1 0.7 - 2.6 ± 0.7 14.50 
Table 5-3: Characteristics of tertiary ammonium salts. 
Table showing characteristics of tertiary ammonium salts. Mean  SEM were 
calculated from 3-5 individual experiments. * SEM removed for clarity; these 
values can be found in Chapter 4. Unpaired 1-way ANOVA, followed by post 
hoc Tukey (“all means”) comparison, with p value adjusted for multiple 
comparisons, shows a significant difference in the ability to reverse the effects 
of rimcazole [F(6,21) = 17.4, p < 0.0001]. Trihexylammonium shows a greater 
ability to reverse the effects of rimcazole than all other agents tested (p < 
0.0001). All other comparisons show no significant difference. 
Trimethylammonium, triisopropylammonium, tributylammonium, 
triisopentylammonium and trioctylammonium were excluded from these 
comparisons. 
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5.2.4 Physiochemical properties of tertiary ammonium salts 
When I looked at the effects of tertiary ammonium salts, several trends were the 
same. Increasing the length of the alkyl groups increased affinity. In this case, 
trihexylammonium had peak affinity (pKi 6.63). Increasing chain length further 
caused a rapid decline. Trihexylammonium was also the only tertiary 
ammonium salt that reduced metabolic activity, albeit with a low pIC50 (3.9). 
Introduction of branched chain alkyl groups showed no reproducible pattern: 
triisopropylammonium had lower affinity than tripropylammonium, 
triisobutylammonium had the same affinity as tributylammonium whereas 
triisopentylammonium showed a slightly higher affinity than tripentylammonium.  
 
When looking at the ability of these compounds to alter the effects of rimcazole, 
again, the agent that reduced metabolic activity was the only one that reversed 
the effects of rimcazole, albeit modestly. Trihexylammonium (1mM) reversed 
rimcazole’s effects by 14%. The clogD (7.4) values for tripropylammonium and 
larger salts were positive, albeit some being very high. It is worth reminding 
ourselves that a clogD (7.4) of 5 means an octanol:water partition coefficient of 
100,000:1, indicating that 99.999% of such a material would reside in the 
octanol phase at pH 7.4. 
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Ammonium salt Sigma-2 
binding 
site affinity 
(pKi) * 
nH pIC50 
MCF7 
% Inhibition 
of 
100M 
rimcazole 
clogD 
(pH 
7.4) 
Tetramethylammonium <3 - - 0.3 ± 0.3 -3.15 
Tetraethylammonium <3 - - 1.0 ± 0.4 -2.79 
Tetrapropylammonium 3.5 0.7 ± 
0.01 
- 0.3 ± 0.3 -1.77 
Tetrabutylammonium 4.2 0.8 ± 
0.03 
- 1.8 ± 0.8 -0.64 
Table 5-4: Characteristic of quaternary ammonium salts. 
Table showing characteristics of quaternary salts. Mean ± SEM were calculated 
from 3-5 individual experiments. * SEM removed for clarity; these values can be 
found in Chapter 4. Unpaired 1-way ANOVA, with p value adjusted for multiple 
comparisons, shows no significant difference in the ability to reverse the effects 
of rimcazole [F(3,12) = 2.08, p = 0.156].  
 
5.2.5 Physiochemical properties of quaternary salts 
Quaternary ammonium salts had little effect on the sigma-2 binding sites and 
did not reverse the effects of rimcazole. On considering the clogD (7.4) of the 
compounds tested, they all have negative values, indicating low solubility in 
octanol and hence are unlikely to gain access to the interior of the cell. 
 
5.2.6 Physiochemical properties of commercial ligands 
Several commercial ligands for the sigma-1 receptor or sigma-2 binding site 
were also considered. (+) Pentazocine, the classical sigma-1 ligand, did bind 
the sigma-2 binding site with low affinity (pKi 6.45) and was found to reduce 
metabolic activity in MCF7 cells, albeit with pIC50 of 3.8. Haloperidol, DTG, 
progesterone, IPAG, PPCC and SKF 10,047 bound but do not affect metabolic 
activity. Ifenprodil, SM21 and AG-205 bound and reduced metabolic activity, 
suggesting these are agonists at the sigma-2 binding site. Haloperidol, 
progesterone, PPCC and AG-205 were able to reverse the effects of rimcazole 
to varying degrees. Spermine and spermidine are naturally occurring agents 
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with similar structures to secondary ammonium salts; these were also 
considered. They were of particularly low affinity and did not alter metabolic 
activity of MCF7 cells either in the absence or presence of rimcazole. With the 
exception of spermine and spermidine, these agents all show clogD (7.4) 
values between 0 and 5. Mifepristone (RU-486), the progesterone receptor 
antagonist was tested. It showed little affinity for the sigma-2 binding site. 
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Ligand Sigma-2 
binding 
site 
affinity 
(pKi) * 
nH * pIC50 
MCF7 
% Inhibition 
of 
100M 
rimcazole 
clogD 
(pH 7.4) 
(+) 
Pentazocine 
6.45 0.73 3.80  ± 
0.00 
1.5 ± 0.3 2.26 
Haloperidol 6.2 1.1 - 10.9 ± 0.9 2.65 
DTG 8.0 0.6 - 2.5 ± 0.9 2.31 
Rimcazole 6.2 0.7 4.47 ± 
0.07 
- 2.63 
Progesterone 4.9 0.7 - 12 ± 3 3.72 
IPAG 6.16 0.7 - 0.8 ± 0.5 2.74 
RU-486 <3 - - 80 ± 9 # 
Precipitation 
5.16 
Ifenprodil 9.4 0.5 3.6 ± 0.1 2.8 ± 0.8 1.66 
PPCC 7.0 0.58 - 34 ± 6 2.17 
SM21 7.2 0.63 4.0 ± 0.2 0 1.19 
SKF10047 4.84 0.94 - 0.8 ± 0.5 2.16 
AG-205 5.40 1.06 3.38 ± 
0.03 
29 ± 4 2.46 
Spermidine <3 - - 0.3 ± 0.3 -5.91 
Spermine <3 - - 0.3 ± 0.3 -6.78 
Table 5-5: characteristics of commercially available sigma-1 and sigma-2 binding 
site ligands. 
Table showing characteristics of commercially available sigma-1 and sigma-2 
ligands. Mean ± SEM were calculated from 3-5 individual experiments. # 
indicates precipitation during the assay, leading to spurious results. * SEM 
removed for clarity; these values can be found in Chapter 4. Unpaired 1-way 
ANOVA, followed by post hoc Tukey (“all means”) comparison, with p value 
adjusted for multiple comparisons, shows a significant difference in the ability to 
reverse the effects of rimcazole [F(10,33) = 25.1, p < 0.0001]. PPCC and AG-
205 show a greater ability to reverse the effects of rimcazole than all other 
agents tested (p < 0.001), except each other (p = 0.92). All other comparisons 
show no significant difference. RU-486 and SM21 were excluded from these 
comparisons. 
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Data on the effects of rimcazole on metabolic activity appears to be confounded 
by precipitation of RU-486 during the time required for its effects to be seen. 
The MTS assay relies on a conversion of the colourless tetrazolium to coloured 
formazan. However, microscopic analysis showed the presence of colourless 
crystals present and, presumably, interference with the colorimetric analysis by 
diffracting light in the plate reader. As we have seen with the ammonium salts, 
very few agents reduced metabolic activity of MCF7 cells. Notable exceptions 
are the archetypal sigma-2 agonist ifenprodil and the PGRMC1 ligand, AG-205. 
My results here are in stark contrast to (Abate et al., 2015a) who found no 
affinity for or effect through the sigma-2 binding site. Ifenprodil has little effect 
on rimcazole-mediated reduction in metabolic activity, but AG-205 greatly 
reverses these effects, suggesting it may be a partial agonist as it causes an 
effect, but also reverses the effects of a fellow agonist. Three of these agents 
showed antagonist activity with no effect by themselves, whilst significantly 
reversing rimcazole-mediated reduction in metabolic activity. Haloperidol and 
progesterone show modest reversal, whereas PPCC gave the best profile to be 
described as an antagonist: it did not affect metabolic activity alone, but 
significantly protected the cells from the effects of rimcazole.   
 
5.2.7 Effects of ligands on intracellular calcium 
The pathways involved in reducing metabolic activity frequently require a pulse 
of calcium to initiate apoptosis, as is seen with activation of the sigma-1 
receptor. Indeed, Vilner and Bowen have proposed that sigma-2 affinity is 
(weakly) correlated to the ability of ligands to mobilise calcium from intracellular 
stores (Vilner and Bowen, 2000). In order to further analyse such a potential 
correlation, I compared the ability of sigma-2 ligands to affect metabolic activity 
with their ability to mobilise calcium. To determine this, the ability of a select 
number of compounds to elicit a calcium response in MCF7 cells pre-loaded 
with Fura-2 ratiometric dye was considered. All drugs were tested to determine 
whether they, like rimcazole, fluoresced causing an artefact. Rimcazole (Figure 
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5-2) showed a dramatic increase in ratiometric signal and so cannot be used in 
these assays. This has previously been reported (Brimson et al., 2011). 
 
 
 
Figure 5-2: Change in fluorescence following addition of rimcazole and 
octylammonium. 
Figure showing change in fluorescence following addition of rimcazole (1mM) or 
octylammonium (1mM) to KLB containing no fluorophore. Ratio refers to 
fluorescence emitted at 520 nm after excitation at 340nm and 380 nm. Artefacts 
are introduced at 22 and 36 seconds due to the opening of the light-tight 
chamber required for the introduction of the drugs at 30 seconds.  
 
In order to determine if sigma-2 ligands do elicit a calcium response as part of 
their mechanism to decrease metabolic activity and lead to cell death by 
apoptosis, each active agent was tested to see if it was able to produce a 
calcium response. Equally, several commercial ligands, described as both 
agonists and antagonists, were tested. 
 
The primary ammonium salts octylammonium and decylammonium both 
produced a calcium response, although the response to decylammonium was 
much larger than that to octylammonium, which, while small did reproducibly 
produce a response (Figure 5-3). 
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Figure 5-3: Effects of octylammonium and decylammonium on 
intracellular calcium. 
Calculated intracellular calcium concentration following the introduction of 
octylammonium or decylammonium (1mM) in MCF7 cells preloaded with Fura-2 
dye. Artefacts are introduced at 20 and 34 seconds due to the opening of the 
light-tight chamber required for the introduction of the drugs at 30 seconds. 
 
 
Dihexylammonium produced a similar response as that seen with 
decylammonium. In contrast, treatment with trihexylammonium caused a fall in 
intracellular calcium (Figure 5-4). Unfortunately, due to time constraints, I was 
unable to pursue this observation, which remains a single experiment. 
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Figure 5-4: Effects of dihexylammonium and trihexylammonium on 
intracellular calcium. 
Calculated intracellular calcium concentration following the introduction of 
dihexylammonium or trihexylammonium (1mM) in MC7 cells preloaded with 
Fura-2 dye. Artefacts are introduced at 20 and 34 seconds due to the opening 
of the light-tight chamber required for the introduction of the drugs at 30 
seconds. 
 
A second agent which appeared to lower intracellular calcium was AG-205 
(Figure 5-6). Addition caused a dose-dependent decline in the signal. This 
could be considered surprising as AG-205 was found to promote a decrease in 
metabolic activity. 
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Figure 5-5: Effects of AG-205 on intracellular calcium. 
Calculated intracellular calcium concentration following the introduction of AG-
205 (1mM or 300µM) in MCF7 cells preloaded with Fura-2 dye. Artefacts are 
introduced at 22 and 36 seconds due to the opening of the light-tight chamber 
required for the introduction of the drugs at 30 seconds. 
 
Whether this apparent reduction in intracellular calcium was real was brought 
into question when the fluorescence of AG-205 alone was monitored: as with 
rimcazole, AG-205 appeared to interfere with the Fura-2 based assay. A small 
change in ratio observed in Figure 5-6 may account for this finding. All other 
drugs tested (apart from rimcazole, see above and trihexylammonium, not 
tested) did not interfere with the ratiometric signal.  
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Figure 5-6: Effects of AG-205 and PB28 on Fura-2’s ratiometric signal  
Figure showing change in fluorescence following addition of PB28 (1mM) or 
AG-205 (100µM) to KLB containing no fluorophore. Ratio refers to fluorescence 
emitted at 520 nm after excitation at 340nm and 380 nm. Artefacts are 
introduced at 20 and 36 seconds due to the opening of the light-tight chamber 
required for the introduction of the drugs at 30 seconds. 
 
 
The small decrease in ratiometric signal was initially missed, permitting many 
experiments to be performed with AG-205. Clearly, such data requires careful 
analysis and are readily prone to overanalysis. 
 
Of the commercial ligands tested, (+) pentazocine caused only a small 
response, whereas progesterone was more effective (Figure 5-7). The 
progesterone response looked slower than that of others. This may be due to 
the drug first precipitating then going into solution as it becomes diluted. 
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Figure 5-7: Effects of progesterone and (+) pentazocine on intracellular 
calcium. 
Calculated intracellular calcium concentration following the introduction of 
progesterone (300µM) or (+) pentazocine (1mM) in MCF7 cells preloaded with 
Fura-2 dye. Artefacts are introduced at 16 and 32 seconds due to the opening 
of the light-tight chamber required for the introduction of the drugs at 30 
seconds. Precipitation was observed with higher concentrations of 
progesterone and may have also caused the delayed response observed at the 
dose shown above. 
 
Higher concentrations of progesterone caused a large dip in the signal which 
recovered more slowly (Figure 5-8). It is assumed that this was due to 
precipitation followed by the progesterone slowly redissolving. 
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Figure 5-8: Effects of Progesterone on intracellular calcium. 
Calculated intracellular calcium concentration following the introduction of 
progesterone (300µM or 1mM) in MCF7 cells preloaded with Fura-2 dye. 
Artefacts are introduced at 16/22 and 32/36 seconds due to the opening of the 
light-tight chamber required for the introduction of the drugs at 30 seconds. 
Note the longer time scale on the x-axis. 
 
PB28 gave a robust calcium signal, whereas SM21 appeared to give a very 
small response indeed (Figure 5-9), routinely raising calcium levels by 30nM. 
 
 
Figure 5-9: Effects of SM21 and PB28 on intracellular calcium 
Calculated intracellular calcium concentration following the introduction of PB28 
(1mM) or SM21 (100µM) in MCF7 cells preloaded with Fura-2 dye. Artefacts 
are introduced at 20 and 34 seconds due to the opening of the light-tight 
chamber required for the introduction of the drugs at 30 seconds. Precipitation 
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was observed with higher concentrations of progesterone and may have also 
caused the delayed response observed at the dose shown above. 
 
Both ifenprodil and haloperidol caused increases in intracellular calcium, 
although haloperidol appeared more efficacious raising calcium by 220nM 
compared to 130nM (Figure 5-10).  
 
 
Figure 5-10: Effects of ifenprodil and haloperidol on intracellular calcium. 
Calculated intracellular calcium concentration following the introduction of 
ifenprodil (100µM) or haloperidol (100µM) in MCF7 cells preloaded with Fura-2 
dye. Artefacts are introduced at 20 and 34 seconds due to the opening of the 
light-tight chamber required for the introduction of the drugs at 30 seconds.  
 
The above results comparing pIC50 at the sigma-2 binding site and calcium 
responses in MCF cells are summarised below (Table 5-6 and Figure 5-11: 
pIC50 and calcium response in MCF7 cells with sigma-2 binding site ligands. 
From my experiments, while limited, it is clear that there is no correlation 
between pIC50 of an agent acting through sigma-2 binding sites and their ability 
to mobilise calcium. It should also be noted that two agents (haloperidol and 
progesterone) did not cause a decrease in metabolic activity yet were able to 
produce a robust calcium response; these cannot be shown on the graph. It is 
noteworthy that PB28 has previously been found not to drive a calcium 
response (Cassano et al., 2006). 
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Ligand pIC50 * Calcium response 
(nM), mean ± SEM 
n 
Octylammonium (1mM) 3.13 130 ± 40 5 
Decylammonium (1mM) 4.06 330 ± 180 3 
Dihexylammonium (1mM) 3.40 210 ± 30 3 
Dicyclohexylammonium (1mM) 4.06 0 1 
Dioctylammonium (1mM) 4.44 Precipitation seen 1 
Trihexylammonium (1mM) 3.9 -100 1 
AG-205 (1mM-100µM) 3.4 See text  
Haloperidol (100µM) No effect 220 ± 120 3 
Ifenprodil (100µM) 3.6 130 ± 50 3 
PB28 (100µM) 3.55 140 ± 30 3 
(+) Pentazocine (1mM) 3.8 80 ± 30 3 
Progesterone (300µM) No effect 160 ± 110 (range) 2 
Rimcazole 4.47 Unable to test  
SM21 (100M) 4.0 33 ± 8 3 
Table 5-6: Summary of pIC50 and calcium response to sigma-2 binding site 
ligands 
Compilation of pIC50 and calcium response to the noted concentration of ligand 
in MCF7 cells. n values are also shown for calcium response experiments. * 
SEM removed for clarity; these values can be found earlier in this chapter. 
Unpaired 1-way ANOVA, with p value adjusted for multiple comparisons, shows 
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no significant difference in the ability to elicit a calcium response [F(8,19) = 1.17, 
p = 0.369]. 
 
 
These ammonium salts have been tested before on MDA-MB-468 cells at lower 
doses and were found to have no effect on calcium or metabolic activity. 
 
 
Figure 5-11: pIC50 and calcium response in MCF7 cells with sigma-2 
binding site ligands. 
Comparison of pIC50 for reduction in metabolic activity of sigma-2 ligands with 
the size of calcium response in MCF7 cells. Linear regression shows the line y 
= -89.74x + 439.9, R2 = 0.055 [F(1,7) = 0.41, p = 0.54], indicating no significant 
correlation between pIC50 and maximum calcium response. 
 
5.2.8 Is there evidence for sigma-1 receptor and sigma-2 binding site 
cross talk? 
The presence of sigma-2 binding sites on all tumour cell lines tested so far, 
along with similar findings with sigma-1 receptors, which have been found in all 
but one cell line (MCF7) led me to then test whether the ligands described, 
which often bind to both sigma-1 and sigma-2 sites would act additively, 
synergistically or in opposition. Those found to reduce metabolic activity in 
MCF7 cells were, therefore, tested in A549 and MDA-MB-468 cells. These cells 
contain a mixture of sigma-1 receptors and sigma-2 binding sites (Chapter 3). 
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Ligand sigma-1 
receptor 
affinity 
(pKi) * 
sigma-2 
binding 
site affinity 
(pKi) # 
pIC50  
MCF7 $ 
pIC50 
MDA-
MB-468 
pIC50 
A549 
Octylammonium 6.1 5.2 3.13 <4* 3.9 ± 0.06 
Decylammonium 6.5 5.4 4.06 <4* 4.7 ± 0.09 
Dihexylammonium 6.8 7.5 3.40 <4* 3.6 ± 0.12 
Dicyclohexyl 
Ammonium 
5.8 6.8 3.75 3.9 ± 0.1 2.9 ± 0.09 
Dioctylammonium n.d. 7.9 4.44 5.0 ± 0.2 4.9 ± 0.00 
Trihexylammonium 8.1 6.6 3.9 <4* 4.2 ± 0.2 
(+) Pentazocine 8.5 6.4 3.80 3.8 ± 0.1 3.8 ± 0.13 
Rimcazole 6.2 6.2 4.47 4.4 ± 
0.2* 
4.7 ± 0.15 
Ifenprodil n.d. 9.4 3.6 4.3 ± 0.3 3.9 ± 0.04 
SM21 n.d. 7.2 4.0 3.9 ± 
0.04 
3.9 ± 0.18 
AG-205 n.d. 5.4 3.38 3.8 ± 
0.10 
3.7 ± 0.2 
PB28 n.d. 7.8 3.55 3.9 ± 
0.03 
4.0 ± 0.07 
 
Table 5-7: Summary of sigma-1 receptor and sigma-2 binding affinities 
and pIC50 values for inhibition of metabolic activities in MCF7, MDA-MB-
468 and A549 cells 
Table of sigma-1 receptor and sigma-2 binding affinities and pIC50 values for 
inhibition of metabolic activities in MCF7, MDA-MB-468 and A549 cells. Values 
represent mean ± SEM values where n=3-8 independent values. * data taken 
from (Brimson, 2010), *, #, $ SEM removed for clarity; these values can be found 
in *Brimson (2010), #Chapter 4 and $earlier in this chapter, respectively. n.d., 
not determined. Unpaired student’s t-test shows that octylammonium and 
decylammonium are significantly more potent against A549 cells over MCF7 
cells (p = 0.0001, p = 0.0018 respectively). Unpaired 1-way ANOVA, followed 
by post hoc Tukey (“all means”) comparison (where appropriate), with p value 
adjusted for multiple comparisons, shows dicyclohexylammonium is significantly 
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more potent [F(2,9) = 47.2, p < 0.0001] against A549 cells over MCF7 (p < 
0.0001) and MDA-MB-468 cells (p < 0.0001). Dioctylammonium [F(2,9) = 5.77, 
p = 0.024] is significantly more potent against MCF7 cells over A549 (p = 
0.027). PB28 [F(2,9) = 10.6, p = 0.0043] is significantly more potent against 
MCF7 cells over both MDA-MB-468 cells (p = 0.019) and A549 cells (p = 
0.0045). 
 
 
From the above table, it is clear that the presence of sigma-1 receptors did not 
affect the potency of these ligands. This was the case for those found by 
Brimson (Brimson, 2010) to be agonists (all ammonium salts shown, (+) 
pentazocine) or antagonists (rimcazole) at the sigma-1 receptor. No further 
analyses were undertaken. 
 
5.3 Discussion 
5.3.1 Definition of agonist and antagonist  at the Sigma-2 binding site 
I have shown that these simple primary, secondary, tertiary and quaternary 
ammonium salts show graded affinity for the sigma-2 binding site. These 
experiments were performed using membranes from sonicated MCF7 cells. 
Returning to the intact cell scenario, many compounds with affinity for the 
sigma-2 binding site had no effect on metabolic activity. Does this make them 
antagonists? No, despite a recent paper in this area claiming this to be the case 
(Zeng et al., 2014). For these agents to be classified as antagonists, they must 
hinder an agonist from performing its functions. This was not the case with 
these agents. 
 
In any emerging field, it is often the early adopters who are permitted to define 
particular parameters. The sigma-2 binding site has been proven of interest to 
mostly those in the area of oncology, yet sigma-2 ligands have also been found 
to affect behaviour. Sigma-2 ligands that induce neck dystonia (a marked 
deviation in head angle) when injected into the red nucleus in one hemisphere 
of experimental animals have been defined as agonists. In such assays, 
antagonists are able to reverse the effects of agonists (Ghelardini et al., 2000). 
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In oncology, an agonist has been defined as a ligand that reduces cellular 
activity (determined using MTS) – often assumed synonymous with cell death. 
The mechanism or mechanisms underlying death are unclear. Activation of a 
calcium response is occasionally seen coupled with activation of caspase-3. At 
other times, no calcium response has been observed. The defining of an 
antagonist has been less clear. Some papers appear to avoid the conflict, 
merely describing all agents as “ligands” (Abate et al., 2011). Unfortunately, 
Zeng et al. have tried to redefine agonists, partial agonists and antagonists 
merely by their “cytotoxic effects” – using the MTS procedure. Using a single 
dose of agent, any agent causing over 90% death after 24 hours was defined a 
full agonist (Zeng et al., 2014). Death of 10-90% of cells was caused by partial 
agonists. Less than 10% death was effected by antagonists. To date (21/01/17) 
this paper has been cited 10 times. This highly flawed approach unfortunately 
undermines the area.  
 
Others correctly describe agents that are cytotoxic (or those reducing metabolic 
activity) as agonists, their effects being reversed by antagonists (Abate et al., 
2012, Colabufo et al., 2004). 
 
Of course, using different tissue and different assays can give different results. 
A classic example would that of tamoxifen, which acts as an antagonist in the 
breast, but a partial agonist in the uterus (Dowsett and Howell, 2002). Closer to 
home, sigma-1 receptor antagonists also show differences, with their effects on 
tumour cell line (producing a large calcium response and causing cell death) 
and cerebellar granule cells (no calcium response, very limited cell death) being 
the reason for the hope that they can act as tumour specific anticancer drugs 
(Spruce et al., 2004). 
 
The effects of decylammonium, while only slight, could suggest that it was 
acting as a partial agonist at the sigma-2 binding site. While it was capable of 
causing a reduction in metabolic activity, it was also able to partially reverse the 
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effects of rimcazole in the same assay. The affinities of the 
adamantylammonium compounds for the sigma-2 binding site were comparable 
with the more simple structure of decylammonium, but the crown-like structures 
have a lower logD, perhaps making them too lipid insoluble to access the 
interior of the cell. 
 
When comparing the effects of the secondary ammonium salts, once again 
affinity increased with increasing size of the side chains. Introduction of a 
second alkyl group has increased affinity by over 100-fold: the highest affinity of 
a primary ammonium salt (decylammonium) had a pKi 5.4, in comparison 
dioctylammonium had a pKi of 7.9. A branched chain compound (bis-2-
ethylhexylammonium) bound with much lower affinity and did not affect 
metabolism of MCF7 cells. This was highly surprising, as branched chains are 
important in the distinction of agonists and antagonists at the sigma-1 receptor 
(Brimson, 2010). While bis-2-(ethyl)hexylammonium also showed reduced 
activity for the sigma-1 receptor when compared with dioctylammonium, it was 
able to reduce metabolic activity in MDA-MB-468 cells and reduce growth of 
MAC 13 mouse adenocarcinoma cells transplanted into NMRI mice in vivo 
(Brimson, 2010). 
 
Dioctylammonium gave some strange results: in my studies, it was the most 
effective at reducing metabolic activity, yet also partially reversed the effects of 
rimcazole. Reasons for this are unclear. The concept of a partial agonist is 
difficult to comprehend with respect to the sigma-2 binding site as its molecular 
identity remains shrouded. It is noted that this phenomenon was also seen with 
decylammonium. 
 
Trihexylammonium also gave somewhat confusing data. While it was capable 
of reducing metabolic activity when used alone, it was also able to partially 
reverse the effects of rimcazole. Furthermore, trihexylammonium appeared to 
lower resting calcium levels in these cells (although this was n=1), suggesting 
that there may be more than one pathway involved. The previously published 
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data showing that rimcazole drives a calcium signal (Spruce et al., 2004) has to 
be ignored as it has also been shown to give a false positive signal in Fura-2 
based assays (Brimson et al., 2011). Further information could be obtained for 
rimcazole, AG-205 and trihexylammonium by using a calcium sensor with 
different spectral qualities. The Fura-2 method has several advantages, two 
being that it is well understood and the ratiometric calculation allows 
intracellular calcium concentration to be determined. Many other dyes are 
available, so comparing the absorbance spectra for rimcazole, AG-205 and 
trihexylammonium with the properties of commercially available calcium dyes 
should allow further experimentation on these compounds. 
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Ligand Sigma-2 
binding site  
affinity 
(pKi) * 
nH * pIC50  
MCF7 $ 
IC50/Ki 
Octylammonium 5.2  0.9 3.13 118 
Decylammonium 5.41 0.92 4.06 22.4 
Dihexylammonium 7.58 0.68 3.40 15100 
Dicyclohexylammonium 6.86 0.72 3.75 1290 
Dioctylammonium 7.9 0.6 4.44 2670 
Trihexylammonium 6.63 0.7 3.9 538 
(+) Pentazocine 6.45 0.73 3.80 446 
Rimcazole 6.2 0.7 4.47 53.8 
Ifenprodil 9.4 0.5 3.6 628000 
SM21 7.2 0.63 4.0 1590 
AG-205 5.40 1.06 3.38 105 
PB28 7.84 0.5 3.55 19500 
 
Table 5-8: Summary of characteristics of sigma-2 binding site ligands 
Table highlighting the affinity of ligands for the sigma-2 binding site, the Hill 
slope of binding and the pIC50 for reduction in metabolic activity. The ratio of 
IC50/Ki has also been calculated. *, $ SEM removed for clarity; these values can 
be found in * Chapter 4 or $ earlier in this chapter. 
 
On comparing IC50 values with Ki values, it was clear that all dose-response 
curves lie well to the right of the binding curves. Normally, this would be 
considered “impossible”. In many cases above, one would have to assume that 
over 99% of receptors have to be occupied before an effect is seen. This has 
been described before. Using a less-well characterised sigma ligand (11C-
SA4503) and uptake assays opposed to ligand binding, Rybczynska et al. 
showed sigma ligands were required at concentrations approximately 100-fold 
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higher to prevent proliferation as was required to prevent uptake (Rybczynska 
et al., 2008). A number of explanations are possible. I shall discuss the most 
plausible here: 
 
Ifenprodil has previously been described as both a sigma-2 agonist (Ishima and 
Hashimoto, 2012) and antagonist (Shin et al., 2007) as well as binding sigma-1 
and NMDA receptors (Ishima and Hashimoto, 2012); (Hashimoto and London, 
1995). Both NMDA receptors (North et al., 2010) and alpha-2 receptors 
(Vazquez et al., 1999) have been found in MCF7 cells. 
 
My data showed that spermine was without effect in our assays. Spermine is 
reported to cause cell death by activation of the NMDA receptor, an effect 
reversed by ifenprodil and a non-competitive NMDA receptor antagonist, MK-
801 (de Vera et al., 2008). However, the effects of a range of sigma-2 ligands 
was not affected by MK-801 in MCF7 cells (Brent and Pang, 1995). This would 
suggest that these receptors are not involved in my observations regarding the 
sigma-2 binding site. 
 
AG-205 has been used to argue whether the sigma-2 binding site is the 
PGRMC1, showing both moderate affinity (10µM displacing 70-90% [125I]-RHM-
4 binding in mouse mammary 66 and HeLa cells (Xu et al., 2011) as well as low 
affinity >10,000nM, (Abate et al., 2015b) binding to sigma-2 binding sites. The 
picture from this study further clouded the matter, AG-205 binding with an 
affinity of 4µM, aligning more closely with data from (Xu et al., 2011). 
 
SM21 has previously been described as a sigma-2 binding site antagonist using 
a behavioural assay, reversing the effects of DTG (Ghelardini et al., 2000). The 
complex nature of these assays and the clear difference in outcomes working 
on a target in non-cancerous cells means no parallels or correlation can be 
drawn at this time. SM21 had previously been shown not to bind sigma-1 
receptors or 5HT3 and 5HT4 receptors (Mach et al., 1999). As expected (due to 
its similarity to the muscarinic receptor antagonist atropine), it does bind 
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muscarinic receptors with Ki 174nM (Gualtieri et al., 1994). No other information 
regarding its selectivity seems available. From these data, it is unlikely that the 
effects of SM21 can be ascribed to any other receptor, but it remains possible. 
 
Little is known about PB28. It is described as a mixed sigma-1/sigma-2 ligand 
(Berardi et al., 1996), specifically a mixed sigma-2 agonist/sigma-1 antagonist 
(Colabufo et al., 2004) that does not effect calcium release, but indeed blocks 
inositol 1,4,5-trisphosphate and calcium-induced calcium release (Cassano et 
al., 2006). PB28 has also been shown to block P-glycoprotein (Colabufo et al., 
2009a). Binding of tritiated PB28 to MCF7 cells could be completely abolished 
by DTG and haloperidol at low doses (Colabufo et al., 2008) suggesting some 
level of selectivity of PB28 binding to the sigma-2 site. Interestingly, 
homologous competition assays with unlabelled PB28 showed a low Hill slope. 
Using PB28 and related ligands, Pati et al. (Pati et al., 2017) have proposed the 
mechanism of action in cytotoxicity relates to mitochondrial superoxide 
production. 
 
Taking these issues together, one can argue that the only common known 
factor is the presence of sigma-2 binding sites in MCF7 cells. The explanation 
regarding comparisons between equilibrium binding to membranes and in vivo 
metabolic activity needs to be addressed. 
 
5.3.2 Correlation between Hill slope and agonistic behaviour 
Until the molecular identity of the sigma-2 binding site is established, it is 
difficult to determine whether differences in Hill slopes for these agents is 
significant. The classic comparison of high- and low-affinity binding of agonists 
to heterotrimeric G-protein coupled receptors which only recognise antagonists 
with a single affinity has been suggested for the sigma-1 receptor (Brimson et 
al., 2011). In this case, agonists binding with the same affinity, whereas 
antagonists expose a GTP-sensitive high-affinity state of the receptor. An 
explanation behind this observation awaits discovery. 
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A range of Hill slopes was identified when binding was considered, ranging from 
0.5 (ifenprodil, the agent with the largest discrepancy between pIC50 and pKi: 
628,000 fold) to AG-205 (nH 1.06, pIC50/pKi 105). On plotting nH against log 
(IC50/Ki), a negative correlation appeared to exist, although one can accept that 
the data are from a relatively small group (12 data points) – the lower the Hill 
slope, the greater the difference between binding affinity and inhibition of 
metabolic activity. While I have taken the time to consider Hill slopes, no 
previous publication has done so, so I am unable to add further data points to 
determine how representative my data are. A parallel is drawn with the sigma-1 
receptor. Although much work had been done previously, it was this lab 
(Brimson et al., 2011) who first showed that sigma-1 receptors bound agonists 
with a Hill slope of unity, whereas the anticancer antagonists showed low and 
high affinity states. The high affinity state in that case was GTP-sensitive, 
suggesting that the sigma-1 receptor is G-protein coupled. Brimson further 
showed that the anti-cancer properties of antagonists could be related to the Hill 
slope and difference between high and low affinity states – the greater the 
difference, the more effective as an anticancer drug. Although the sigma-1 
receptor and sigma-2 binding site are believed to be very different on a 
molecular level, one can speculate that a similar process could be taking place 
here. This correlation between Hill slope and IC50/Ki was only discovered 
following completion of access to the laboratory, so I am unable to pursue this 
observation. Hence, I would propose: further testing of other compounds 
believed to reduce metabolic activity through the sigma-2 binding site and a 
more detailed study of the Hill slopes of binding using many more 
concentrations of the cytotoxic drugs. The competition curves would need to be 
repeated in the absence and presence of GTP and suramin (Brimson et al., 
2011) to see if the Hill slope reverted to unity upon their addition. Should 
binding be sensitive to GTP, I would advise the use of bacterial toxins known to 
interact directly with heterotrimeric G-proteins: pertussis toxin to disrupt 
coupling to Gi (Hausdorff et al., 1990) cholera toxin to disrupt coupling to Gs 
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(Sidhu et al., 1998) removing high-affinity, GTP-sensitive binding to receptors 
coupling through these receptors. 
 
 
Figure 5-12: Relationship between Hill slope (nH) and log (IC50/Ki) in MCF7 
cells. 
Comparison of the Hill slope (nH) for binding of ligands to the sigma-2 binding 
site and the log of discrepancy between binding Ki and dose required to inhibit 
metabolic activity by 50% in MCF7 cells. Linear regression shows the line y = -
5.8x + 7.2, R2 = 0.61 [F(1,10) = 15.7, p = 0.0027], indicating a statistically 
significant correlation. 
 
Whilst such a correlation is familiar with GPCRs, the pEC50 is to the left of the 
pKi, and we attribute the lower Hill slope to the agonist showing greater 
selectivity for the active form of the receptor. In this case, the opposite is true – 
the lower the Hill slope, the greater the relative concentration over the affinity is 
required. Further work must be undertaken in order to determine whether this is 
a coincidence or meaningful correlation. 
One possible explanation is that agents are able to drive receptors into a new 
conformation. The low affinity state could exist for a few seconds or less but be 
part of the drive for reduced metabolic activity/cell death/apoptosis. This could 
then switch to a high affinity state which is what is seen in equilibrium binding 
assays. This scenario is seen with the nicotinic receptor. Heidmann et al. have 
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shown that ligand affinity for the nAChR can increase 10,000-fold in less than a 
minute, as the receptor transitions from a low affinity active form to a high 
affinity desensitised form through an intermediate affinity (Heidmann et al., 
1983). Several similar studies with different combinations of nAChR 
components show that desensitisation and recovery rates vary greatly (Quick 
and Lester, 2002). Other ligand-gated receptors show similar properties, 
including GABA(A) receptors (Chang et al., 2002) and, possibly, the 5-HT3 
receptor (Sepulveda et al., 1991). Interestingly, this final paper shows a much 
smaller discrepancy between binding and EC50 for a partial agonist.  
 
It is proposed that phosphorylation plays a part in nAChR desensitisation, as 
with many other receptors, including G-protein coupled (Tobin, 2008) and 
tyrosine kinase receptors (Yamamoto et al., 2014). My experimental design 
(preparing washed membranes) would have greatly diluted, if not removed, 
ATP and hence would suggest that sigma-2 binding sites are not 
phosphorylated during the protocol used. 
 
In order to determine whether such a change from low to high affinity could 
occur with the sigma-2 binding site at this time would be problematic. I could 
propose looking at time courses of binding association and dissociation of 
sigma-2 ligands (the 12 above would be a good starting point, especially as 
ifenprodil is in clinical trials (Ifenprodil tartrate treatment of adolescents with 
post-traumatic stress disorder: a double blind placebo controlled trial. 
NCT01896388). 
 
If one could observe a step which would suggest a switching from low to high 
affinity one could speculate this to be plausible. However, as the sigma-2 
binding site is intracellular and there are several unknowns I would advise such 
assays to be undertaken once the target’s identity has been verified. Even then, 
this may be difficult as the low affinity, active state may be very short-lived and 
there is no suggestion that the protein would have channel-like activity. 
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Measuring potential conformational changes could be impossible, especially 
with the lack of tools available. 
 
A second factor to consider is whether there is a physiological reason for such a 
switch. Moving to a high-affinity, desensitised state would “encourage” agonist 
binding to this state, mopping up ligand, and reducing the opportunity for an 
accidental activation caused by binding to active receptors which would then 
drive cell death. 
  
5.3.3 Do Sigma-2 ligands meet Lipinski’s rule of Five 
A further factor to consider which can explain the discrepancy between binding 
affinities and the IC50 for inhibition of metabolic activity as the cellular 
localisation of the sigma-2 binding site. Using antibodies prepared against the 
PGRMC1 receptor, showed it was present in the nucleus, cytoplasm and at the 
segments of the plasma membrane (Peluso et al., 2009). Earlier work has 
described it as predominantly nuclear (Engmann et al., 2011). Fluorescent 
labelling of novel sigma-2 binding site ligands showed they are internalised via 
an active, endocytic pathway. In contrast to the work obtained with antibodies, 
Zeng et al. showed that sigma-2 ligands were concentrated in the mitochondria, 
endoplasmic reticulum, lysosomes and plasma membranes (Zeng et al., 2011, 
Zeng et al., 2007). Using a similar approach, Abate et al. (2010) showed 
fluorescent analogues of PB28 were endocytosed to the endoplasmic reticulum 
and lysosome (Abate et al., 2010). Of course, with such an approach it is easy 
to envision user-introduced artefacts. The presence of a ligand does not 
necessarily determine the presence of the binding partner. Equally, such drugs 
may alter the processing and location of their targets. More traditional 
approaches, including sub-cellular fractionation have been tried. Using this 
approach, Gabreselassie and Bowen (2004) proposed the sigma-2 binding site 
was located in the membrane lipid rafts (Gebreselassie and Bowen, 2004). 
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These factors would suggest that the sigma-2 binding site is not readily 
available to ligands approaching the cell. Although quite varied and unclear, all 
the locations mentioned above are intracellular, possibly nuclear, indicating that 
the ligand will have to traverse the plasma membrane to gain access and bind. 
In order to assess what barriers these compounds may have to overcome, I 
have considered their physicochemical natures. 
 
Such a scenario was famously assessed by Chris Lipinski, working at Pfizer. 
His assessment of physicochemical properties of drugs and whether they were 
orally active allowed him to propose that predictions can be made as to the 
relative success of future drugs in such a setting. Lipinski’s “rule of 5” states 
that “poor absorption or permeation is more likely when there are more than 5 
H-bond donors, 10 H-bond acceptors, the molecular weight is greater than 500 
and the calculated logP (the calculated logarithm of the partition coefficient 
between n-octanol and water) is greater than 5” (Lipinski et al., 2001). Whilst I 
am not considering the oral absorption of these drugs, these guidelines also 
help guide whether such materials will enter cells in vitro. Analysis of these 
compounds should also determine whether they meet all 5 of Lipinski’s “rules”. 
 
One consideration for access to the interior of the cell is how charged 
molecules pass through the membrane. Classical understanding is that they 
would not be able to traverse the hydrophobic region comprising the tails of 
phospholipids. Many organic cation and anion transporters (OCT and OATs) 
exist. These merely permit a route for such molecules to traverse down a 
concentration gradient across the membrane (Girardin, 2006). 
 
However, the membrane distribution of charged amines has been known for 
some time not to follow that expected from the octanol:water distribution 
coefficient. Indeed, charged amines have a surprisingly high membrane affinity 
(Austin et al., 1995). Austin et al. also showed that amlodipine, an L-type 
calcium channel blocker that is a primary amine, had vastly different 
membrane:aqueous distribution than octanol:water. As such, this charged 
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molecule is able to act on the L-type calcium channel at a site embedded in the 
membrane (Tang et al., 2014). It is possible that the alkyl tail of these 
ammonium salts aligns with the hydrophobic tails of the phospholipids and the 
positively charged head interacts with the negatively charged phosphate groups 
of the phospholipids (Austin et al., 1995). Such interactions are not possible 
with the uncharged octanol. Whether this would lock the ammonium salts into a 
single conformation in the plasma membrane and inhibit transfer is unclear.  
 
Further predictions regarding these compounds can be achieved. Their 
likeliness of crossing the blood brain barrier, again despite being charged, 
appears high. Clark has highlighted 5 ‘rules of thumb’ regarding such 
permeation predictions (Clark, 2003): 
1. Sum of N + O <5 
2. clogP – (N + O) >0  
3. Polar surface area (PSA) <60-70 Å2 
4. MW <450 
5. 1 < logD < 3 
Clark also says that a +1 charge favours access of drugs to the brain, but that 
pKa >10 does not. This second factor would exclude most of the compounds 
discussed here (Clark, 2003, Fischer et al., 1998). 
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Ligand clogD 
(pH 7.4) 
MW* 
 
logP Hydrogen 
bond 
donors/ 
acceptors 
pKa Charge  
at pH 
7.4 
PSA 
Propylammonium -2.45 95.6 0.40 1/1 10.7 +1 26 
Butylammonium -2.12 109.6 0.93 1/1 10.8 +1 26 
Pentylammonium -1.34 123.7 1.46 1/1 10.6 +1 26 
Hexylammonium -1.02 137.7 1.99 1/1 10.2 +1 26 
Octylammonium -0.07 165.7 3.06 1/1 10.2 +1 27.6 
Decylammonium 1.07 193.7 4.12 1/1 10.6 +1 27.6 
1-adamantyl 
ammonium 
-0.37 187.7 2.22 1/1 10.7 +1 26 
2-adamantyl 
ammonium 
-0.61 187.2  1/1 10.5 +1 26 
Dimethyl 
ammonium 
-3.18 81.6 -0.43 1/1 10.5 +1 12 
Diethylammonium -2.21 109.6 0.63 1/1 10.5 +1 12 
Dipropylammoniu
m 
-1.25 137.7 1.70 1/1 10.7 +1 12 
Diisopropyl 
ammonium 
-1.45 137.7 1.33 1/1 10.7 +1 12 
Dibutylammonium -0.43 165.7 2.76 1/1 10.7 +1 12 
Diisobutyl 
ammonium 
-0.61 165.7 2.39 1/1 11.0 +1 12 
Di sec butyl 
ammonium 
-0.62 165.7 2.39 1/1 10.9 +1 12 
Dipentyl 
ammonium 
0.65 193.8 3.82 1/1 10.7 +1 12 
Dihexyl 
Ammonium 
1.38 221.8 4.88 1/1 10.7 +1 12 
Dicyclohexyl 
ammonium 
0.62 217.8 3.69 1/1 11.1 +1 12 
Bis-2-ethylhexyl 
ammonium 
3.38 277.9 6.64 1/1 11.1 +1 12 
Dioctylammonium 3.88 277.9 7.01 1/1 10.7 +1 12 
Trimethyl 
ammonium 
-2.14 95.6 0.06 0/1 9.5 +1 3.2 
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Triethyl 
ammonium 
-1.18 137.7 1.66 0/1 10.2 +1 3.2 
Ethyldiisopropyl 
ammonium 
-0.55 165.7 2.35 0/1 10.7 +1 3.2 
Tripropyl 
ammonium 
0.52 179.8 3.25 0/1 10.8 +1 3.2 
Triisopropyl 
ammonium 
-0.18 179.8 2.70 0/1 11.0 +1 3.2 
Tributyl 
ammonium 
1.69 221.8 4.84 0/1 10.8 +1 3.2 
Triisobutyl 
ammonium 
2.03 220.8 4.29 0/1 11.5 +1 3.2 
Tripentyl 
ammonium 
3.73 263.9 6.44 0/1 10.8 +1 3.2 
Triisopentyl 
ammonium 
2.68 263.9 5.89 0/1 10.9 +1 3.2 
Trihexyl 
ammonium 
 
4.85 
 
306.0 
 
8.03 
 
0/1 
 
10.8 
 
+1 
 
3.2 
Trioctyl 
ammonium 
8.10 390.1 11.22 0/1 10.8 +1 3.2 
Tridodecyl 
ammonium 
 
14.50 
 
558.5 
 
17.60 
 
0/1 
 
10.8 
 
+1 
 
3.2 
Tetramethyl 
ammonium 
-3.15 109.6 -2.89 0/1 - +1 0 
Tetraethyl 
ammonium 
 
-2.79 
 
165.7 
 
-3.17 
 
0/1 
 
- 
 
+1 
 
0 
Tetrapropyl 
ammonium 
-1.77 221.9 -2.64 0/1 - +1 0 
Tetrabutyl 
ammonium 
-0.64 278 -1.72 0/1 - +1 0 
(+) Pentazocine 2.26 285.4 4.53 1/2 9.5, 
10.4 
+0.99 23.5 
Haloperidol 2.65 375.9 3.01 1/3 8.0, 
13.9 
+0.82 40.5 
DTG 2.31 239.3 3.77 2/3 10.6 +1 50.4 
Rimcazole 2.63 321.5 5.10 1/3 4.0, 
9.8 
+1 20.2 
Progesterone 3.72 314.5 4.04 0/2 - 0 34.1 
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IPAG 2.74 395.3 5.42 3/3 -1.41, 
10.61 
+1 50.4 
RU-486 5.16 429.6 4.95 1/3 4.8, 
12.8 
0 40.5 
Ifenprodil 1.66 325.4 4.25 2/3 9.0, 
9.6, 
14.0 
+0.97 43.7 
PPCC 2.17 379.5 2.90 1/4 8.7, 
14.0 
+0.95 249 
SM21 1.19 337.8 3.64 0/4 9.3 +0.99 38.8 
SKF 10047 2.16 257.2 3.46 ½ 9.3, 
10.3 
+0.99 23.5 
AG-205 2.46 455.0 5.39 0/7 8.0, 
8.6, 
12.4, 
14.5 
+1.74 92.4 
Spermidine -5.91 145.2 -0.84 5/3 8.1, 
10.0, 
10.6 
+2.84 64.1 
Spermine -6.78 202.3 -0.96 6/4 7.8, 
8.4, 
10.3,1
0.8 
+3.73 76.1 
 
Table 5-9: Physiochemical properties of all the ligands 
Table showing a range of physicochemical properties of the ligands tested in 
this thesis. * MW of hydrochloride salt, where appropriate. Values are obtained 
using ACD from chemspider.com and chemicalize.com. Values in italic bold 
are outside Lipinski’s rules. 
 
The pKa values of all the simple amines is above 10. This would mean that 
these compounds are protonated and hence positively charged at all times 
under physiological conditions. Looking at the calculated log of the 
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octanol:water partition coefficient (clogD), most of the compounds tested have 
clogD values below 5. Although I present logP (partition coefficient of the 
uncharged species) as well as clogD, I have chosen to focus on clogD, as this 
is more appropriate to consider when most compounds are highly charged. As 
can be seen in Table 5-9, most of the compounds tested meet Lipinski’s rule of 
5. A group of tertiary ammonium salts have logP greater than 5, with the 
corresponding clogD of the highest ammonium salts also exceeding 5. Several 
highly prized laboratory tools (rimcazole, IPAG and AG-205) also possess logP 
values over 5. As these materials also possess a positive charge at pH 7.4, 
their clogD values are all well below 5. 
 
One may consider that access to the sigma-2 binding site may then, be the 
barrier to inhibiting cellular metabolism. In comparing log (IC50/Ki) with clogD 
there is clearly no correlation, and so this explanation can be dismissed (Table 
5-10 and figure 5-13). 
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Compound clogD IC50/Ki 
Octylammonium -0.07 118 
Decylammonium 1.07 22.4 
Dihexylammonium 1.38 15100 
Dicyclohexylammonium 0.62 1290 
Dioctylammonium 3.88 2670 
Trihexylammonium 4.85 538 
(+) Pentazocine 2.26 446 
Rimcazole 2.63 53.8 
Ifenprodil 1.66 628000 
SM21 1.19 1590 
AG-205 2.46 105 
PB28 3.6 19500 
 
Table 5-10: log (IC50/Ki) and clogD of sigma-2 binding site ligands. 
Table showing the showing clogD and ratio between IC50 in MTS assays and Ki 
of binding to membranes of MCF7 cells of a range of sigma-2 ligands. 
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Figure 5-13: log (IC50/Ki) and clogD of sigma-2 binding site ligands. 
Plot showing lack of correlation between clogD and log of ratio between IC50 in 
MTS assays and Ki of binding to membranes of MCF7 cells. Linear regression 
shows the line y = 0.094x + 2.8, R2 = 0.012 [F(1,10) = 0.12, p = 0.74], indicating 
no correlation. 
 
PB28, another sigma-2 binding site ligand, has been used as a lead compound 
in identifying clinically useful compounds. PB28 was considered too lipophilic, 
with clogD (7.4) 3.99, logP 5.05, for development as a positron emission 
tomography (PET) or single photon emission computed tomography (SPECT) 
agent, being described as “abundantly out of the range that was considered 
optimal”, which is estimated as being around log D (7.4) 2.0-2.5. (Abate et al., 
2011). 
 
In summary, I have characterised a series of novel sigma-2 ligands as well as 
several previously identified commercial ligands. Some of these appeared to 
reduce cellular proliferation in MCF7 cells; I believe these effects were 
mediated by the sigma-2 binding site. Several of these compounds also 
affected intracellular calcium concentration. There appeared to be no or little 
correlation between the ability of a compound to elicit a calcium response and 
its ability to reduce metabolic activity of a cell. Likewise, there was no 
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correlation between a sigma-2 ligand’s ability to access the cell interior and 
cause a reduction in metabolic activity. 
 
In this respect, my attempts to determine and identify agonists at the sigma-2 
binding site have been unsuccessful. Without knowing the molecular identity of 
the sigma-2 binding site such molecules may prove difficult to characterise. A 
recent publication suggests that CM572 is a partial agonist. It is described as a 
cytotoxic agent that mobilises calcium, is selectively toxic towards cancer cell 
lines and partially reverses the effects of the sigma-2 agonist, CB-64D 
(Nicholson et al., 2015). I, too, have observed agonists that are effective at 
reducing metabolic activity also partially reverse the effects of rimcazole. The 
mechanism may be specific, or related to how much organic cations are able to 
enter the cell. The reduction observed may be competition on cell entry rather 
than effects at the binding site. 
 
More importantly, there does appear to be a correlation between the Hill slope 
of binding of a ligand and its ability to reduce metabolic activity. Equally, the 
decreased Hill slope of binding correlates well with the discrepancy between the 
Ki of binding and the IC50 in MTS assays. This discrepancy, while frequently 
noted, has not previously been explained. I propose that agonists at the sigma-
2 binding site are able to drive a response when binding to a low-affinity state of 
the binding site and then cause desensitisation of the receptor. This 
desensitised state of the receptor possesses a much higher affinity than the 
active state and explains the discrepancy previously observed. 
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The debate regarding the identity of the sigma-2 binding site continues, with 
most focus on whether or not it is the progesterone receptor membrane 
component-1. This controversy will be soon resolved and interested parties can 
continue studying the regulation and therapeutic uses of this site. Levels of the 
sigma-2 binding site do seem related to proliferative status of a cell and so all 
tumours appear to express this protein (with some reservation, as some 
systems may have been mis-labelled as possessing sigma-2 binding sites when, 
in fact, they have merely seen “unmasked” sigma-1 receptors, discussed in 
chapter 3). The use of sigma-2 ligands in imaging looks likely to become a 
reality, with several successful animal models. Indeed, while no data have yet 
been published on the completed phase 1 clinical trials NCT00968656, 
recruitment for further phase 1 trials has already started (NCT02762110 
NCT02284919, to determine whether such tools should join the battery of 
agents in the imaging and treatment of cancers. 
 
The effects of certain ligands on cancer cells causing reduced cell proliferation 
and apoptosis should also continue to be studied. The results shown here 
confirm that the binding pocket for ligands/agonists is far more simple than 
previously described. Earlier findings were, perhaps, starting from a point where 
complex drugs were being tested for other receptors (e.g., sigma-1) which were 
then found to also act at the sigma-2 binding site. 
 
These results will have a positive effect on the sigma-2 field in several ways: 
6.1 Correct designation of sigma-1 and sigma-2 levels    in 
cells and tissue. 
The use of masking agents (pentazocine and dextrallorphan) and cells 
expressing sigma-1 receptors must be reconsidered. It is shown clearly that 
protocols using a pan sigma radioligand (DTG) and cells or tissue expressing 
both sigma-1 receptors and sigma-2 binding sites presents many issues the 
researchers cannot address or compensate for. Whiles the use of [3H] (+) 
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pentazocine for sigma-1 studies appears safe due to its low affinity for the 
sigma-2 binding site, sigma-2 binding assays must be revised. It can be 
recommended to use [3H] DTG and cells or tissues lacking sigma-1 receptors 
(as is used here, with MCF7 cells verified as lacking sigma-1 receptors). Equally, 
the development and use of novel sigma-2-selective fluorescent or radioligands 
would be satisfactory once characterised. The use of [3H] DTG in competition 
assays with selective sigma-1 or sigma-2 ligands would also be a 
recommended means by which total sigma Bmax and proportion of sigma-1: 
sigma-2 sites can be determined. This may (and does in my hands) result in 
different determinations of sigma-1 receptor density, which may be important. 
However, it appears that many researchers are interested in the relative ratios 
of these sites in cells and tissue, as such it appears to be a more transparent 
and direct assessment of this. Also, the use of a single radioligand to 
characterise both sites removes the problems caused by artefacts introduced 
when working with two drugs with unknown contaminants or levels of chemical 
decay, as described by Lazareno  and Birdsall (Lazareno and Birdsall, 2000) By 
using [3H] (+) pentazocine and [3H] DTG to characterise, then compare, the two 
sigma sites two sets of independent errors are introduced. As Segal’s Law 
states, “A man with a watch knows the time, a man with two is never sure”.  
 
6.2 Identification of simple, high-affinity ligands. 
Having redefined the manner in which sigma-2 binding sites should be 
characterised, it was then shown that simple ammonium salts show a structure-
affinity relationship, with increasing alkyl chain length affecting affinity for 
primary, secondary and tertiary ammonium salts. The affinities of the highest 
affinity ammonium salts was not dissimilar to that of many commercial ligands 
used in sigma-2 studies in this thesis and many publications. 
It is, however, in the characterisation of the pharmacological effects of sigma-2 
ligands that I wish to focus here. Several key observations and hypotheses that 
will aid research in this area.  
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6.3 Biologically active drugs have a low Hill slope 
Firstly, the Hill slope of the binding of agents that were effective in decreasing 
cellular metabolic activity was low. This observation should now be further 
assessed. Do these findings suggest that the sigma-2 binding site has more 
than one affinity state for cytotoxic ligands. Are these high affinity states 
sensitive to the addition of GTP, which would suggest that the sigma-2 binding 
site is coupled through G-proteins. My findings are based on a relatively small 
number of drugs tested. Large-scale tests would be required before such an 
observation could be used in predicting whether a sigma-2 ligand is an agonist 
(causing cytotoxicity) or antagonist (preventing the effects of an agonist). 
Should my prediction hold up, high-throughput screening of compounds 
becomes a possibility: looking for agents with low Hill slopes to identify active 
drugs. 
 
6.4 Sigma-2 activity is not related to calcium or lipophilicity 
It has previously been proposed that a correlation exists between the ability of 
sigma-2 ligands to drive a calcium response. Whilst the original data showed 
only a very weak correlation, my results would strongly argue against this. 
Equally, as the sigma-2 binding site is believed to be located inside the cell, 
access may require passage through the plasma membrane. I have shown that 
there is no correlation between the lipophilicity of a compound and its ability to 
drive a biological effect.  
 
6.5 Desensitisation of sigma-2 binding sites raises the affinity. 
A further observation on the effects of these drugs affecting metabolic activity, 
is the possibility that sigma-2 binding sites have an active and desensitised 
state. Previous publication in this field have not explained how and why the 
EC50 for any biological effect through this binding site is much higher than the 
affinity for the site. One such explanation described it necessary to occupy 
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99 % of the sigma-2 binding sites before a biological effect is observed 
(Rybczynska et al., 2008). This is contrary to pharmacological understanding, 
yet remains a commonly held belief. Taking the corollary from ligand-gated ion 
channels, I propose that an agonist binds to a low-affinity state of the receptor 
which cases a biological effect. This receptor then undergoes desensitisation to 
a high-affinity state, which is the one observed when equilibrium competition 
binding assays are performed. Returning to point 3 above, there was also a 
strong correlation between low Hill slope for binding and the discrepancy 
between binding Ki and EC50 for reducing metabolic activity. In the case of 
ligand-gated ion channels, this desensitisation step occurs very rapidly (on the 
millisecond or second level). Testing for such a step with the sigma-2 binding 
protein will require far more advanced tools than we have at the moment. Such 
a concept can be revisited once the molecular identity of sigma-2 binding sites 
has been established. I am unaware that desensitised receptors of any other 
class show a shift to a high affinity than active receptors. One very provocative 
question can then be raised: is the sigma-2 binding site a ligand-gated ion 
channel? 
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